Document:

ovid-ex1025_869.htm

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

Exhibit 10.25

 

COLLABORATION AND LICENSE Agreement

This Collaboration and License Agreement (the “Agreement”) is entered into as of July 8, 2020 (the “Effective Date”), by and between Ovid Therapeutics Inc., a Delaware company having an address at 1460 Broadway, Suite 15021 New York, NY 10036, USA (“Ovid”) and Angelini Pharma Rare Diseases AG, a Swiss company under direction and control of Angelini Pharma S.p.A. and having an address at Consulting GmbH Sumpfstrasse 26 6312 Steinhausen, Zurich, Switzerland (“Licensee”).  Ovid and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.  

Recitals

Whereas, Ovid, a biopharmaceutical company, owns or controls certain patents, know-how, and other intellectual property relating to its proprietary compound known as OV101, a selective agonist of the GABAA receptor, including certain intellectual property rights in-licensed from H. Lundbeck A/S, which Ovid has been developing for the treatment of Angelman syndrome and Fragile X syndrome and potentially other Rare Diseases indications;

Whereas, Licensee is a subsidiary, 100% under direction and control of Angelini Pharma S.p.A., an Italian pharmaceutical company, which is experienced in the development and commercialization of pharmaceutical products; and

Whereas, Licensee and Ovid desire to form a collaboration for the continued development and commercialization of OV101, with the status of Orphan Medicine and with Final Label 1a, 1b and/or 2, all on the terms and conditions set forth below. 

Agreement

Now, Therefore, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Ovid and Licensee hereby agree as follows:

	
1.
	
Definitions

1.1“Additional Development Activities” has the meaning set forth in Section 4.3(a).

1.2“Additional Indications” means any Rare Diseases Indication other than the Initial Indication and the Second Indication that has been submitted to and approved by the CGB.

1.3“Additional Pivotal Trial” means the additional Phase 3 Clinical Trial of the Product for the Initial Indication, if required by the EMA or by Licensee at its own discretion, for the purpose of seeking or maintaining MAA Approval of the Product for the Initial Indication in the Licensee Territory, as described in Exhibit H.

1.4“Affiliate” means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such party, but for only so long as such control exists.  As used in this Section 1.4, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate 

1

 

 

governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.

1.5“Allocated Quantity of Compound” means [***] of the Compound in Ovid’s control as of the Effective Date, which Ovid has agreed, under the Supply Agreement, to allocate exclusively for the purpose of fulfilling Licensee’s or Licensee Affiliate’s Purchase Orders under the Supply Agreement.

1.6“Allowable Increases” has the meaning set forth in Section 4.5(b).

1.7“Amended Development Budget” has the meaning set forth in Section 4.2.

1.8“Amended Development Plan” has the meaning set forth in Section 4.2.

1.9“Angelini Commercially Reasonable Efforts” means, with respect to Licensee and its obligations under this Agreement, commercially reasonable efforts and resources as commonly used by a similar size pharmaceutical company to Develop and Commercialize a product controlled by Licensee or to which it has exclusive rights, which product is at similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved and/or anticipated labelling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, likelihood of regulatory approval given the regulatory structure involved, the profitability of the product, [***] and other relevant factors, including technical, legal, scientific and/or medical factors. Commercially Reasonable Efforts shall be determined on a country-by-country basis and indication-by-indication basis for a particular Product, and it is anticipated that the level of effort will change over the time, reflecting changes in the status of the Product and the country(s) involved.  [***]. 

1.10“Applicable Laws” means the applicable provisions (including Data Protection Legislation) of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, Regulatory Authority, or governmental agency or authority having jurisdiction over or related to the subject item.

1.11“Auditor” has the meaning set forth in Section 9.4.

1.12“Calendar Quarter” means each respective period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31.

1.13“Calendar Year” means each respective period of twelve (12) consecutive months ending on December 31. 

1.14“cGCP” means the current good clinical practice standards as set out in (a) ICH Harmonized Guidance on current Good Clinical Practice (CPMP/ICH/135/95), (b) U.S. 21 C.F.R. Parts 50, 54, 56, 58, 210, 211 and 312, and (c) the equivalent law or regulation in any other applicable jurisdiction in the Territory, each as may be amended from time to time.

2

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.15“cGLP” means current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S.), as may be amended from time to time.

1.16“cGMP” means the current standards for systems to assure the proper design, monitoring, and control of processes and facilities to be used for the manufacture, processing, packing, or holding of a drug as specified by applicable laws of the relevant countries at the time of manufacturing conducted in accordance with this Agreement, defined under (a) U.S. 21 C.F.R. Parts 210 and 211 and (b) the equivalent law or regulation in any other applicable jurisdiction in the Territory, each as may be amended from time to time.

1.17“Claim” has the meaning set forth in Section 12.3.

1.18“Clawback” means post sales clawback policies applied to manufacturers, requiring them to pass a part of their revenues in respect of a product to a national health service or other Governmental Authority. 

1.19“Clinical Trial” or “Clinical Trials” means Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, or Phase 4 Clinical Trial, as the context dictates.

1.20“Collaboration Governance Board” or “CGB” has the meaning set forth in Section 3.1.

1.21“Combination Product” means any pharmaceutical product containing the Compound as an active pharmaceutical ingredient in combination with one or more other therapeutically active ingredients, in any and all forms, presentations, dosages, and formulations.

1.22“Commercialization” means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical and patient support and services, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering Products to customers) of Products in the Field, including sales force efforts, detailing, advertising, market research, market access (including price and reimbursement activities), medical education and information services, publication, scientific and medical affairs, advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales (including receiving, accepting and filling Product orders) and distribution.  “Commercialize” and “Commercializing” have correlative meanings. 

1.23“Commercialization Plan” has the meaning set forth in Section 6.2.

1.24“Committee” means the CGB, JPT, or any other subcommittee established by the CGB, as applicable. 

1.25“Committee for Medicinal Products for Human Use (CHMP)” means the EMA committee responsible for human medicines. 

1.26“Competing Acquirer” means a Third Party that, as of the closing date of the applicable transaction, is engaged in [***] of products, other than Products, for [***].

3

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.27“Competing Product” means any product or compound, other than the Compound and Products and the Current Licensee Pipeline Products, (a) [***], or (b) [***]. 

1.28“Compound” means the δ-selective extrasynaptic GABAA receptor agonist known internally by Ovid as OV101, having the chemical structure set forth in Exhibit A. 

1.29“Compound Invention” has the meaning set forth in Section 10.1(b)(i).

1.30“Compounding” or “Compounding Activities” means [***].

1.31“Confidentiality Agreement” means that certain Confidential Disclosure Agreement between Ovid and Licensee dated as of July 8, 2019.

1.32“Confidential Information” means all Know-How and other proprietary scientific, marketing, financial, or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement; provided that all Ovid Technology will be deemed Ovid’s Confidential Information, all Licensee Technology will be deemed Licensee’s Confidential Information, and all Joint Inventions and Joint Patents will be deemed both Parties’ Confidential Information.

1.33“Control” or “Controlled” means, with respect to any Know-How, Patents, or other intellectual property rights, the legal authority or right (whether by ownership, license, or otherwise, but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such Know-How, Patents, or other intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.

1.34“Cost of Goods” means, with respect to the Drug Product, the fully burdened cost to manufacture and supply such Drug Product, which means: (a) in the case of products and services acquired from Third Parties, [***]; and (b) in the case of manufacturing services performed by a Party or its Affiliates, including manufacturing services to support products and services acquired from Third Parties as contemplated in subsection (a), [***].

1.35“Current Licensee Pipeline Products” means, in each case as of the Effective Date, Licensee’s pipeline for products related to (a) [***], (b) [***], and (c) [***], in each case as better defined in Exhibit I. 

1.36“Data” means any and all scientific, technical, test, marketing, or sales data pertaining to any Product that is generated by or on behalf of Ovid, Licensee, and their respective Affiliates and (sub)licensees, including research data, clinical pharmacology data, pre-clinical data, clinical data, clinical study reports, or submissions made in association with an IND or MAA with respect to any Product.  

4

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.37“Data Protection Legislation” means all applicable legislation relating to the protection and processing of personal data, data privacy and the privacy of electronic communications in any relevant jurisdiction, including the General Data Protection Regulation ((EU) 2016/679), and any national implementing laws, regulations and secondary legislation, as amended or updated from time to time.

1.38“Development” means all non-clinical and clinical drug development activities, including toxicology, pharmacological, and other non-clinical efforts, statistical analysis, the performance of Clinical Trials, including the Manufacturing of the Products for use in the Clinical Trials, Manufacturing Development or other activities reasonably necessary in order to obtain or maintain Regulatory Approval of Products in the Field in the Territory, as detailed in a Development Plan for the Products. “Development” shall exclude all Commercialization activities. When used as a verb, “Develop” means to engage in Development activities. 

1.39“Development Budget” means the initial reasonably detailed budget estimated by the Parties for all Development activities set forth in the Development Plan.

1.40“Development Costs” means the costs incurred by a Party or for its account or by the Parties jointly, during the Term and pursuant to this Agreement, that are specifically directed (or reasonably allocable) to the Development of a Product.  The Development Costs shall include amounts that a Party pays to Third Parties involved in the Development of a Product (at cost), and all internal costs (calculated on an FTE basis at the then-current FTE Rate) and out-of-pocket costs incurred by or on account of a Party in performing Development in accordance with the Development Plan.  For clarity, [***]. 

1.41“Development Plan” means the initial plan of Development activities for the Product set forth in Exhibit C.

1.42“Drug Product” means the Compound, filled and finished into unit doses, but not packaged or labelled.

1.43“Elara Trial” means the open-label extension study for patients with Angelman Syndrome who have previously been enrolled in a Clinical Trial of the Product (including the Neptune Trial) as of the Effective Date, as further described in Exhibit J.  [***].

1.44“EMA” means the European Medicines Agency, and any successor agency or authority having substantially the same function.

1.45“Executive Officers” means the [***] of Ovid and the [***] of Licensee. 

1.46“Export Control Laws” means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C. §§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22 U.S.C. §§ 2778 and 2779, and the 

5

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986, in each case, as amended.

1.47“Extended Commercialization Term” means the period commencing on the expiration of the Royalty Term and continuing for so long as Ovid continues to supply to Licensee or Licensee Affiliate the Product under the terms of the Lundbeck License Agreement.

1.48“FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended. 

1.49“FDA” means the U.S. Food and Drug Administration, and any successor agency or authority having substantially the same function. 

1.50“Field” means the treatment of (a) the Initial Indication, (b) the Second Indication (subject to Section 4.2(e)) and (c) any Additional Indication(s) for which the Parties agree to incorporate Additional Development Activities into the Development Plan and Development Budget in accordance with Section 4.3.

1.51“Final Label” refers to the information regarding an approved Indication and population target that is included with a prescription drug as approved by an applicable Regulatory Authority.

1.52“Final Label 1a” means the Final Label for a population from two (2) years of age up to twelve (12) years of age.

1.53“Final Label 1b” means the Final Label for a population from four (4) years of age up to twelve (12) years of age. 

1.54“Final Label 2” means the Final Label for the population from twelve (12) years of age up to, at least seventeen (17) years of age or more. 

1.55“First Commercial Sale” means, on a Product-by-Product and country-by-country basis, the first sale of such Product in such country by Licensee or its Affiliates or Sublicensees to a Third Party after Regulatory Approval for such Product has been obtained in such country.  

1.56“FTE” means the equivalent of a full-time individual’s work for a twelve (12) month period, consisting of a total of [***] hours per year of dedicated effort.  Any person who devotes more or less than [***] hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such person on such activities, divided by [***].  For clarity, the hours spent by temporary workers and contractors on applicable activities may be treated as FTE on a pro-rata basis.

1.57“FTE Rate” means an initial rate of (a) with respect to Ovid’s personnel, [***] per FTE per year and (b) with respect to Licensee’s personnel, [***] per FTE per year, which rates shall apply through [***].  Thereafter, the FTE Rate shall be changed annually on a Calendar Year basis to reflect any year-to-year percentage increase or decrease (as the case may be) (i) with respect to Ovid, in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics, and (ii) with respect to Licensee, in 

6

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

the Italy Consumer Price Index as published by the Italian National Statistical Institute (both changes based on the change from the most recent applicable index available as of the Effective Date to the most recent applicable index available as of the date of the calculation of such revised FTE Rate).

1.58“Generic Product” means, (a) any pharmaceutical product which has received Regulatory Approval [***] of the Product; and/or (b) any other pharmaceutical product, approved under an Abbreviated New Drug Application, or ANDA, in the United States, under Section 505(b)(2) of the Food Drug and Cosmetic Act, or similar regulatory pathways outside of the U.S., in any case, with the Product as the reference product. 

1.59“Generic Product Competition” with respect to a Product, on a country-by-country basis, Generic Product Competition shall exist if [***] there are one or more Generic Products sold [***] in such country and the sales of such Generic Product(s) account for [***] or more of the sales revenue of the Product and its Generic Product(s) in the given country during such [***] as determined by reference to applicable sales data obtained from IMS Health, Verispan, or from such other reputable source for such sales data as may be used and relied upon by the Parties from time to time, provided however if sale of such Generic Product(s) [***], Generic Product Competition shall no longer exist.

1.60 “Governmental Authority” means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization, or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).

1.61“ICH” means the International Conference on Harmonization (of Technical Requirements for Registration of Pharmaceuticals for Human Use).

1.62“IND” means an application filed with a Regulatory Authority for authorization to commence Clinical Trials, including (a) an Investigational New Drug Application or any successor application or procedure filed with the FDA, (b) a Clinical Trial Application or any successor application or procedure filed with the EMA, (c) any equivalent of the applications in (a) and (b) in countries or regulatory jurisdictions outside the U.S. and EU, and (d) all supplements, amendments, variations, extensions, and renewals thereof that may be filed with respect to the foregoing.

1.63“Indemnitee” has the meaning set forth in Section 12.3. 

1.64“Indemnitor” has the meaning set forth in Section 12.3. 

1.65“Independent Development Activities” has the meaning set forth in Section 4.3(d).

1.66“Independent Development Costs” has the meaning set forth in Section 8.2(b).

7

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.67“Indication” means a separate and distinct disease, disorder, illness, or health condition and all of its associated signs, symptoms, stages, or progression (including precursor conditions), in each case for which a separate MAA may be filed.  Subpopulations or patients with a primary disease or condition, however stratified (including stratification by stages or progression, particular combinations of symptoms associated with the primary disease or condition, prior treatment courses, response to prior treatment, family history, clinical history, phenotype, or other stratification) shall not be deemed to be separate “Indications” for the purposes of this Agreement.

1.68“Initial Indication” means Angelman syndrome (AS). 

1.69“International Transparency Reporting Requirements for Europe” means EFPIA consolidated Code for Pharmaceutical Companies to report transfers of value related to HCPs: donations and grants, contribution to costs related to events, fees for service and consultancy, research and development.

1.70“Inventions” means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice in the course of activities contemplated by this Agreement.

1.71“JPT” has the meaning set forth in Section 3.2. 

1.72“Joint Development Activities” has the meaning set forth in Section 4.2(d). 

1.73“Joint Inventions” has the meaning set forth in Section 10.1(b)(ii).

1.74“Joint Patents” has the meaning set forth in Section 10.1(b)(ii).

1.75“Know-How” means all technical and scientific information, know-how, and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models, and other physical, biological, or chemical materials, expertise, and other technology applicable to development, registration, use, or marketing or to methods of assaying or testing them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, and analytical safety, nonclinical, and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise, and information relevant to the research, development, use, importation, offering for sale, or sale of, or which may be useful in studying, testing, developing, Products.  Know-How excludes Patents.  

1.76“Licensee Data” has the meaning set forth in Section 10.1(a).

1.77“Licensee Indemnitee” has the meaning set forth in Section 12.1.

1.78“Licensee Know-How” means all Know-How that Licensee or its Affiliate(s) Controls as of the Effective Date or during the Term, including any Joint Inventions, that is necessary or reasonably useful for the research, Development, manufacture, use, importation, offer for sale, or sale of the Compound or any Product in the Field.  For clarity, subject to Section 8.2(b) in the case of any Licensee Data generated as a result of Licensee’s Independent Development Activities, the Licensee Know‐How includes the Licensee Data.

8

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.79“Licensee Patents” means all Patents that Licensee or its Affiliate(s) Controls as of the Effective Date or during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale, or sale of any Compound or Product (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Licensee or its Affiliate).

1.80“Licensee Technology” means the Licensee Know-How and the Licensee Patents, including Licensee’s interest in the Joint Inventions and Joint Patents.

1.81“Licensee Territory” or “Licensed Territory” means Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.

1.82“Licensee Territory Development Activities” has the meaning set forth in Section 4.2(b).

1.83“Losses” has the meaning set forth in Section 12.1.

1.84“Lundbeck License Agreement” means the License Agreement by and between Ovid and H. Lundbeck A/S (“Lundbeck”) dated 25 March, 2015, and amended on July 7, 2020 to clarify certain sights of sublicensees upon termination of such agreement (such amendment, the “Lundbeck Sublicense Amendment”). 

1.85“MAA” means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in any country or jurisdiction.  For clarity, MAA does not include any application for Pricing and Reimbursement Approval.

1.86“MAA Approval” means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a Product in the applicable country or jurisdiction, but excluding any Pricing and Reimbursement Approval. 

1.87“Major European Market” means [***].

1.88Manufacturing Development” means any of the following with respect to the Compound or a Product: manufacturing process development, process improvements and any analytical development or validation associated with such development or improvements.

1.89“Market Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by a Regulatory Authority with respect to a Product other than patents, including Directive 2001/83/EC and 2004/27/EC (as amended) in the EU and rights equivalent to those conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity).

9

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.90“Medical Affairs” or “Medical Affairs Activities” means activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, the Product, including by way of example:  (a) activities of medical scientific liaisons/medical advisors who, among their other functions, may: (i) conduct service based medical activities including providing input and assistance with consultancy meetings, proposing investigators for clinical trials sponsored or co-sponsored by a Party or Affiliate, and providing input in the design of such trials and other research related activities; and/or (ii) deliver non-promotional communications and conduct non-promotional activities; (b) grants to support continuing medical education, symposia, or Third Party research related to the Product; (c) development, publication, and dissemination of original and literature review data relating to the Products; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call, or email; (e) conducting advisory board meetings, international advisory board activities, or other consultant programs, including the engagement of key opinion leaders and health care professional in individual or group advisory and consulting arrangements; and (f) the evaluation of applications submitted for support of investigator-initiated trials.  

1.91“Neptune Trial” means the Phase 3 Clinical Trial of the Product for Angelman Syndrome ongoing as of the Effective Date and for which Ovid is the sponsor, as further described in Exhibit J. 

1.92“Net Sales” means, with respect to any Product, the aggregate gross amount invoiced by Licensee, its Affiliates, or Sublicensees for the sale of the Product to a Third Party, less the following deductions to the extent allowed and actually taken on such sales: 

(a)transportation charges relating to the Product to the extent actually invoiced to Licensee’s, its Affiliate’s, or Sublicensee’s customers, including handling charges and insurance premiums relating thereto;

(b)sales taxes, excise taxes, use taxes, VAT, and duties paid by Licensee, its Affiliate, or Sublicensee in relation to the Product and any other equivalent governmental charges imposed on the importation, use, or sale of the Product;

(c)government-mandated rebates (including any Paybacks or Clawbacks charged with respect to the Product) and other rebates or fees;

(d)customary trade, quantity, and case discounts allowed on the Product;

(e)allowances or credits to customers on account of retrospective price reductions affecting the Product; and

(f)customary rebates (including confidential discount agreements Success Fee and Performance based Payments). 

The transfer of Product between Licensee and its Affiliates and Sublicensees shall not be considered a sale unless the Affiliate or Sublicensee is a bona fide purchaser at fair market value for resale.  If the Affiliate or Sublicensee is not an end user, Net Sales shall be determined based 

10

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

on the invoiced sale price by the Affiliate or Sublicensee to the first Third Party trade purchaser, less the deductions allowed under this Section 1.92.  Disposal of Product for or use of Product in Clinical Studies or as free samples in quantities common in the industry for this sort of Product shall not give rise to any deemed sale under this definition. 

Net Sales shall be calculated and accounted for in accordance with accounting standards during the Term (i.e., IFRS), consistently applied. 

If Product is sold for other than cash payment, Net Sales of the Product shall be deemed to be the cash value of such other payment.

If the Product is sold as part of a Combination Product, Net Sales of such Product shall be deemed to be an amount equal to the following:

(X divided by Y) multiplied by Z,

where “X” is the average sales price during the applicable reporting period achieved for the relevant Product in the country in which such sale occurred when the Product contains only the Compound and no other active pharmaceutical ingredient;

“Y” is the sum of the average sales price as a single entity during the applicable reporting period achieved in that country (as applicable) of each product included in the Combination Product when such product is sold as a separate product and not as part of a Combination Product; and

“Z” is the single price at which the relevant Combination Product was actually sold.

In the event that no separate sale of either (a) the Product comprising the Compound as the sole active pharmaceutical ingredient, or (b) a product containing the other active pharmaceutical ingredient(s) included in the Combination Product, are made during the accounting period in which the sale was made or if the price for a particular therapeutically active ingredient cannot otherwise be determined for an accounting period, Net Sales allocable to the Product shall be determined by mutual agreement of the Parties prior to the end of the accounting period in question based on an equitable method of determining the same that takes into account, in the Territory, variations in potency, the relative contribution of each therapeutically active ingredient in the Combination Product, and relative value to the end user of each therapeutically active ingredient; provided, that if the Parties cannot reach mutual agreement prior to the end of the applicable accounting period, such matter shall be resolved in accordance with Article 15. 

1.93“Orphan Drug Designation” means a status assigned to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.

1.94“Orphan Drug Designation of the Product” means the EMA orphan drug designation obtained for the Product. 

11

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.95“Orphan Medicine” means a medicine that continues to meet the criteria for maintaining its orphan status in parallel with the assessment of an application for marketing authorisation by the European Medicines Agency (EMA).

1.96“Ovid Commercially Reasonable Efforts” means, with respect to Ovid and its obligations under this Agreement, commercially reasonable efforts and resources as commonly used by a similar size pharmaceutical company to Develop and Commercialize a product controlled by Ovid or to which it has exclusive rights, which product is at similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved and/or anticipated labelling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, likelihood of regulatory approval given the regulatory structure involved, the profitability of the product, [***], and other relevant factors, including technical, legal, scientific and/or medical factors. Commercially Reasonable Efforts shall be determined on a country-by-country basis and indication-by-indication basis for a particular Product, and it is anticipated that the level of effort will change over the time, reflecting changes in the status of the Product and the country(s) involved. 

1.97“Ovid Data” has the meaning set forth in Section 10.1(a).

1.98“Ovid Indemnitee” has the meaning set forth in Section 12.2. 

1.99“Ovid Know-How” means all Know-How that Ovid Controls as of the Effective Date or, subject to Section 2.7(b), during the Term, including any Joint Inventions, that is necessary or reasonably useful for the Development, use, importation, offer for sale, or sale of any Compound or Product in the Field in the Licensee Territory.  For clarity, any Ovid Data generated during Ovid’s Independent Development Activities will be included within the Ovid Know‐How following reimbursement by Licensee of its share of Development Costs in accordance with Section 8.2(b). 

1.100“Ovid Ongoing Trials” means the Rocket Trial, Elara Trial, and Neptune Trial.

1.101“Ovid Patents” means all Patents in the Licensee Territory that Ovid Controls as of the Effective Date or, subject to Section 2.7(b), during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the Development, use, importation, offer for sale, or sale of any Compound or Product in the Field in the Licensee Territory (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Ovid).  The Ovid Patents existing as of the Effective Date are set forth in Exhibit B.

1.102“Ovid Technology” means the Ovid Know‐How and the Ovid Patents, including Ovid’s interest in the Joint Inventions and Joint Patents.

1.103“Ovid Territory” means the world outside the Licensee Territory. 

1.104“Paediatric Investigational Plan (PIP)” is the development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the 

12

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

authorisation of a medicine for use in children. Any Applicants must obtain EMA approval of the PIP before MAA.

1.105“Patents” means (a) all patents, certificates of invention, applications for certificates of invention, priority patent filings, provisional patent applications and patent applications, and (b) any renewals, divisions, or continuations (in whole or in part) of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.

1.106“Payback” means payback policies which require manufacturers to pay back a share of their revenue in respect of a product, if a prespecified budget ceiling for public pharmaceutical expenditures is exceeded.

1.107“Pharmacovigilance Agreement” has the meaning set forth in Section 5.4.

1.108“Phase 1 Clinical Trial” means a human clinical trial of a pharmaceutical product that satisfies the requirements for a Phase 1 study as defined in 21 CFR § 312.21(a) (or any amended or successor regulations), regardless of where such clinical trial is conducted.

1.109“Phase 2 Clinical Trial” means a human clinical trial of a pharmaceutical product that satisfies the requirements for a Phase 2 study as defined in 21 CFR § 312.21(b) (or any amended or successor regulations), regardless of where such clinical trial is conducted.

1.110“Phase 3 Clinical Trial” means a human clinical trial of a pharmaceutical product for an indication on a sufficient number of subject that is designed to establish that the pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with the pharmaceutical product in the dosage range to be described, and to support Regulatory Authority to market such Product in patients having the indication being studied and that satisfies the requirements for a Phase 3 study as defined in 21 CFR § 312.21(c) (or any amended or successor regulations), regardless of where such clinical trial is conducted.

1.111“Phase 4 Clinical Trial” means a product support clinical trial of a Product that is commenced after receipt of MAA Approval in the country where such trial is conducted. Phase 4 Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and post-marketing surveillance trials. 

1.112“PIP Compliance Check” means that PIP has been checked by EMA for compliance with all the measures mentioned in the PIP decision, including the timelines for the conduct of the studies or collection of the data.

1.113“Pricing and Reimbursement Approval” means, with respect to a Product, the approval, agreement, determination, or decision of any applicable Governmental Authority establishing the price or reimbursement level for such Product, as required in a given country or jurisdiction prior to sale of such Product in such country or jurisdiction.

13

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.114“Product” means any pharmaceutical product containing the Compound as an active ingredient, alone or in combination with one or more other active pharmaceutical ingredients, in any form, presentation, dosage, or formulation, and for any mode of administration.

1.115“Product Infringement” has the meaning set forth in Section 10.3(a).

1.116“Promotional Materials” has the meaning set forth in Section 6.4(c).

1.117“Proposal” has the meaning set forth in Section 4.3.

1.118“Proposing Party” has the meaning set forth in Section 4.3. 

1.119“Public Official or Entity” means (a) any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality, or subdivision of any government, military, or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b) any candidate for political office, any political party, or any official of a political party. 

1.120“Rare Disease” means a disease that affects one person per two thousand (2,000).

1.121“Recall” has the meaning set forth in Section 5.7.

1.122“Regulatory Approval” means, with respect to a country or jurisdiction, any and all approvals (including MAA Approval and, if required by Applicable Law, Pricing and Reimbursement Approval), licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of a Product in such country or jurisdiction.

1.123“Regulatory Authority” means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of pharmaceutical products in a given jurisdiction.  For countries where Pricing and Reimbursement Approval is required, Regulatory Authority shall also include any Governmental Authority whose grant of Pricing and Reimbursement Approval of the Product is required.  

1.124“Regulatory Filing” means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, manufacture, or Commercialization of any Product made to or received from any Regulatory Authority in a given country, including INDs and MAAs.

1.125“Regulatory Meeting” has the meaning set forth in Section 5.1(c)(ii).

1.126“Regulatory Milestone Event” has the meaning set forth in Section 8.3(a).

14

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.127“Rocket Trial” means the Phase 2 Clinical Trial of the Product for Fragile X Syndrome ongoing as of the Effective Date and for which Ovid is the sponsor, as further described in Exhibit J. 

1.128“Safety Data” means Data related solely to any adverse drug experiences and serious adverse drug experience as such information is reportable to Regulatory Authorities.  Safety Data also includes “adverse events”, “adverse drug reactions”, and “unexpected adverse drug reactions” as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.

1.129“SEC” means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent, as applicable.

1.130“Safety Reason” has the meaning set forth in Section 4.15.

1.131“Sales Milestone Event” has the meaning set forth in Section 8.4(a).

1.132“Scientific Advice” means any report of the advice provided by EMA to medicine developers on the most appropriate way to generate robust evidence on a medicine’s benefits and risks.

1.133“Second Indication” means Fragile X syndrome (FXS).

1.134“Second Indication Opt-In” means the election by Licensee, following the Licensee’s exercise of the Second Indication Opt-Out, to resume the Licensee’s rights granted to Licensee according to Section 2.1 with respect to the Second Indication.

1.135“Second Indication Opt-Out” means the election by Licensee, in accordance with the terms hereof, not to participate in Development and/or Commercialization activities for the Product for the Second Indication.

1.136“Segregate” means, with respect to a Competing Product, to [***] segregate the Development, Manufacturing and Commercialization of such Competing Product in the Field from Development, Manufacture and Commercialization activities with respect to Compounds and Products under this Agreement, including [***]; provided that, [***]. 

1.137“Sponsor” means the Party that takes the ultimate responsibility for the initiation, performance, and management of, including financing or arranging the financing for, the applicable Clinical Trial.

1.138“Sublicensee” means a Third Party to whom Licensee grants a sublicense to Develop, use, import, promote, offer for sale, or sell any Product in the Field in the Licensee Territory.  In no event shall Ovid or any of its Affiliates be deemed a Sublicensee. 

1.139“Success Fee” or “Performance Based Payments” means the returned part of the Product-generated revenues for those cases where outcomes are not meeting pre-defined clinical goals set by National Health Authority (e.g.QoL Gain, Survival, Progression, Course of Disease Modification).

15

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

1.140“Sunshine Reporting Laws” has the meaning set forth in Section 5.8.

1.141“Supply Agreement” means the supply agreement between Ovid and Licensee attached hereto as Exhibit K.

1.142“Take the Lead” means, with the respect to a particular Party and a particular activity, that such Party is primarily responsible for, and has the authority to make, all day-to-day operational decisions, in accordance with the Development Plan and Commercialization Plan and the terms of this Agreement; provided that [***]; and provided further that [***].  For clarity, [***]. 

1.143“Technology Transfer Completion Date” means the earlier of (a) the date on which the activities [***], as set forth in the Technology Transfer Plan, has been completed, but for clarity, excluding [***] and (b) the [***].

1.144“Technology Transfer Agreement” has the meaning set forth in Section 11.4(e).

1.145“Technology Transfer Plan” has the meaning set forth in Section 11.4(e).

1.146“Term” has the meaning set forth in Section 14.1. 

1.147“Third Party” means any entity other than Ovid or Licensee or an Affiliate of Ovid or Licensee.

1.148“Threshold Price Sale” means, on a Product-by-Product and country-by-country basis, the first sale of such Product in such country (after Regulatory Approval for such Product has been obtained in such country) for which Licensee or its Affiliate or Sublicensee, as applicable, invoices a Third Party (a) [***], or (b) [***]. 

1.149“Total Supply Price” means, for any Product, [***]. 

1.150“U.S.” means the United States of America, including its territories and possessions (including Puerto Rico).

1.151“Valid Claim” means (a) a claim of an issued and unexpired patent that has not been revoked or held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination, or disclaimer or otherwise, or (b) a claim of a pending patent application that has not been cancelled, withdrawn, or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. 

	
2.
	
Grant of Licenses

2.1Licenses Granted to Licensee.  Subject to the terms and conditions of this Agreement, Ovid hereby grants to Licensee, during the Term:

16

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(a)an exclusive (even as to Ovid, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses (through multiple tiers) solely as provided in Section 2.2, under the Ovid Technology to use and have used, sell, offer for sale, import, and otherwise Commercialize and have Commercialized (but not to make or have made, unless otherwise provided herein) the Products in the Field in the Licensee Territory; 

(b)a non-exclusive license, with the right to grant sublicenses (through multiple tiers) solely as provided in Section 2.2, under the Ovid Technology to Develop (but not to make or have made unless otherwise provided herein) the Products on a worldwide basis in accordance with the Development Plan, and to use the Products for that purpose; and 

(c)a non-exclusive, royalty-bearing license, with the right to grant sublicenses (through multiple tiers) solely as provided in Section 2.2, under the Ovid Technology to make or have made the Products solely for use in the Field in the Licensee Territory in accordance with the licenses granted in Sections 2.1(a) and 2.1(b), provided that, for clarity, Licensee’s rights under any Patents and Know-How Controlled by Lundbeck that are included within the Ovid Technology shall be subject to the completion of the Technology Transfer and the terms of the Lundbeck License Agreement; and

(d)solely as and to the extent provided in Section 14.5, an exclusive (even as to Ovid, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses (through multiple tiers) solely as provided in Section 2.2, under the Ovid Technology to Develop, have developed, use and have used, sell, offer for sale, import, and otherwise Commercialize and have Commercialized the Products in the Field in the Licensee Territory.

2.2Sublicenses.  Licensee shall have the right to grant sublicenses under the licenses granted in Section 2.1: 

(a)to an Affiliate of Licensee without Ovid’s express prior written consent but with written notice to Ovid, provided that such sublicense will terminate if such sublicensee no longer qualifies as an Affiliate of Licensee.

(b)to a Third Party other than as set forth in Section 2.2(a) with Ovid’s express prior written consent (not to be unreasonably withheld, conditioned or delayed).

All sublicenses granted under the licenses granted in Section 2.1 shall be in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement and shall provide that any such Sublicensee (including any distributor) shall not further sublicense except with the written consent of Licensee and Ovid.  Licensee shall ensure that each agreement with a Sublicensee grants Ovid all rights with respect to Data, Inventions, and Regulatory Filings made or generated by such Sublicensee as if such Data, Inventions, and Regulatory Filings were made or generated by Licensee. Licensee shall be responsible for the compliance of its Affiliates, Sublicensees (including any distributors), and subcontractors with the terms and conditions of this Agreement.  Licensee shall provide written notice to Ovid of each sublicense granted to a Third Party hereunder, specifying the name of the Sublicensee, the territory, and the duration of the sublicense.

17

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

2.3Reserved Rights.  Ovid hereby expressly reserves:

(a)the right under the Ovid Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more licensees or subcontractors; and 

(b)all rights to practice, and to grant licenses under, the Ovid Technology outside of the scope of the licenses granted in Section 2.1. 

2.4Licenses Granted to Ovid.  Subject to the terms and conditions of this Agreement, including Section 2.8, Licensee hereby grants to Ovid:

(a)a non-exclusive, royalty-free, fully paid-up license, with the right to sublicense (through multiple tiers), under the Licensee Technology to use, sell, offer for sale, import, and otherwise Commercialize the Products in the Ovid Territory; and 

(b)a non-exclusive, worldwide, royalty-free, fully paid-up license, with the right to sublicense (through multiple tiers), under the Licensee Technology to (i) Develop the Compound and Products on a worldwide basis under the Development Plan, and (ii) to make and have made the Compound and Products anywhere in the world. 

2.5No Implied Licenses; Negative Covenant.  Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.  Neither Party shall, nor shall it permit any of its Affiliates or (sub)licensees to, practice any Patents or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.

2.6Disclosure of Know-How.  For as long as the Parties are conducting Development activities under the Development Plan, upon Licensee’s written request no more frequently than [***], Ovid shall disclose and make available to Licensee, in electronic form where possible, all Ovid Know-How that comes into existence after the Effective Date and that was not previously provided to Licensee, promptly after the earlier of the development, making, conception, or reduction to practice of such Ovid Know-How.  For as long as the Parties are conducting Development activities under the Development Plan, upon Ovid’s written request no more frequently than [***], Licensee shall, and shall cause its Affiliates to, disclose and make available to Ovid, in electronic form where possible, any Licensee Know-How not previously provided to Ovid, promptly after the earlier of the development, making, conception, or reduction to practice of such Licensee Know-How.  The CGB shall establish a mechanism for the reciprocal disclosure of such Know-How. 

2.7Third Party Licenses.  

(a)Notice. Licensee shall promptly notify Ovid if it becomes aware of any Third Party Know-How or Patent that is necessary or reasonably useful to Develop, make, have made, use, sell, offer for sale, or import the Compound or Product in the Field in the Licensee Territory, and [***].

18

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(b)Sublicense under Third Party License.  If Ovid enters into any agreement with a Third Party after the Effective Date that includes a license from such Third Party to Ovid under any Know-How or Patents that are necessary to Develop, use, sell, offer for sale, or import the Products in the Field in the Licensee Territory, and Ovid has the right to grant a sublicense under such Know-How or Patents to Licensee, then Ovid shall notify Licensee and identify the relevant Know-How or Patents and provide Licensee with the substantive terms of the applicable Third Party license agreement to Licensee, in each case to the extent applicable to the rights that would be sublicensed to Licensee.  Such Know-How and Patents, to the extent falling within the definition of Ovid Technology, will be sublicensed to Licensee only if Licensee provides Ovid with written notice in which (i) Licensee consents to adding such Patents and Know-How to the definition of Ovid Technology and (ii) Licensee acknowledges in writing that its sublicense under such license agreement is subject to the terms and conditions of such license agreement. 

(c)Licensee Restriction.  Except with the prior written consent of Ovid, Licensee shall not obtain a license to any Third Party Patent or Know-How that is necessary to Develop, make, have made, use, sell, offer for sale, or import the Products in the Ovid Territory.

2.8Exclusivity.

(a)Exclusivity.  Subject to Section 2.8(c), for the period starting from the Effective Date and for [***] in the Licensee Territory, neither Party shall, directly or indirectly (including through an Affiliate or a Third Party), develop or commercialize any Competing Product that is directed to the treatment of the Initial Indication or Second Indication in the Licensee Territory. 

(b)Competing Program Exclusivity.  If a Third Party becomes an assignee of this Agreement from a Party, or becomes an Affiliate of a Party after the Effective Date through merger, acquisition, consolidation, or other similar transaction, and such Third Party, as of the closing date of such transaction, is engaged in the development or commercialization of a Competing Product in the Licensee Territory (a “Competing Program”), then such Competing Program shall not be a breach of Section 2.8(a), so long as (i) such Third Party, or such Party or its Affiliates, [***], and (ii) [***] such Competing Product.  [***] of such Competing Program.  

(c)Territory Exclusivity.  During the Term, Licensee shall not, directly or indirectly (including through an Affiliate or a Third Party), Commercialize the Product in the Ovid Territory. Ovid shall not, directly or indirectly (including through an Affiliate or a Third Party), Commercialize the Product in the Licensee Territory, except as provided in Section 2.3(a).

(d)Effect of Triggering Acquisition. In the event of an acquisition of Ovid by a Competing Acquirer that closes prior to [***] (a “Triggering Acquisition”), then Ovid shall provide notice to Licensee of such Triggering Acquisition within [***] after the date upon which the Triggering Acquisition closes or otherwise becomes effective. On or before the date that is [***] after the date on which Licensee receives notice of a Triggering Acquisition, Licensee shall have the right to elect to Take the Lead on any or all then current Joint Development Activities and future Licensee activities in the Licensee Territory, [***] remaining in full force and effect. For sake of clarity, [***]. 

19

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

2.9Licensee’s access to Ovid Data, Know-How and Patents

(a)Ovid hereby agrees to provide to Licensee, within [***] following the Effective Date, a list of (a) [***] the Ovid Know-How [***] and (b) [[***] the Compound and/or Product necessary for Licensee’s Development, use, manufacture, and Commercialization of the Product in the Field in the Licensee Territory, [***].

(b)Promptly following the Effective Date, Ovid shall transfer to Licensee information in its possession and control that relate to [***].

(c)From time to time during the Term, and at no additional cost to Licensee (subject to Section 4.5), Ovid shall provide to Licensee [***] the Ovid Know-How solely relating to the Compound and/or the Product, reasonably requested by Licensee and necessary for Licensee’s Development, use, manufacture, and Commercialization of the Product.

(d)Ovid hereby agrees that, [***] following the Effective Date, Ovid will provide to Licensee the Ovid Know-How [***] for Licensee to Develop, manufacture, use, and Commercialize the Compound and the Product in  the Field in the Licensee Territory in accordance with the terms of this Agreement. Licensee shall reimburse Ovid all out of pocket costs and reasonable, internal cost related to such technology transfer. 

2.10Licensee’s Access to Ovid Personnel.  The Parties acknowledge the significant contribution and experience of Ovid and Ovid employees to the Development, manufacture, use, and Commercialization of the Compound and Product prior the Effective Date and that these contributions and experience may be valuable to Licensee. Accordingly, Licensee is entitled to meet with employees of Ovid who hold significant experience or expertise in the Development activities, and manufacture, use, and Commercialization of the Compound and Product. Licensee shall provide reasonable notice to Ovid requesting such a meeting and Ovid’s approval of date and agenda of meeting shall not be unreasonably withheld. Each Party shall bear its own cost in relation to such meetings.

	
3.
	
Governance

3.1Collaboration Governance Board.  As of the Effective Date, the Parties have established a board to govern their collaboration under this Agreement (the “Collaboration Governance Board” or the “CGB”), composed of an equal number of up to [***] employees of each Party, to oversee and guide the strategic direction of the collaboration of the Parties under this Agreement.  The CGB shall act as a joint consultative body and, to the extent expressly provided herein, a joint decision-making body.  The CGB shall in particular: 

(a)review and discuss the strategy for the Development of the Product worldwide, coordinate and oversee the overall implementation of the Development Plan; 

(b)provide a forum for discussion of the Development and Commercialization of the Compound and Products in the Licensee Territory; 

20

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(c)monitor performance of Development activities in and for the Licensee Territory, including performance against agreed budgets, and discuss and approve any budget overruns;

(d)oversee the activities of the JPT, and serve as a forum for resolution of disputes arising at the JPT; 

(e)review and discuss any proposed amendments to the Development Plan, including corresponding budgets, and approve any proposed amendments to Joint Development Activities under the Development Plan;

(f)review, discuss, and approve Clinical Trial protocols for jointly-conducted Clinical Trials, and monitor the progress of all Clinical Trials in the Licensee Territory;

(g)review Clinical Trial Data from jointly-conducted Clinical Trials to determine whether progress to the next phase Clinical Trial is merited;

(h)review, discuss, and approve Proposals, including amendments to the Development Plan with respect to activities directed to Additional Indications; 

(i)monitor and coordinate regulatory strategy and activities for the Licensee Territory, including activities directed to obtaining Regulatory Approval in Additional Indications;

(j)coordinating reporting of pharmacovigilance and safety matters for the Product worldwide (monitoring and coordinating of pharmacovigilance and safety matters will conducted in accordance with the pharmacovigilance agreement); 

(k)oversee and coordinate Medical Affairs Activities for the Product in all Indications in the Licensee Territory; 

(l)review and discuss the Commercialization Plan for the Licensee Territory, including any amendments proposed thereto, and oversee the Commercialization of Products in the Licensee Territory in accordance with the global commercialization strategy for Products;

(m)provide a forum for discussion regarding launch sequencing, pricing and reimbursement strategy for Products in the Licensee Territory and discuss potential international pricing reference by relevant Regulatory Authorities;

(n)oversee the manufacturing and supply strategy and monitor supply of Products for the Licensee Territory;     

(o)oversee and facilitate the Parties’ communications and activities with respect to publications under Section 13.4;

(p)establish joint subcommittees as it deems necessary or advisable to further the purpose of this Agreement, including as set forth in Section 3.7; and 

21

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(q)perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or allocated to it by the Parties’ written agreement, including providing financial oversight of the activities conducted pursuant to this Agreement.

3.2Joint Project Team.  No later than [***] following the Effective Date, the Parties will establish a cross-functional joint project team (the “JPT”), composed of an equal number of up to [***] employees of each Party, to (a) design and implement the Development Plan (subject to CGB review and approval), and (b) oversee the commercial strategy and Commercialization of the Products in the Licensee Territory.  The JPT shall in particular:

(a)oversee the conduct of activities under the Development Plan in the Licensee Territory and report to the CGB on such activities;

(b)provide a forum for, and facilitate communications between the Parties with respect to the Development of Products in the Licensee Territory, including sharing of Data in accordance with Section 4.7;

(c)prepare and submit to the CGB for approval protocols for jointly-conducted Clinical Trials;

(d)prepare amendments to the Development Plan as needed (including corresponding changes to the Development Budget) and submit such amendments to the CGB for approval; 

(e)review and discuss Proposals and make recommendations to the CGB with respect thereto; 

(f)review and discuss the CMC components of the Regulatory Filings in the Licensee Territory, and oversee and coordinate the manufacture and supply of Drug Product to Licensee for use in Clinical Trials for which Licensee is the Sponsor in the Licensee Territory;

(g)prepare and submit to the CGB for approval a plan for manufacture and supply of Drug Product for commercialization in the Licensee Territory; 

(h)review the Commercialization Plan prepared by Licensee for alignment with the global commercialization strategy for Products, and provide comments thereto;

(i)monitor the conduct of Commercialization of Products in the Licensee Territory; and 

(j)perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Development of Products.

3.3Committee Membership and Meetings.

(a)Committee Members.  Each Committee representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make 

22

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

decisions arising within the scope of such Committee’s responsibilities.  Each Party may replace its representatives on a Committee on written notice to the other Party.  The CGB chairperson shall be one of the representatives appointed by Ovid.  The chairperson of the JPT shall alternate between one of the representatives appointed by Ovid and one of the representatives appointed by Licensee.  The chairperson shall prepare and circulate agendas to Committee members at least [***] before each Committee meeting and shall direct the preparation of reasonably detailed notes for each such Committee meeting, which shall be approved by the chairperson and circulated to Committee members within [***] after such meeting.  If not determined as of the Effective Date, the Parties shall determine their respective initial members of each Committee promptly following the Effective Date. 

(b)Meetings.  Each Committee shall hold meetings at such times as it elects to do so, but in no event shall meetings of the JPT be held less frequently than [***], and meetings of the CGB once every [***].  The first CGB meeting and first JPT meeting shall be held within [***] after the Effective Date.  Committee meetings may be held in person or by audio or video teleconference.  In-person Committee meetings shall be held at locations alternately selected by the Parties.  Each Party shall be responsible for all of its own expenses of participating in any Committee meeting.  No action taken at any Committee meeting shall be effective unless at least one (1) representative of each Party is participating.  In addition, upon written notice to the other Party, either Party may request that a special ad hoc meeting of a Committee be convened for the purpose of resolving any disputes in connection with, or for the purpose of reviewing or making a decision pertaining to any material subject-matter within the scope of such Committee, the review or resolution of which cannot be reasonably postponed until the following scheduled Committee meeting.  Such ad hoc meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than [***] following the notification date of request that such meeting be held.    

(c)Non-Member Attendance.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend Committee meetings in a non‐voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party’s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.  Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.

3.4Decision-Making.  

(a)All decisions of a Committee shall be made by unanimous vote, with each Party’s representatives collectively having one (1) vote.  If after reasonable discussion and good faith consideration of each Party’s view on a particular matter, the representatives of the Parties cannot reach an agreement as to such matter within [***] after such matter was first considered, then if such disagreement arose within the JPT, it shall be referred to the CGB for resolution.  If the CGB cannot resolve such matter within a further [***], or if the disagreement first arose within the CGB, then prior to any formal dispute resolution process such issue shall be referred to the Executive Officers for resolution.  

23

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(b)If the Executive Officers cannot resolve such matter within [***] after such matter has been referred to them, then: 

(i)Ovid shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to (A) Ovid’s Independent Development Activities, (B) the Ovid Ongoing Trials, (C) all manufacturing matters outside the Licensee Territory, and (D) Joint Development Activities necessary for obtaining Regulatory Approvals for Products in any Indication in the Licensee Territory for which Ovid is the sponsor (including any necessary updates to the Development Plan and Development Budget pursuant to Section 4.2, but subject in all cases to Sections 3.4(b)(i)(1) and 3.4(b)(i)(2)), except for:

(1) the addition of new Clinical Trials to the Development Plan as Joint Development Activities (the cost of which would be shared by the Parties); and

(2)any material modification to a previously agreed upon Clinical Trial that is set forth in the Development Plan as Joint Development Activities (unless such modification is required by a Regulatory Authority or any local or regional IRB/ethics committee, or is reasonably necessary to protect patient safety); for the purpose of this Section 3.4(b)(i)(2), “material modification” means [***].

(ii)Licensee shall have the final decision making authority with respect to (A) Joint Development Activities necessary for obtaining Regulatory Approvals for Products in any Indication in the Licensee Territory for which Licensee is the sponsor (including any necessary updates to the Development Plan and Development Budget pursuant to Section 4.2, but subject in all cases to Sections 3.4(b)(i)(1) and 3.4(b)(i)(2)), (B) the determination of whether the Additional Pivotal Trial is necessary to obtain Regulatory Approval in the Licensee Territory (although [***] for the Additional Pivotal Trial) (C) Commercialization of the Product in the Licensee Territory, (D) Licensee Territory Development Activities and (E) Licensee’s Independent Development Activities in the Licensee Territory, and (F) Phase 4 Clinical Trials for the Licensee Territory (but subject in all cases to Sections 3.4(b)(i)(1) and 3.4(b)(i)(2)), in each case (A) through (F) provided that Licensee’s exercise of any such decision right does not adversely affect, the Development, manufacture, or Commercialization of the Product in the Ovid Territory, and complies with the terms and conditions of this Agreement.  For clarity, [***].

(iii)Neither Party shall have the final decision making authority with respect to the matters in Sections 3.4(b)(i)(1) and (2), and the status quo shall persist with respect to such matter unless and until the Parties are able to agree. 

3.5Limitations on Authority.  Each Committee shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, no Committee will have the power to amend this Agreement, and no Committee decision may be in contravention of any terms and conditions of this Agreement.

24

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

3.6Discontinuation of the Committees. The activities to be performed by each Committee shall solely relate to governance under this Agreement and are not intended to be or involve the delivery of services.  Each Committee shall continue to exist until the first to occur of (a) the Parties mutually agree to disband such Committee or (b) Ovid provides written notice to Licensee of its intention to disband and no longer participate in such Committee. Once the Parties mutually agree or Ovid has provided written notice to disband a Committee, such Committee shall have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under this Agreement or such exchange of information shall be made through Alliance Managers, and decisions of such Committee shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.  [***]. 

3.7Alliance Managers. Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the “Alliance Manager”).  Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Term.  The Alliance Manager will ensure communication to the CGB of all relevant matters raised at the JPT and any other subcommittee.  Each Alliance Manager shall be permitted to attend meetings of the CGB and JPT, in each case as appropriate and as non-voting participants.  The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder.  Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.  Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.  Each Party shall bear its own costs of its Alliance Manager, which costs shall be excluded from the Parties’ respective Development and manufacturing costs (including Cost of Goods) under this Agreement.

3.8Supply Contacts.  Each Party shall designate one (1) qualified and experienced supply chain professional to serve as that Party’s primary supply contact regarding the supply of Drug Product under this Agreement (“Supply Contacts”).  Each Party may replace its Supply Contact with an alternative representative at any time with prior written notice to the other Party.  The Supply Contacts shall be responsible for facilitating information exchange and discussion between the Parties regarding the supply of Drug Product under this Agreement.  The Supply Contacts shall have decision-making authority with respect to the supply of Drug Product under this Agreement within the guidance of the JPT and subject to the review and approval of the CGB.  Each Party shall bear its own costs of its Supply Contact, which costs shall be excluded from the Parties’ respective Development and manufacturing costs (including Cost of Goods) under this Agreement.

	
4.
	
Development

4.1Overview.  Subject to the terms and conditions of this Agreement, the Parties will collaborate with respect to the Development of the Compound and Products and share the Data resulting from such collaboration as provided in this Article 4 to facilitate the Development of the Compound and Products throughout the Licensee Territory and the Ovid Territory. 

25

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

4.2Amendments to Development Plan. Any amendment to the Development Plan for the Compound and Products under this Agreement, including the Ovid Ongoing Trials, Licensee Territory Development Activities for registrational purposes, all Joint Development Activities, and all Independent Development Activities shall be conducted pursuant to a comprehensive written updated (from time to time) Development Plan (the “Amended Development Plan”), which shall be incorporated by reference into this Agreement.  The Amended Development Plan will include Clinical Trials for the Initial Indications that the Parties have agreed to conduct jointly (unless modification is required by a Regulatory Authority or any local or regional IRB/ethics committee, or is reasonably necessary to protect patient safety), the Clinical Trials for the Second Indication that Ovid may conduct under its sole responsibility and cost if Licensee exercises the Second Indication Opt-Out and not the Second Indication Opt-In, as well as Clinical Trials for the Additional Indications that the Parties (through the CGB) mutually agree to conduct and include in accordance with Section 4.3. The Amended Development Plan will also include:

	
 
	
(1)
	
any other Development activities approved by the CGB in accordance with Article 3; and

	
 
	
(2)
	
the PIP for the Initial Indication; and

	
 
	
(3)
	
the Additional Pivotal Trial, if applicable. 

The Amended Development Plan shall also set forth the amendments to the detailed budget of the anticipated costs for all Development activities (the “Amended Development Budget”) on a study-by-study or Clinical Trial-by-Clinical Trial basis.  As of the Effective Date, the Parties have agreed upon an initial Development Plan and Development Budget, attached to this Agreement as Exhibit C.  If the terms of the Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. In addition, the following shall apply to the Development of the Compound and Products under the Development Plan:

(a)Neptune Trial, Rocket Trial and Elara Trial.  Ovid shall be responsible for, and shall use Commercially Reasonable Efforts to conduct, at its own expense, (i) the Neptune Trial, (ii) the Rocket Trial, and (iii) the Elara Trial ((i)-(iii) collectively, the “Ovid Ongoing Trials”).

(b)PIP. Ovid shall be responsible for the full applying process to obtain EMA agreement for the Paediatric Investigational Plan in order to allow the Licensee to submit the MAA for the Product for the Initial Indication in the Licensee Territory. Ovid shall discuss and agree with the Licensee the PIP before moving forward with the application process.

(c)Licensee Territory Development Activities for Initial Indication.  

(i)Licensee shall be solely responsible for and shall use Angelini Commercially Reasonable Efforts to conduct, at its sole expense, all Development activities that are exclusively for the benefit of one or more countries within the Licensee Territory for the Initial Indication, including (A) any and all Development activities required or recommended by a 

26

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Regulatory Authority for the exclusive benefit of the Licensee Territory, including any Phase 4 Clinical Trials for the Initial Indication in the Licensee Territory, and (B) any and all Development activities required for any Pricing and Reimbursement Approval in the Licensee Territory. 

(ii) Licensee shall be solely responsible for the Additional Pivotal Trial, and for the Phase 4 Clinical Trials of the Product in the Licensee Territory, but Licensee shall bear [***] and Ovid shall bear [***] of the Development Costs for the Development Activities for the Additional Pivotal Trial, up to a total amount of [***], and for any Additional Pivotal Trial Development Costs in excess of [***] Licensee shall bear [***] and Ovid shall bear [***].

(iii)The activities specified in the foregoing subsections (i) and (ii) shall be referred to collectively as the “Licensee Territory Development Activities”.  Prior to commencing any Licensee Territory Development Activities, Licensee shall provide the CGB with a draft workplan therefor, and following review and approval of such Licensee Territory Development activities by the CGB, such Licensee Territory Development Activities shall be included in and conducted in accordance with the Development Plan, subject to the oversight of the CGB and JPT as set forth in Article 3.  Notwithstanding anything to the contrary herein, Licensee shall consider in good faith and incorporate Ovid’s reasonable comments on any proposed Licensee Territory Development Activities. 

(d)Joint Development Activities for Initial Indication and Second Indication. The Development Plan shall set forth the timeline and details ([***]) of all preclinical (if any) and clinical Development activities ([***]) to be conducted jointly by the Parties in order to generate Data sufficient to meet the common requirements of the FDA, EMA, and other Regulatory Authorities agreed upon by the Parties for MAA Approval of the Compound and Products for each of the Initial Indication and eventually and separately for the Second Indication, ([***]) (such activities, the “Joint Development Activities”).  All Joint Development Activities shall be included in and conducted in accordance with the Development Plan, subject to the oversight of the CGB and JPT as set forth in Article 3. The Development Plan shall also set forth the allocation of responsibility for all Joint Development Activities as between the Parties.  All Development Costs Associated with Joint Development Activities shall be borne in accordance with Section 8.2(a).  

(e)Second Indication Opt-Out and Second Indication Opt-In.  

(i)Second Indication Opt-Out. If Licensee determines, at its sole and absolute discretion, within [***], not to pursue further additional Development activities with respect to the Second Indication, Licensee shall have the right to exercise the Second Indication Opt-Out, exercisable by written notice to Ovid. The Second Indication Opt-Out shall be effective as of the date of such notice. If Licensee exercises the Second Indication Opt-Out, then the definition of Field shall automatically be deemed to not include the Second Indication, provided that if Ovid undertakes to submit an MAA for the Product for the Second Indication in the Licensee Territory it shall do so with a trademark other than the Trademark for the Initial Indication. 

(ii)Second Indication Opt-In. In any case, after Licensee has made the Second Indication Opt-Out, Licensee will have the right, at any time as below and for any reason, to exercise the Second Indication Opt-In, exercisable by written notice to Ovid [***]. The Second 

27

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Indication Opt-In shall be effective as of the date of such notice.  If Licensee makes the Second Indication Opt-In, then Licensee shall reimburse to Ovid an amount equal to [***] of all Development Costs incurred by Ovid in the conduct of Development activities for the Second Indication during the period of Licensee’s Second Indication Opt-Out, and [***] of all Development Costs incurred for such Development activities following the Second Indication Opt-In. Then the definition of Field shall automatically be deemed to include the Second Indication

(f)Regulatory Filings.  The Development Plan shall include a coordinated Development and regulatory strategy, including the Parties’ respective roles in the development of the registration dossier and Regulatory Filings for the Products, and the countries in which Clinical Trials of the Products will occur.  All costs associated with regulatory activities in connection with Regulatory Filings and obtaining MAA Approval for Products in the Licensee Territory shall be borne solely by Licensee. 

(g)Updates. During the Term (at least on a [***] basis), the JPT shall review the Development Plan and prepare updates and amendments, as appropriate, to the then-current Development Plan, including budgets, and submit such updates and amendments to the CGB for review and approval.  If the CGB determines that any pre-clinical studies or Clinical Trials not included in the Development Plan are required in order to obtain or maintain MAA Approval for a Product for the Initial Indication in one or more countries in the Licensee Territory, then the CGB shall review and approve an amendment to the Development Plan reflecting such additional studies, including associated budget.  Such additional Development activities for the Initial Indication shall be either Licensee Territory Development Activities or Joint Development Activities and the costs of such additional studies shall be borne by the Parties as provided in Section 4.5(a).

4.3Additional Indications.  

(a)Proposal.  If either Party (the “Proposing Party”) desires to pursue additional Development of a Product in order to seek Regulatory Approval of the Product in one or more Additional Indications for the benefit of (a) the Ovid Territory and Licensee Territory in the case of Ovid, or (b) the Licensee Territory in the case of Licensee, in each case beyond what is set forth in the then-current Development Plan, then such Party shall provide the other Party (the “Reviewing Party”) with a written detailed plan and budget for such additional work (the “Proposal”).  Within [***] after the Reviewing Party’s receipt of the Proposal (or at such other time as the Parties may mutually agree), the JPT shall meet to review and discuss in good faith the Proposal and permit the Reviewing Party an opportunity to ask questions and request additional information from the Proposing Party related to the Proposal, including whether such Proposal is reasonably likely to have any adverse effect on the Development or Commercialization of the Product in the Reviewing Party’s territory.  No work under any Proposal shall proceed unless and until (i) the CGB determines in its reasonable discretion that such Proposal is not likely to adversely affect the Development or Commercialization of the Product in the Reviewing Party’s territory, and (ii) in the case of Licensee as the Proposing Party, Ovid consents in writing to such activities being included as Joint Development Activities, or to Licensee performing such additional Development as Licensee Territory Development Activities (where such Development Activities solely and specifically relate to the Licensee Territory), or as Independent Development Activities, such consent not to be unreasonably withheld.  For clarity, (i) Licensee’s final decision 

28

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

right under Section 3.4(b)(ii) shall not apply to Licensee Territory Development Activities proposed in connection of initiation of Development for any Additional Indication, but once Development Activities have been commenced in such Additional Indication in and for the Licensee Territory, any further Licensee Territory Development Activities proposed by Licensee in respect of such Additional Indication shall be subject to the process set forth in Section 4.2(b) and (ii) Ovid will not develop in the Licensee Territory any Product in additional indications other than Rare Diseases without Licensee’s prior written consent. Following each such determination and, if applicable, consent, the CGB shall incorporate such additional Development activities and the corresponding budget into the Development Plan (the “Additional Development Activities”).  

(b)Costs.  If the Parties jointly agree to conduct Additional Development Activities, such Additional Development Activities shall be included in the Development Plan and conducted as Joint Development Activities, subject to the allocation of responsibility for leading such activities set forth in Section 4.3(c), and the costs of such Joint Development Activities shall be shared as further set forth in Section 8.2(a).  Notwithstanding the foregoing, for Additional Development Activities that would otherwise be Joint Development Activities (if the Parties agreed to conduct such activities together), the Reviewing Party may elect, at its discretion, and by written notice delivered to the Proposing Party within [***] following the receipt of the Proposal, to opt out of funding its share of the Development Costs for such Additional Development Activities.  Upon such an election, such Additional Development Activities shall be deemed the “Independent Development Activities” of the Proposing Party and the Proposing Party may pursue such work subject to the remainder of this Section 4.3, and the Development Costs with respect thereto shall be Independent Development Costs subject to Section 8.2(b).  

(c)Conduct of Additional Development Activities.  In general, except as the Parties may agree in an amendment to the Development Plan, including to allocate specific activities to Licensee in the Licensee Territory, (i) Ovid shall be the lead Party responsible for conducting Additional Development Activities that relate to both the Ovid Territory and the Licensee Territory, provided that such activities shall be subject to the oversight of the CGB to the extent such activities impact the Licensee Territory, and (ii) Licensee shall be the lead Party responsible for conducting Additional Development Activities that relate to the Licensee Territory and not the Ovid Territory.  

(d)Independent Development Activities.  The CGB shall amend the Development Plan to include any Additional Development Activities in the Rare Diseases indications that are Independent Development Activities, and thereafter the Proposing Party may conduct such Independent Development Activities, provided that: (i) the Proposing Party shall have the right to make the final decision in the event of any dispute regarding the conduct of the Independent Development Activities, except to the extent that, where the Proposing Party is Licensee, Ovid reasonably believes that Licensee’s exercise of such right would adversely impact Ovid’s Development and Commercialization of Products outside the Licensee Territory, (ii) the Proposing Party shall have the right to make the final decision in the event of any dispute regarding the conduct of the Independent Development Activities, except to the extent that, where the Proposing Party is Ovid, Licensee reasonably believes that Ovid’s exercise of such right would adversely impact Licensee’s Development and Commercialization of Products in the Licensee Territory, (iii) to the extent applicable to the Licensee Territory, Independent Development Activities shall be conducted in accordance with the amended Development Plan, (iv) the 

29

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Proposing Party shall provide updates to the CGB with respect to such Independent Development Activities impacting the Licensee Territory at each regularly scheduled CGB meeting, and (v) neither Party shall conduct any Independent Development Activities in a manner that would have any adverse effect on the Development or Commercialization of the Product in either Party’s territory. The Investigator initiated trials (IIT) proposed to each Party for the Licensee Territory shall be discussed and agreed between the Parties before providing feedback to the proposing Investigator. The Party receiving the proposal will be responsible for the costs to support the IIT unless a different specific agreement is entered among the Parties. For sake of clarity, Independent Development Activities shall not include indications other than Rare Disease.

(e)Ovid’s Right to Develop.  Notwithstanding anything to the contrary herein, Ovid shall have the right to conduct any Development activities with respect to the Compound or Product in or relating to the Ovid Territory outside the scope of the Development Plan.  Such Development activities shall be at Ovid’s expense and Licensee shall have the right of reference to the Safety Data generated in such Development activities as necessary for regulatory purposes without any reimbursement obligation to Ovid.

4.4Annual Update to Development Budget.  The CGB shall review, discuss, and, with respect to Joint Development Activities, agree upon the subsequent year’s Development Budget on an annual basis no later than [***] of each year.  

4.5Development Costs. 

(a)Licensee Territory Development Costs.  Licensee shall be solely responsible for all Development Costs incurred in connection with Licensee Territory Development Activities, except as provided in Section 4.2(c)(ii) with respect to the Additional Pivotal Study.

(b)Joint Development Costs.  The Development Costs associated with all Joint Development Activities that are shared by the Parties in accordance with Section 8.2(a) shall include Allowable Increases. “Allowable Increases” means increased Development Costs resulting from [***]. 

(c)Independent Development Costs.  The Party conducting Independent Development Activities pursuant to Section 4.3 shall be solely responsible for all Independent Development Costs as provided in Section 8.2(b). 

4.6Development Responsibilities.  Ovid shall be responsible for, and shall use Ovid Commercially Reasonable Efforts in connection with, the conduct of the Ovid Ongoing Trials.  Licensee shall be responsible for the conduct of the Licensee Territory Development Activities, other than Additional Pivotal Study which shall be shared by the Parties as set forth in Section 4.2(c)(ii).  The Parties shall each be responsible for the conduct of the Joint Development Activities, and the allocation of such agreed responsibility therefore (including which Party shall be the Sponsor for each applicable Clinical Trial), shall be set forth in the Development Plan.  Each Party shall have the operational responsibility and be the Sponsor for its own Independent Development Activities.

30

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

4.7Data Exchange and Use.  

(a)General. With respect to all Joint Development Activities, Licensee Territory Development Activities, and Independent Development Activities (but subject to Section 4.7(c)), each Party shall promptly provide the other Party with [***].  The Parties shall cooperate [***] to facilitate the sharing of reports, Data, and other information on a routine basis.  

(b)Joint Development Activities Data.  Each Party shall have the right to use and reference, without additional consideration, any and all Data generated by or on behalf of the other Party (including by any Sublicensee) in the performance of Joint Development Activities for obtaining and maintaining Regulatory Approval for the Products and Commercializing the Products in its territory in accordance with the terms of this Agreement.  Notwithstanding the foregoing, should Licensee fail to obtain the foregoing use and reference rights from any Sublicensee, Licensee shall not have the right to grant use and access or other rights to such Sublicensee to any Data or other documentation provided to Licensee by Ovid pursuant to Section 4.7(a).  

(c)Independent and Licensee Territory Development Activities Data.  The Party receiving Data resulting from the other Party’s Independent Development Activities shall have the right to use such Data only to the extent reasonably necessary for the receiving Party to comply with its regulatory reporting and compliance obligations, including safety reporting obligations.  Licensee shall have the right to use such Data only to support its own Development, Regulatory Approval, or Commercialization of the Product in the Field in such Party’s territory for the Initial Indication unless Licensee reimburses Ovid for Licensee’s share of Development Costs pursuant to Section 8.2(b). Ovid shall have the right to use Data resulting from the Licensee Territory Development Activities as necessary for Ovid or its Affiliates or licensees (other than Licensee) to comply with its regulatory reporting and compliance obligations, including safety reporting obligations, and to support its own Development, Regulatory Approval, or Commercialization of the Product in the Ovid Territory.  

(d)Any data transfer between the Parties under this Agreement shall comply with the applicable data privacy laws of the EU and USA. 

4.8Diligence.  Each Party shall use its Commercially Reasonable Efforts to perform the Development activities assigned to such Party under and in accordance with the Development Plan and the Amended Development Plan. In addition, Licensee shall use Commercially Reasonable Efforts to perform any Independent Development Activities of Licensee, and Licensee Territory Development Activities and file MAAs and seek and maintain Regulatory Approval (including Pricing and Reimbursement Approval, as applicable) for the Products throughout the Licensee Territory.

4.9Compliance.  Each Party shall perform Development activities for the Compound and Products in and for the Licensee Territory in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.

31

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

4.10Development Records.  Each Party shall maintain complete, current, and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities.  Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.  Each Party shall document all non-clinical studies and Clinical Trials and/or Studies in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP).    

4.11Development Reports.  At each regularly scheduled JPT meeting, each Party shall provide the JPT with regular reports detailing its Development activities for the Products under this Agreement, and the results of such activities.  In addition, after the completion of any Clinical Trial or other study of the Products, the Party responsible for the conduct of such Clinical Trial or study shall promptly provide the other Party with a data package consisting of, at a minimum, [***], as well as any other Data specified in the Development Plan or otherwise agreed by the Parties.  The Parties shall discuss the status, progress, and results of each Party’s Development activities under this Agreement at such JPT meetings.

4.12Use of Subcontractors. Each Party may perform its Development activities under this Agreement through one or more subcontractors, provided that (a) such Party will remain responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself, (b) each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article 13, (c) each subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work to such Party (or, in the event such assignment is not feasible, a license to such intellectual property with the right to sublicense to such other Party), and (d) in the case of Licensee engaging any subcontractor to conduct significant activities under this Agreement (e.g., a contract research organization to manage a Clinical Trial), Licensee will be responsible for the selection of the subcontractor and will inform Ovid on the selection process including the criteria applied and shall first obtain Ovid’s written consent to such subcontractor, such consent not to be unreasonably withheld.  The Parties may also subcontract work on terms other than those set forth in this Section 4.12 with the prior approval of the CGB.

4.13Restrictions. During the Term, neither Party nor any of its Affiliates or Sublicensees shall, directly or through any Third Party, sponsor, conduct, cause to be conducted, otherwise assist in, supply any Product for use in connection with, or otherwise fund any research or Development of any Product in the Licensee Territory outside the scope of the Development Plan.  For clarity and without limiting the foregoing, if Licensee wishes to perform or sponsor any study or test on the Compound or Products, including any pre-clinical or non-clinical study, toxicology study, CMC-related study, or comparator study, Licensee shall first prepare and provide to Ovid for Ovid’s approval a Proposal detailing such study in accordance with Section 4.3. 

4.14Materials Transfer.  In order to facilitate the Development activities contemplated by this Agreement, either Party may provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively, “Materials”) for use by the other Party in furtherance of such Development activities.  Except as otherwise provided for under this Agreement, all such Materials delivered to the other Party will remain the sole property of the 

32

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

supplying Party, and will be used only in furtherance of the Development activities conducted in accordance with this Agreement, will not be used or delivered to or for the benefit of any Third Party, except to subcontractors, without the prior written consent of the supplying Party, and will be used in compliance with all Applicable Laws.  The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known.  Except as expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 

4.15Suspension and Termination for Safety Reasons. Each Party shall have the right, at any time, to request that the CGB meet promptly to discuss whether to suspend the continued Development and/or Commercialization of the Products in the Field in the Licensee Territory for a period of [***] (the “Suspension”), upon providing written notice to the other Party, if such Party reasonably determines in good faith that the Compound or any other Product caused or is likely to cause a safety issue (a “Safety Reason”).  If the CGB does not come to a consensus with regard to such Safety Reason during the Suspension, either Party may terminate the Agreement (with the understanding that the other Party shall have the continuing right to Develop and Commercialize the Product; provided, however, that if the other Party is Licensee and Licensee wishes to continue the Development and Commercialization of the Product, this Agreement shall remain in force and effect, but the provisions of Section 14.5 shall apply) with immediate effect, upon written notice to the other Party if: (i) the Executive Officers meet (in person or otherwise) within [***] to resolve the dispute in good faith; and (ii) such Executive Officers are unable to resolve the dispute.

	
5.
	
Regulatory Activities

5.1Regulatory Responsibilities.  

(a)General.  

(i)The Development Plan shall set forth the regulatory strategy for seeking Regulatory Approval for the Compound and Products by the appropriate Regulatory Authorities in the Licensee Territory and Ovid Territory.  Subject to the oversight of the CGB and except as otherwise set forth in the Development Plan and the remainder of this Section 5.1(a)(i), each Party shall be responsible for implementing such regulatory strategy in its territory.  The Development Plan shall also specify which Party shall apply for and hold Regulatory Filings in each country with respect to the conduct of Development activities, provided that (1) Ovid shall apply for and hold all Regulatory Filings and Regulatory Approvals for the Ovid Ongoing Trials and Ovid’s Independent Development Activities and (2) Licensee shall apply for and hold all Regulatory Filings for the Licensee Territory arising from the Licensee Territory Development Activities, Licensee’s Independent Development Activities, and Joint Development Activities.  Except as otherwise provided herein or in the Development Plan or required by Applicable Law, each Party shall (A) be responsible for the preparation and submission of any and all Product 

33

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

registrations and MAAs in its territory and (B) own and hold all such Regulatory Filings (including Regulatory Approvals).  For the avoidance of doubt, in no event shall Licensee submit any Regulatory Filing for the Product in the Ovid Territory.  

(ii)Each Party shall be responsible for the costs of all regulatory activities in its territory, except that any costs incurred by Ovid in connection with regulatory activities in the Licensee Territory pursuant to Ovid’s Independent Development Activities shall be Independent Development Costs of Ovid and subject to Section 8.2(b).  

(iii)Licensee acknowledges that Ovid may be required from time to time to communicate with Regulatory Authorities in the Licensee Territory as a result of Development and manufacturing activities in such territory. Ovid shall notify Licensee as soon as reasonably practicable of such communication with Regulatory Authorities in the Licensee Territory. 

(iv)Ovid will provide to Licensee [***].  Licensee shall have the right to use such information to [***] for the Product for the Initial Indication [***] under this Agreement. 

(v)Prior to [***], Ovid will not, without Licensee’s input, (A) withdraw the IND for the Product in the Licensee Territory for any reason other than a Safety Reason, (B) file an MAA for the Product in the Licensee Territory, or (C) finalize the PIP for the Initial Indication.  Prior to [***], Ovid shall notify Licensee of any scheduled meeting with a Regulatory Authority in the Licensee Territory that relates to the any of the Ovid Ongoing Trials and, to the extent permitted by Applicable Law and the relevant Regulatory Authority, shall permit a representative of Licensee to attend such meeting, at Licensee’s request and expense.  

(vi)Ovid will, upon Licensee’s reasonable request, cooperate with Licensee in [***] Product in the Initial Indication in the Licensee Territory.

(vii)Ovid shall [***] for the Compound [***].  Licensee shall have the right to perform a Scientific Advice with the applicable Regulatory Authorities in the Licensee Territory.

(b)Regulatory Filing Right of Reference.  Except as set forth in Section 5.1(c), Ovid shall grant and hereby grants to Licensee a right of reference and access to all Regulatory Approvals and Regulatory Filings Controlled by Ovid in the Licensee Territory for the Compound and Product, in each case to the extent necessary for Licensee to submit Regulatory Filings and obtain MAA Approvals for Products in the Initial Indication in the Licensee Territory.  For the purposes of this Agreement, “right of reference” means the “right of reference or use” as defined in 21 C.F.R. §314.3(b) and any equivalent regulation outside the U.S., as each may be amended. 

(c)Licensee Regulatory Information Sharing and Right of Reference.  

(i)Licensee shall promptly provide Ovid with copies of any Regulatory Filings prepared (including any drafts), submitted, or received by Licensee in the Licensee Territory pertaining to the Compound and Products, and Ovid shall have the right to comment on 

34

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

drafts of such Regulatory Filings.  Licensee shall share with Ovid the following communications/correspondence with any Regulatory Authority: (1) [***], (2) [***], and (3) [***] relating to the Compound or Product.  If any Regulatory Filing to be provided under this Section 5.1(c) was originally created in a language other than the English language, then Licensee shall provide an English translation along with the original document to Ovid.  Licensee shall use Commercially Reasonable Efforts to grant to Ovid access and rights to use any such communications with any Regulatory Authority generated by or on behalf of any Sublicensee.  Should Licensee fail to obtain such access and rights from any Sublicensee despite the application of Commercially Reasonable Efforts, Licensee shall not have the right to grant access or rights to such Sublicensee to any Regulatory Filing or right of reference granted to Licensee by Ovid pursuant to Section 5.1(b).

(ii)Licensee hereby grants to Ovid a right of reference to all Regulatory Filings for the Compound and Products submitted by or on behalf of Licensee.  Ovid may use such right of reference to seek, obtain, and maintain Regulatory Approval of the Products in the Ovid Territory, except that Ovid may use such right of reference to any Regulatory Filings based on Data resulting from Licensee’s Independent Development Activities only to comply with its safety reporting obligations, unless Ovid reimburses Licensee for such work as set forth in Section 8.2(b).

5.2Meetings with Regulatory Authorities.  On a current and ongoing basis, each Party (through the JPT) shall provide the other Party with a list and schedule of any in-person meeting or material teleconference with Regulatory Authorities (or related advisory committees) in the Licensee Territory planned for [***] that relates to the Development of the Compound and Products under the Development Plan in the Licensee Territory (each, a “Regulatory Meeting”).  In addition, each Party shall notify the other Party as soon as reasonably possible if such Party becomes aware of any additional Regulatory Meetings that become scheduled for such Calendar Quarter and will keep the other Party informed of any significant interface or communication with any Regulatory Authority which might affect efforts to obtain Regulatory Approval for the Product in the Licensee Territory. Each Party shall be solely responsible for any communications with any Regulatory Authorities occurring or required in connection with performing its regulatory responsibilities set forth in this Article 5 with respect to the Product in the Licensee Territory. With respect to Regulatory Meetings for which Licensee is the responsible Party, Ovid shall have the right to comment in preparation for all such Regulatory Meetings and the right, but not the obligation, to have its representatives attend any such Regulatory Meetings.

5.3Regulatory Inspections.  Licensee shall permit the Regulatory Authority(ies) in the Ovid Territory to conduct inspections of Licensee, its Affiliates, and its Sublicensees and subcontractors (including Clinical Trial sites) relating to the Development of the Product under the Development Plan, and shall ensure that such Affiliates and Sublicensees and subcontractors permit such inspections.  In addition, Licensee shall promptly notify Ovid of any such inspection and shall supply Ovid with all information pertinent thereto.  Ovid shall have the right to have a representative attend any such inspection. Ovid shall permit the Regulatory Authority(ies) in the Licensee Territory to conduct inspections of Licensee, its Affiliates, and its Sublicensees and subcontractors (including Clinical Trial sites) relating to the Development of the Product in the Licensee Territory under the Development Plan, and shall ensure that such Affiliates and Sublicensees and subcontractors permit such inspections.  In addition, Ovid shall promptly notify the Licensee of any such inspection in the Licensee Territory and shall supply the Licensee with 

35

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

all information pertinent thereto.  The Licensee shall have the right to have a representative attend any such inspection.

5.4Adverse Event Reporting; Pharmacovigilance Agreement.  [***] after the Effective Date, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Products, such as Safety Data sharing, adverse event reporting, and safety signal and risk management (the “Pharmacovigilance Agreement”), which agreement shall be amended by the Parties from time to time as necessary to comply with any changes in Applicable Laws or any guidance received from Regulatory Authorities.  Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws (including, to the extent applicable, those obligations contained in ICH guidelines) to monitor patients’ safety.  Ovid has established, and shall continue to hold (either by itself or through a vendor engaged by Ovid) the global safety database for the Products, and shall maintain such global safety database for so long as such Product is under Development or Commercialization by the Parties.  The Parties envision that Ovid will separately maintain the Product global safety database and Licensee will maintain its own Product safety database with respect to the Licensee Territory and the Parties will synchronize the Product databases in accordance with the Pharmacovigilance Agreement so that they each maintain all Product safety data; however, the Parties agree that the Ovid global safety database will be the source for all periodic reports. Ovid shall [***] from its database and Licensee will maintain [***] its own Product safety database. The CGB shall establish a safety subcommittee to draft the Pharmacovigilance Agreement to define the process for exchanging adverse event reports using the Ovid global safety database, as well as periodic reports, regulatory communication, and other key elements.  The Parties will collaboratively agree on data cut points for periodic safety reports and Ovid will review and approve all such reports.  The Parties will jointly review and approve such reports before submission to Regulatory Authorities in the Licensee Territory as required.  Such safety subcommittee shall implement the Pharmacovigilance Agreement and coordinate with respect to any Safety Data reporting for the Products to the Regulatory Authorities in the Licensee Territory including,  responding to safety issues, communicating with Regulatory Authorities related to the Products under any MAA or Regulatory Approval for the Product held by such Party and filed with such Regulatory Authorities, including maintaining the qualified person for Pharmacovigilance and individual case safety report processing, in each case at its own cost. Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees, and Sublicensees to comply with such obligations. 

5.5No Harmful Actions.  If a Party reasonably believes that the other Party is taking or intends to take any action with respect to a Product that could reasonably be expected to have a material adverse impact upon the regulatory status of such Product in such Party’s territory, then such Party may bring the matter to the attention of the CGB and the Parties shall discuss in good faith to promptly resolve such concern.  

5.6Notification of Threatened Action.  Each Party shall notify the other Party within twenty-four (24) hours of any information it receives regarding any threatened or pending action, inspection, or communication by any Regulatory Authority which may affect the safety or efficacy claims of any Product or the continued Development or Commercialization of any Product.  Upon 

36

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.  

5.7Recalls.  In the event that a recall, withdrawal, or correction (including the dissemination of relevant information) of any Product in a Party’s territory is required by a Regulatory Authority of competent jurisdiction, or if any Regulatory Authority requires or advises either Party or such Party’s Affiliates or sublicensees to distribute a “Dear Doctor” letter or its equivalent regarding use of such Product in a Party’s territory, or if a recall, withdraw, or correction of a Product in its territory is deemed advisable by such Party in its sole discretion, such Party shall so notify the other Party no later than [***] in advance of the earlier of (a) [***], or (b) [***].  Any such recall, withdrawal, correction, or dissemination of information (e.g., “Dear Doctor” letter) shall be referred to herein as a “Recall”.  Promptly after being notified of a Recall, each Party shall provide the other Party with such assistance in connection with such Recall as may be reasonably requested by such other Party.  All costs and expenses in connection with a Recall [***].  Each Party shall handle exclusively the organization and implementation of all Recalls of Products in its territory.  Notwithstanding the foregoing, any Recall related to the manufacture and supply of the Product by Ovid to Licensee shall be governed by the terms and conditions of the Supply Agreement. 

5.8Sunshine Reporting Laws and the International Transparency Reporting Requirements for Europe.  Each Party acknowledges that the other Party may be subject to federal, state, local, and international laws, regulations, and rules related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities, including, as applicable, International Transparency Reporting Requirements for Europe (collectively, “Sunshine Reporting Laws”), and agrees to provide the other Party with all information regarding such payments or transfers of value by such Party as necessary for such other Party to comply in a timely manner with its reporting obligations under the Sunshine Reporting Laws.     

	
6.
	
Commercialization

6.1General.  Subject to the terms and conditions of this Agreement, including this Article 6, Licensee shall have the sole and exclusive responsibility, at its own expense, for all aspects of the Commercialization of the Products in the Licensee Territory, including (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Products, (c) marketing and promotion, (d) booking sales and distribution and performance of related services, (e) handling all aspects of order processing, invoicing and collection, inventory and receivables, (f) providing customer support, including handling medical queries, and performing other related functions, and (g) conforming its practices and procedures to Applicable Laws applying to the promotion, sales and marketing, access, and distribution of the Products in the Licensee Territory.  

6.2Commercialization Plan.  As soon as reasonably practicable, but no later than [***], Licensee shall prepare and present to the CGB a reasonably detailed plan for the Commercialization of the Product in the Licensee Territory (the “Commercialization Plan”).  The Commercialization Plan will include specific information on a country-by-country basis, as 

37

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

applicable, and shall be consistent with the global commercialization plan for branding and messaging.  Licensee shall update and amend the Commercialization Plan [***] following the First Commercial Sale of the Product in the Licensee Territory and present such updates and any amendments to the CGB for review and discussion.  Subject to the terms of this Agreement and compliance with the Commercialization Plan, Licensee shall have full Control and authority with respect to the day-to-day Commercialization of the Products and implementation of the Commercialization Plan.

6.3 Diligence.  

(a)General.  During the Term, Licensee shall use Commercially Reasonable Efforts to Commercialize the Products for each and every Indication that receives Regulatory Approval in the Licensee Territory.  

(b)Product Launch.  Licensee shall use Angelini Commercially Reasonable Efforts to launch the Product for each Indication that has received Regulatory Approval and, if required by Applicable Law, Pricing and Reimbursement Approval in the Licensee Territory (including any Indication that received Regulatory Approval as a result of Ovid’s Independent Development Activities). As applicable, Licensee shall obtain all necessary Pricing and Reimbursement Approvals necessary to list and to launch such Product for such Indication following receipt of MAA Approval of such Product in a country.  Without limiting the generality of the foregoing, Licensee shall use Angelini Commercially Reasonable Efforts to launch the Product in each country in the Licensee Territory within [***] after receiving Regulatory Approval, or, where required by Applicable Law, after the publication of the Pricing and Reimbursement Approval, of the Product for an Indication from the applicable Regulatory Authority in such country.  Thereafter, Licensee shall utilize Commercially Reasonable Efforts in the ongoing support for such Product in such country. 

(c)Commercial Updates.  Licensee shall update the CGB on [***] basis regarding its Commercialization activities with respect to the Products in the Licensee Territory.  Each such update shall be in a form to be agreed by the CGB and shall summarize Licensee’s and its Affiliates’ and Sublicensees’ significant Commercialization activities with respect to the Products in the Licensee Territory, and shall contain at least such information at a level of detail reasonably required by Ovid to determine Licensee’s compliance with its diligence obligations set forth in this Section 6.3.  Such updates shall include Licensee’s sales activities, sales forecasts for at least the next [***], marketing activities, and Medical Affairs Activities. 

6.4Coordination of Commercialization Activities.  

(a)Generally.  The Parties, through the CGB (or JPT or other designated team), shall update each other on Commercialization strategies for the Product (e.g., for market and payor research, branding and messaging, international congresses, advisory boards) in their respective territories, and the Parties shall work together to identify and take advantage of any potential global strategies and messaging.  The foregoing shall not be construed as requiring either Party to seek the other Party’s consent in connection with such first Party establishing or implementing any sales, marketing, or medical affairs practices in such first Party’s territory.

38

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(b)Pricing. Following the CGB discussion and processes, Licensee shall keep Ovid timely informed on the status of any application for Pricing and Reimbursement Approval or material updates to an existing Pricing and Reimbursement Approval in the Licensee Territory, including any discussion with a Regulatory Authority with respect thereto. Licensee and its Affiliates and Sublicensees shall [***] include a Product, [***] of the Product [***] and the Product [***].

(c)Sharing of Promotional Materials.  Licensee shall, at its own expense, prepare, develop, produce, or otherwise obtain and utilize sales, promotional, advertising, marketing, website, educational, and training materials (the “Promotional Materials”) to support its Commercialization activities in the Licensee Territory, and shall ensure that such Promotional Materials, as well as all information contained therein, comply with all Applicable Laws and are consistent with the Regulatory Approvals obtained for the Product in the applicable jurisdiction in the Licensee Territory.  At Ovid’s request, Licensee shall share samples of and updates to Promotional Materials with respect to the Commercialization of the Products with Ovid. If Ovid has such promotional materials available for the Product for the Ovid Territory prior to the commercial launch of such Product in the Licensee Territory, Ovid will share such materials with the Licensee upon its request.

(d)Commercialization in Ovid Territory.  For clarity, Ovid shall have the exclusive right to Commercialize the Product in the Ovid Territory at its own expense, with or without Third Party(ies). 

6.5Medical Affairs Activities. 

(a)Coordination of Global Medical Affairs Activities.  Ovid shall be responsible for all Medical Affairs Activities for the Product in the Ovid Territory in accordance with the medical affairs portion of the Development Plan.  Licensee shall be responsible for Medical Affairs Activities in the Licensee Territory in accordance with the medical affairs portion of the Development Plan, provided, however, that Ovid shall have the right, but not the obligation, to also conduct Medical Affairs Activities in the Licensee Territory in global support of the Product, consistent with the medical affairs portion of the Development Plan and in coordination and agreement with Licensee, such agreement not to be unreasonably withheld, conditioned, or delayed.  Licensee will not undertake Medical Affairs Activities in the Ovid Territory without Ovid’s prior written consent, to be given on a case-by-case basis in Ovid’s sole discretion. 

(b)Advisory Panels.  To the extent practicable, each Party shall give the other Party written notice at least [***] in advance of any major market or international level advisory panel meetings with key opinion leaders with respect to the Commercialization of the Products in the Licensee Territory and the Ovid Territory that are held, sponsored, or attended by either Party or its Affiliate or sublicensee, and each Party shall have the right to attend and participate in such meetings with the consent of the other Party.  

(c)Medical Information. Ovid will provide Licensee with any relevant materials developed by Ovid for the Product in the Ovid Territory for medical information, including reports of collected and answered inquires, which Licensee may use in connection with 

39

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

medical affairs activities in the Licensee Territory.  For clarity, Ovid shall provide such materials in the form used by Ovid in the Ovid Territory.

(d)Scientific Training. At times reasonably agreed by the Parties, Ovid will deliver the onboarding scientific training to Licensee’s medical and commercial team and to share updates with respect to the Commercialization of the Product.  Each Party shall bear its own cost in relation to such meetings.

6.6Diversion.  To enforce the Parties’ respective rights and obligations set forth in Sections 2.1, 2.4, and 2.8 of the Agreement, to the extent permitted by Applicable Law, each Party hereby covenants and agrees that it and its Affiliates shall not, and it shall contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligation) its sublicensees not to, directly or indirectly, promote, market, distribute, import, sell, or have sold any Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like in the other Party’s territory.  Neither Party shall engage, nor permit its Affiliates and sublicensees to engage, in any advertising or promotional activities relating to any Product for use directed primarily to customers or other buyers or users of such Product located in any country or jurisdiction in the other Party’s territory, or solicit orders from any prospective purchaser located in any country or jurisdiction in the other Party’s territory.  If a Party or its Affiliates or sublicensees receives any order for a Product for use from a prospective purchaser located in a country or jurisdiction in the other Party’s territory, such Party shall immediately refer that order to such other Party and shall not accept any such orders.  Neither Party shall, nor permit its Affiliates and sublicensees to, deliver or tender (or cause to be delivered or tendered) any Product for use in the other Party’s territory.

6.7Ovid’s Right to Commercialize.  Notwithstanding anything to the contrary herein, if Ovid conducts Development activities for the Product in the Licensee Territory as provided in Section 2.3(a) for any Additional Indication(s) for which Licensee has elected to not share Development Costs as provided in Section 8.2(a) and/or Section 8.2(b), as applicable, then prior to filing for Regulatory Approval for the Product in any Additional Indication, the Parties shall discuss in good faith whether Licensee wishes to include such Additional Indication within the Field  and to Commercialize such Product in such Additional Indications.  For clarity, neither Party may file for Regulatory Approval or Commercialize Products in (i) any Additional Indication for which Licensee has elected not to share Development Costs or (ii) any additional indication other than Rare Diseases unless the Parties mutually agree to do so. 

	
7.
	
Manufacture and Supply

7.1Upon Licensee’s request, Ovid will manufacture and supply, itself or through a Third Party contract manufacturer, all Drug Product for use in the Development and Commercialization of the Products under this Agreement and according to the Supply Agreement.  All Drug Product supplied by Ovid to Licensee or Licensee Affiliate for use for Development and Commercial purposes shall be supplied at [***], provided that [***] (“Total Supply Price Threshold”). In case the Total Supply Price will be [***], the Cost of Good for such Drug Product will be [***] the Total Supply Price Threshold.  For clarity, the Total Supply Price Threshold [***].  Payment shall be due within [***] after Licensee’s receipt from Ovid of an invoice for such Drug Product.  Drug Product shall be delivered EXW (Incoterms 2020) at supplier facility (or that 

40

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

of its Third Party contract manufacturer), and Licensee shall be responsible for all costs of freight, insurance, taxes and duties associated with shipment of Drug Product to Licensee’s designated delivery point.  Licensee shall be responsible, at its expense, for the final packaging and labeling of the Product for all countries in the Licensee Territory.  Licensee shall also be responsible, at its sole expense, for any specific manufacturing requirements, such as stability studies or development of finished Product presentations, necessary to obtain MAA Approval of the Product in the Licensee Territory.  If Licensee is manufacturing Drug Product following the Technology Transfer Completion Date, Ovid may request, and Licensee or Licensee Affiliate will supply Drug Product to Ovid, on the same terms as set forth above, pursuant to a mutually agreed supply agreement.  

	
8.
	
Financial Provisions 

8.1Upfront and Technology Transfer Financials.  

(a)Upfront Payment.  Licensee shall make a one-time, non-refundable, non‐creditable upfront payment to Ovid of twenty million dollars ($20,000,000) within five (5) business days after the Effective Date.

(b)Technology Transfer and Compound Delivery Payment. 

(i)Within [***] following (A) the transfer to Licensee of [***], (B) the delivery ([***]) to Licensee or to Licensee Affiliate of [***] and (C) [***], Licensee shall pay to Ovid a one-time, non-refundable, non-creditable payment of (1) five million dollars ($5,000,000) if [***] is transferred by Ovid to Licensee before December 10, 2020, or (2) [***] if [***].  Licensee shall use Angelini Commercially Reasonable Efforts to cooperate with Ovid and Lundbeck to implement the foregoing transfers within the timelines set forth in this Section 8.1(b)(i). 

(ii)Within [***] following the Technology Transfer Completion Date, Licensee shall make a one-time, non-refundable, non-creditable technology transfer payment of [***]. Licensee shall use Angelini Commercially Reasonable Efforts to cooperate with Ovid and Lundbeck to implement the Technology Transfer Agreement within [***] after the Effective Date. 

8.2Sharing/Reimbursements of Development Costs.

(a)Shared Development Costs.  With respect to Joint Development Activities conducted pursuant to Section 4.2(b) or Section 4.3 directed to obtaining Regulatory Approval for any Indication, excluding the Ovid Ongoing Trials, Ovid shall bear [***] and Licensee shall bear [***] of all Development Costs for such Joint Development Activities.  No later than [***] after the beginning of each Calendar Quarter during which a Party will perform any Joint Development Activities pursuant to Section 4.2(b) or Section 4.3 in such Calendar Quarter, such Party shall submit to the other Party a statement setting forth the Development Costs incurred, including the other Party’s share (calculated in accordance with the foregoing sentence) of (i) estimated Development Costs for the then current quarter; (ii) variances from prior invoiced estimates and actual Development Costs; and (iii) Development Costs incurred by or on account of such Party in the past quarter not previously invoiced.  Such invoice shall include a reasonably detailed report for such Development Costs, including reasonable supporting documents.  The other Party shall 

41

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

pay the amount invoiced within [***] after the receipt of the invoice, subject to the other Party’s right to audit the invoicing Party’s records and books related to such costs as provided in Section 9.4.  If both Parties will perform Joint Development Activities pursuant to Section 4.2(b) or Section 4.3 under the Development Plan in such Calendar Quarter, the Parties shall consolidate the payments for such Calendar Quarter into a single payment from one Party to the other Party, as applicable.

(b)Independent Development Costs.  In general, each Party shall bear all Development Costs incurred by or on account of such Party in performing its own Independent Development Activities (the “Independent Development Costs”).  After the completion of such Independent Development Activities, such Party shall provide the other Party (the “Non-Funding Party”) with a report of such Independent Development Costs.  If a Non-Funding Party desires to submit any portion of the Data, or reference any portion of a Regulatory Filing, resulting from Independent Development Activities conducted by the other Party to support any Regulatory Approval in the Non-Funding Party’s territory, then such Non-Funding Party may notify the other Party in writing of such request at any time following the completion of such Independent Development Activities.  Within [***] after its receipt of such notice, the Party having conducted such Independent Development Activities shall submit to the other Party a reasonably detailed invoice for, [***] of the Independent Development Costs incurred [***] in connection with the performance of such Independent Development Activities, with such invoiced amount representing the Non-Funding Party’s base share of Development Costs ([***]), had such Party originally opted in, plus [***], provided that in no event will either Party be required to pay, as a result of the application of such premium, more than [***] the costs actually incurred in conducting such Independent Development Activities.  If the Non-Funding Party subsequently uses or references such Data, in whole or in part to support Regulatory Approval of the Product in the applicable Indication in its territory, then such Party shall notify the conducting Party in writing of such decision and pay the amount set forth in the invoice within [***] after its submission of a Regulatory Filing including or referencing such Data.  

(c)Internal Development Cost. Each Party shall record and calculate its Development Costs for the Development Activities implemented from the Effective Date on an FTE basis at the applicable FTE Rate.  The Parties agree that [***] from the Effective Date. 

8.3Development Milestone Payments.

(a)Development Milestones.  Subject to the remainder of this Section 8.3, Licensee shall pay to Ovid the one-time, non-refundable, non-creditable payments set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Licensee or its Affiliates or Sublicensees or Ovid or its Affiliates or licensee(s) (other than Licensee)).  

		
	
Regulatory Milestone Event
	
Regulatory Milestone Amount

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

 

(b)Notice and Payment.  Each Party shall notify the other Party in writing within [***] after the achievement of any milestone event set forth in this Section 8.3 by such Party or its Affiliates or Sublicensees.  Licensee shall pay to Ovid the applicable development milestone payment within [***] after the delivery or receipt of such notice.

(c)One-time Payment. Each of the above Regulatory Milestone amounts shall only be payable once no matter how many times the corresponding Regulatory Milestone Event is achieved.  

(d)For clarity, Licensee shall pay to Ovid each Regulatory Milestone amount the first time that the corresponding Regulatory Milestone Event is achieved.

8.4Sales Milestones Payments.  

(a)Licensee shall pay to Ovid the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in the Licensee Territory in any Calendar Year first reach the values indicated in the table below.  For clarity, each payment in this Section 8.4 shall be payable once only upon first achievement of the applicable milestone event, regardless of the number of times such milestone is subsequently achieved.

		
	
Aggregate Net Sales of all Products in the Licensee Territory in a Calendar Year
	
Sales Milestone Payment Amount

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

42

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

(b)Notice and Payment.  As part of the report in Section 9.1, Licensee shall provide written notice to Ovid if the aggregated Net Sales of all Products in the Licensee Territory in any Calendar Year first reach the values set forth in Section 8.4(a), and Licensee shall pay to Ovid the corresponding Net Sales milestone payment along with its payment of royalties in accordance with Section 9.1, following the end of the Calendar Quarter in which such Net Sales milestone is achieved. 

(c)One-time Payment. Each of the above Sales Milestone amounts shall only be payable once during the Term of this Agreement no matter how many times the corresponding Sales Milestone Event is achieved.  For clarity, Licensee shall pay to Ovid each Sales Milestone amount the first time that the corresponding Sales Milestone Event is achieved.

8.5Royalty During the Royalty Term.

(a)Royalty Rate. Subject to the remainder of this Section 8.5, during the Royalty Term, Licensee shall make quarterly non-refundable, non-creditable royalty payments to  Ovid on the annual Net Sales of all Products sold in the Licensee Territory at the applicable rate to the relevant portion of annual Net Sales as set forth below:

		
	
Annual Net Sales of all Products in the Licensee Territory
	
Royalty Rate

	
Portion of annual Net Sales up to [***]
	
[***]%

	
Portion of annual Net Sales greater than [***] and less than or equal to [***]
	
[***]%

	
Portion of annual Net Sales greater than [***] and less than or equal to [***] 
	
[***]%

	
Portion of annual Net Sales greater than [***]
	
[***]%

For example purposes only, [***].

(b)Royalty Term. Royalties shall be paid on a Product-by-Product and country-by-country basis in the Licensee Territory from the First Commercial Sale of such Product in such country by or on behalf of Licensee, its Affiliates, or Sublicensees, until the last to occur of (i) the expiration of the last‐to‐expire Valid Claim of the Ovid Patents (ii) the expiration of all Market Exclusivity covering such Product in such country, and (iii) fifteen (15) years after the First Commercial Sale of such Product in such country  (the “Royalty Term”). 

(c)Royalty Stacking Reduction.  If it is necessary for Licensee to obtain a license from a Third Party under any Patent in a particular country in the Licensee Territory in order to sell the Compound or the Compound incorporated into a Product for the Initial Indication or, if Licensee does not exercise the Second Indication Opt-Out, the Second Indication in such country and Licensee obtains such a license, then solely during the Royalty Term, Licensee may 

43

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

deduct from the royalty payment that would otherwise have been due pursuant to Section 8.5(a) with respect to Net Sales of such Product in such country in a particular Calendar Quarter an amount equal to [***] of the royalties paid by Licensee to such Third Party pursuant to such license on account of the sale of such Product in such country during such Calendar Quarter. 

(d)Royalty Floor.  Notwithstanding the foregoing Sections 8.5(c) and Section 8.7 with respect to any Product in any Calendar Quarter, the royalties that would otherwise have been due under Section 8.5(a) with respect to Net Sales of such Product in the applicable country(ies) during such Calendar Quarter shall not be reduced by more than [***] as a result of all such reductions.

8.6Royalties During the Extended Commercialization Term.  During the Extended Commercialization Term, Licensee shall pay to Ovid a quarterly non-refundable, non-creditable royalty of [***] on the annual Net Sales of all Products sold in the Licensee Territory, as calculated by multiplying the foregoing royalty rate by the amount of Net Sales of the Product in the Territory in the applicable Calendar Quarter.

8.7Royalty Reduction for Generic Competition. If at any time Generic Product Competition exists in a given country with respect to a Product, then the royalty rate set forth in Section 8.5(a) with respect to sales of such Product in such country shall be reduced by [***].  For clarity, if Generic Product Competition ceases to exist, then the royalty rate shall no longer be reduced. 

8.8Upstream License Agreement Payments.  Any and all payments that become due under the Lundbeck License Agreement as a result of activities under this Agreement, whether by or on behalf of Ovid or by Licensee or its Affiliate or Sublicensee, shall be the responsibility of Ovid and Ovid shall make such payment in accordance with the terms of the Lundbeck License Agreement. 

	
9.
	
Payment; Records; Audits

9.1Payment; Reports.  All royalty payments due under this Agreement shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Products by Licensee and its Affiliates and Sublicensees in the Licensee Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, for each country, the number of Products sold, the gross sales and Net Sales of Products, including the deductions from gross sales to arrive at Net Sales, the royalty payable, the exchange rates used, any adjustments to the royalty paid during the Royalty Term pursuant to Section 8.5(c), and whether any Net Sales milestone under Section 8.4 has been achieved.  Within [***] following the end of each Calendar Quarter during the Royalty Term and Extended Commercialization Term, Licensee shall provide Ovid with the foregoing report and the payment due for such Calendar Quarter.  For clarity, royalty payments during the Extended Commercialization Term shall not be subject to any offsets or reductions whatsoever, including those set forth in Section 8.5(c).  Prior to the First Commercial Sale of the Product in the Licensee Territory, the Parties will agree on the form of royalty report.  Licensee shall submit a single report for all Net Sales during a Calendar Year, including all of Licensee’s and its Affiliates’ and Sublicensees’ Net Sales, but shall separately identify the Net Sales and other information applicable to each entity.

44

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

9.2Exchange Rate; Manner and Place of Payment.  All references to dollars and “$” herein shall refer to U.S. dollars.  Unless otherwise specified herein, all payments due under this Agreement shall be payable in U.S. dollars.  When conversion of Net Sales from any currency other than U.S. dollars is required, such conversion shall be at the exchange rate equal to the conversion rate for the U.S. dollar for the currency of the country in which the applicable Net Sales were made as published by [***].  All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Ovid, unless otherwise specified in writing by Ovid.  

9.3Taxes. 

(a)Taxes on Income.  Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.  

(b)Tax Cooperation.  The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of the milestone payments, royalty payments, and other payments made by Licensee to Ovid under this Agreement.  To the extent that Licensee is required by Applicable Laws to deduct and withhold taxes on any payment to Ovid, Licensee shall withhold the amount of such taxes otherwise payable to Ovid and, if and when necessary pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Ovid an official tax certificate or other evidence of such payment sufficient to enable Ovid to claim such payment of taxes.  Ovid shall provide Licensee any tax forms that may be reasonably necessary in order for Licensee to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so.  Ovid shall use reasonable efforts to provide any such tax forms to Licensee in advance of the due date.  Licensee shall provide Ovid with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Ovid.  Licensee shall have the right to deduct any such tax, levy, or charge actually paid from payment due to Ovid.  Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.

(c)Taxes Resulting From Licensee’s Action. If a Party takes any action of its own discretion (not required by a Regulatory Authority and without consent of the other Party), including any assignment, sublicense, change of place of incorporation, or failure to comply with Applicable Laws or filing or record retention requirements, which results in a withholding or deduction obligation (a “Withholding Tax Action”), then such Party shall pay the sum associated with such Withholding Tax Action.  For clarity, if Licensee undertakes a Withholding Tax Action, then the sum payable by Licensee (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Ovid receives a sum equal to the sum which it would have received had no such Withholding Tax Action occurred.  If a change in Applicable Laws results in a withholding or deduction obligation absent either Party taking a Withholding Tax Action, then the amount of such withholding or deduction obligation shall be paid by Licensee to the applicable Governmental Authority on behalf of Ovid, provided that Licensee shall assist Ovid in minimizing or recovering such withholding or deduction obligation.  

45

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

The Parties shall use commercially reasonable efforts to invoke the application of any applicable bilateral income tax treaty that would reduce or eliminate otherwise applicable taxes with respect to payments payable pursuant to this Agreement.

9.4Records; Audit.  Each Party shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit the other Party to confirm the accuracy of the amount of Development Costs to be reimbursed or shared, achievement of Net Sales milestones, and the amount of royalty and other payments payable under this Agreement.  Each Party will keep such books and records for at least [***] following the Calendar Year to which they pertain.  Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the “Auditor”) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement.  Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.  Such audits may occur no more often than [***].  Each Party shall only be entitled to audit the books and records from the [***] in which the audit request is made.  The Auditor shall not disclose the audited Party’s Confidential Information to the auditing Party, and shall only verify the accuracy or inaccuracy of the financial reports furnished by the audited Party or the amount of payments by such Party under this Agreement, and, in the case of any inaccuracy, the amount of such inaccuracy.  In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within [***] after the Auditor’s report.  The auditing Party shall bear the full cost of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party, which underpayment or overpayment was more than [***], in which case the audited Party shall reimburse the auditing Party for the costs for such audit.  For clarity, the foregoing audit rights may also be exercised by Ovid on behalf of Lundbeck pursuant to the terms of the Lundbeck License Agreement.  

9.5Late Payments.  In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due [***]; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.  The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.  

	
10.
	
Intellectual Property 

10.1Ownership.  

(a)Data. All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Ovid and its Affiliates and licensees (other than Licensee) (the “Ovid Data”) shall be the sole and exclusive property of Ovid or such Affiliates or licensees, as applicable.  All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Licensee or its Affiliates or Sublicensees (the “Licensee Data”) shall be the sole 

46

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

and exclusive property of Licensee or such Affiliates or Sublicensees, as applicable.  All Data generated in connection with any Joint Development Activities or joint Commercial activities with respect to any Product and for which the Parties are sharing Development Costs pursuant to Section 8.2(a) shall be jointly owned by the Parties.  For clarity, each Party shall have access and right to use and reference the other Party’s Data as and to the extent set forth in this Agreement. 

(b)Inventions.  Inventorship of any Inventions will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.  The Parties will work together to resolve any issues regarding inventorship or ownership of Inventions.  Ownership of Inventions will be allocated as follows: 

(i)Ovid shall solely own all data, Inventions, and Patents claiming such Inventions that relate to the composition, formulation, manufacture, dosing, new indications or method of use of the Compound, or any improvement of any such composition, manufacture, or use, including in combination with other agents or components (each, a “Compound Invention”).  All Compound Inventions will be included in the Ovid Know-How, and Patents in the Licensee Territory claiming such Inventions will be included in the Ovid Patents.  To the extent that any Compound Invention is made by Licensee, whether solely or jointly with Ovid, Licensee shall, and hereby does, transfer and assign to Ovid, without additional consideration, all of its right, title, and interest in such Compound Invention.  To effectuate the foregoing assignment, Licensee shall ensure that all entities and individuals that perform any Development under this Agreement are under a written or other legally enforceable obligation to assign all of its right, title, and interest in such Invention to Licensee or to an entity that is obligated to assign all right, title, and interest to Licensee. 

(ii)Except for Compound Inventions, each Party shall solely own any Inventions made solely by it and its Affiliates’ employees, agents, or independent contractors, and the Parties shall jointly own any Inventions that are made jointly by employees, agents, or independent contractors of one Party and its Affiliates together with employees, agents, or independent contractors of the other Party and its Affiliates (“Joint Inventions”).  All Patents claiming patentable Joint Inventions shall be referred to herein as “Joint Patents”.  Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign, and otherwise exploit its interest under the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.  

10.2Patent Prosecution and Maintenance.  

(a)Ovid Patents. 

(i)Subject to the remainder of this Section 10.2(a), and as between the Parties, Ovid shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, inter partes review, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of the Ovid Patents (other than Joint Patents) worldwide, using counsel of its own choice.  Subject to the terms of the Lundbeck License Agreement, Ovid shall (A) keep Licensee informed of material 

47

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

progress with regard to the preparation, filing, prosecution, and maintenance of the Ovid Patents in the Licensee Territory, sufficiently in advance for Licensee to be able to review any material documents, including content, timing, and jurisdiction of the filing of such Ovid Patents in the Licensee Territory, (B) consult with, and consider in good faith the requests and suggestions of, Licensee with respect to strategies for filing, prosecuting, and defending, if any, the Ovid Patents in the Licensee Territory, and (C), [***].

(ii)In the event that Ovid desires to abandon or cease prosecution or maintenance of any Ovid Patent in any country in the Licensee Territory, Ovid shall provide reasonable prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Ovid Patent in the relevant patent office).  In such case, upon Licensee’s written election provided no later than [***] after such notice from Ovid, Ovid shall continue prosecution and maintenance of such Ovid Patent at Licensee’s direction and expense.  If Licensee does not provide such election within [***] after such notice from Ovid, Ovid may, in its sole discretion, continue prosecution and maintenance of such Ovid Patent or discontinue prosecution and maintenance of such Ovid Patent.

(b)Licensee Patents.  

(i)Subject to the remainder of this Section 10.2(b), Licensee shall have the first right, but not the obligation, to control the preparation, filing, prosecution and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) of all Licensee Patents (other than Joint Patents) worldwide, at its sole cost and expense and by counsel of its own choice in the Licensee Territory and by counsel mutually agreed to by the Parties in the Ovid Territory.  Licensee shall keep Ovid informed of the status of filing, prosecution, maintenance, and defense, if any, of the Licensee Patents, and Licensee shall consult with, and consider in good faith the requests and suggestions of, Ovid with respect to strategies for filing, prosecuting, and defending the Licensee Patents.

(ii)In the event that Licensee desires to abandon or cease prosecution or maintenance of any Licensee Patent, Licensee shall provide reasonable prior written notice to Ovid of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Licensee Patent in the relevant patent office).  In such case, upon Ovid’s written election provided no later than [***] after such notice from Licensee, Ovid shall have the right to assume prosecution and maintenance of such Licensee Patent at Ovid’s expense and Licensee shall assign to Ovid all of its rights, title, and interest in and to such Licensee Patent.  If Ovid does not provide such election within [***] after such notice from Licensee, Licensee may, in its sole discretion, continue prosecution and maintenance of such Licensee Patent or discontinue prosecution and maintenance of such Licensee Patent.

(c)Joint Patents.  

(i)Subject to the remainder of this Section 10.2(c), Ovid shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain (including any 

48

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) Joint Patents using a patent counsel selected by Ovid in the Ovid Territory and counsel mutually agreed to by the Parties in the Licensee Territory.. Ovid shall keep Licensee informed of material progress with regard to the preparation, filing, prosecution, maintenance, and defense, if any, of the Joint Patents, including content, timing, and jurisdiction of the filing of such Joint Patents, and Ovid shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to filing, prosecuting, and defending of the Joint Patents in the Licensee Territory.

(ii)In the event that Ovid desires to abandon or cease prosecution or maintenance of any Joint Patent in any country in the Licensee Territory, Ovid shall provide reasonable prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than sixty (60) days prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).  In such case, at Licensee’s sole discretion, upon written notice from Licensee to Ovid, Licensee may elect to continue prosecution or maintenance of any such Joint Patent at its own expense, and Ovid shall execute such documents and perform such acts, at Licensee’s expense, as may be reasonably necessary to allow Licensee to continue the prosecution and maintenance of such Joint Patent in such country in the Licensee Territory.  Any such assignment shall be completed in a timely manner to allow Licensee to continue prosecution and maintenance of any such Joint Patent and any such Patent so assigned shall cease to be either a Joint Patent or a Licensee Patent and shall no longer be subject to the licenses and other rights granted by Licensee to Ovid under this Agreement 

(d)Cooperation. Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance, and defense, if any, of Patents under Section 10.2 and in the obtaining and maintenance of any patent term extensions and supplementary protection certificates and their equivalents, at its own cost (except as expressly set forth otherwise in this Section 10).  Such cooperation includes (i) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 10.2; and (ii) promptly informing the other Party of any matters coming to such Party’s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent application and the obtaining of any patent term extensions or supplementary protection certificates or their equivalents.

10.3Patent Enforcement. 

(a)Notice.  Each Party shall notify the other within [***] of becoming aware of any alleged or threatened infringement by a Third Party of any of the Ovid Patents (including Joint Patents) in the Licensee Territory, which infringement adversely affects or is reasonably expected to adversely affect any Product, including any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability, or non-infringement of any of the Ovid Patents (collectively, “Product Infringement”).  

(b)Enforcement Right.  Ovid shall have the first right to use Ovid Commercially Reasonable Efforts to bring and control any legal action in connection with such 

49

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Product Infringement at its own expense as it reasonably determines appropriate.  If Ovid (i) decides not to bring such legal action against a Product Infringement (the decision of which Ovid shall inform Licensee promptly) or (ii) Ovid otherwise fails to bring such legal action against a Product Infringement within [***] after first becoming aware of such Product Infringement, subject to the terms of the Lundbeck License Agreement, Licensee shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after [***] Ovid. 

(c)Collaboration.  Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action.  The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court.  The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.  

(d)Expense and Recovery.  

(i)Except as set forth in Section 10.3(d)(ii), the enforcing Party shall be solely responsible for any cost and expenses incurred by such Party as a result of such enforcement action.  If such Party recovers monetary damages in such enforcement action, such recovery shall be allocated [***].

(ii)Notwithstanding the foregoing, if [***] to bring such action.  If [***], then [***]. 

(e)Other Infringement.  Except for Product Infringement as set forth above, each Party shall have the exclusive right to enforce its own Patents against any infringement anywhere in the world.  For clarity, as between the Parties, Ovid shall have the exclusive right to enforce (i) the Ovid Patents against any infringement in the Licensee Territory that is not a Product Infringement, and (ii) the Ovid Patents and Joint Patents against any infringement in the Ovid Territory, in each case at its own expense as it reasonably determines appropriate, and subject to the terms of the Lundbeck License Agreement. The Parties shall discuss global enforcement strategy for the Ovid Patents and Licensee Patents, including the defense of validity and enforceability challenges arising from any enforcement action.    

10.4Infringement of Third Party Rights.  If any Product used or sold by Licensee, its Affiliates, or Sublicensees becomes the subject of a Third Party’s claim or assertion of infringement of any intellectual property rights in a jurisdiction within the Licensee Territory, Licensee shall promptly notify Ovid and the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a “common interest agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.  Absent any agreement to the contrary, and subject to claims for indemnification under Article 12, each Party may defend itself from any such Third Party claim at its own cost and expense, provided that [***].  If [***]. 

50

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

10.5Trademarks.

(a)Product Trademarks.  Ovid shall develop and adopt trademarks, including trade names, trade dresses, branding, and logos, to be used for the Products (the “Product Marks”).  Ovid shall own all Product Marks throughout the world and all goodwill in the Product Marks shall accrue to Ovid.  The Parties shall collaborate to have a global, worldwide trademark to be used on the Product.  In the event Ovid is unable to obtain or maintain the Product Marks for the Product in the Licensee Territory or in some countries in the Licensee Territory, the Parties shall collaborate to select such other Product Marks as may be available for registration and marketing of the Product in those countries. Ovid shall be responsible for the registration, maintenance, defense and enforcement of the Product Marks using counsel of its own choice in the Ovid Territory and counsel mutually agreed to by the Parties in the Licensee Territory.  Ovid shall keep Licensee informed of material progress with regard to the registration, prosecution, maintenance and defense, if any, of the Product Trademarks in the Licensee Territory, including content, timing, and jurisdiction of the filing of such Product Trademarks in the Licensee Territory, sufficiently in advance for Licensee to be able to review any material documents, and Ovid shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to strategies for filing, prosecuting and defending the Product Trademarks in the Licensee Territory. 

(b)Trademark License.  Licensee shall use the Product Marks to Commercialize the Product in the Licensee Territory.  In addition, unless prohibited by Applicable Laws, Licensee shall use Commercially Reasonable Efforts to include Ovid’s corporate trademark on the packaging and product information of the Products sold in the Licensee Territory to indicate that the Product is licensed from Ovid.  Ovid hereby grants to Licensee a limited, royalty-free license to use Ovid’s corporate trademark and Product Marks solely in connection with the Commercialization of the Product in the Licensee Territory under this Agreement.  All use of the Product Marks and Ovid’s corporate trademark shall comply with Applicable Laws and shall be subject to Ovid’s review and approval.  For clarity, Licensee shall also include its (or its Affiliate’s or Sublicensee’s, as applicable) corporate logo in the Product sold in the Licensee Territory.

(c)Product Domain Names.  In the Licensee Territory, Licensee shall have the exclusive right to register Product Marks as domain names, including all internet domain names under all existing top level domains. This includes as example top level domains such as .com, .net., .info and country code top level domains such as .dk, .uk and .it.

	
11.
	
Representations and Warranties

11.1Mutual Representations and Warranties.  Each Party represents and warrants to the other that, as of the Effective Date: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof, (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action, (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction 

51

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

over it, (d) it has the right to grant the licenses granted by it under this Agreement; (e) the execution and delivery of this Agreement and the performance of such Party’s obligations under this Agreement do not and will not result in the breach of, constitute a default, cause the acceleration of performance, require any consent under, or result in the creation of any lien, charge or encumbrance upon any of its property or assets pursuant to any material instrument or agreement to which it is a party, or by which it or its properties may be bound or affected, as of the Effective Date; and (f) it is not a party to any agreement, arrangement or understanding with any Third Party which in any significant way prevents it from fulfilling any its material obligations under the terms of this Agreement. 

11.2Covenants. 

(a)Employees, Consultants, and Contractors.  Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions, in each case in a manner consistent with the provisions of this Agreement. 

(b)Debarment.  Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to the Compound or any Product.  In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.

(c)Compliance.  Licensee covenants as follows: 

(i)In the performance of its obligations under this Agreement, Licensee shall comply and shall cause its and its Affiliates’ employees and contractors to comply with all Applicable Laws. 

(ii)Licensee and its and its Affiliates’ employees and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including, Licensee (and Licensee represents and warrants that as of the Effective Date, Licensee, and to its knowledge, its and its Affiliates’ employees and contractors, have not directly or indirectly promised, offered, or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection with the performance of Licensee’s obligations under this Agreement, and Licensee covenants that it and 

52

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

its Affiliates’ employees and contractors shall not, directly or indirectly, engage in any of the foregoing).   

(iii)Licensee and its Affiliates, and their respective employees and contractors, in connection with the performance of their respective obligations under this Agreement, (1) shall not violate or cause the violation of the FCPA, Export Control Laws, or any other Applicable Laws, or otherwise cause any reputational harm to Ovid, and (2) shall immediately notify Ovid if Licensee has any information or suspicion that there may be a violation of any of the foregoing in connection with activities under this Agreement. 

(iv)In connection with the performance of its obligations under this Agreement, Licensee shall comply and shall cause its and its Affiliates’ employees and contractors to comply with Licensee’s own anti-corruption and anti-bribery policy, a copy of which has been provided to Ovid prior to the Effective Date. 

(v)Ovid will have the right, upon reasonable prior written notice and during Licensee’s regular business hours, to conduct at its own cost and expenses inspections of and to audit Licensee’s books and records in the event of a suspected violation or to ensure compliance with the representations, warranties, and covenants of this Section 11.2(c); provided, however, that in the absence of good cause for such inspections and audits, Ovid may exercise this right no more than annually. 

(vi)In the event that Licensee has violated or been suspected of violating any of the representations, warranties, or covenants in this Section 11.2(c), Licensee will cause its or its Affiliates’ personnel or others working under its direction or control to submit to periodic training that Licensee will provide on anti-corruption law compliance.

(vii)Licensee will, at Ovid’s request, annually certify to Ovid in writing Licensee’s compliance, in connection with the performance of Licensee’s obligations under this Agreement, with the representations, warranties, or covenants in Section 11.2(c), which certification shall be issued by Licensee’s global commercial head for the Product.

(viii)Ovid shall have the right to suspend or terminate this Agreement in its entirety where there is a credible finding, after a reasonable investigation, that Licensee, its Affiliates, or its Sublicensees, in connection with performance of Licensee’s obligations under this Agreement, has engaged in chronic or material violations of the FCPA. 

 

11.3Additional Ovid Representations and Warranties.  Ovid represents, warrants, and covenants, on behalf of itself and its Affiliates, as applicable, to Licensee that, as of the Effective Date:

(a)to the extent applicable to the performance of its obligations under this Agreement, Ovid shall comply and shall cause its and its Affiliates’ employees and contractors to comply with all Applicable Laws;

53

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(b)Exhibit B lists all of the Ovid Patents as of the Effective Date that are necessary or useful for the Development, registration, use or Commercialization of the Product in the Licensee Territory;

(c)to Ovid’s knowledge, Ovid has the right to grant all rights and licenses it purports to grant to Licensee with respect to the Ovid Technology under this Agreement;

(d)as set forth above, Ovid is not a party to any agreement, arrangement or understanding with any Third Party which in any manner prevents it from fulfilling or affects its ability to perform any of its obligations under the terms of this Agreement to a material extent;

(e)Ovid and its Affiliates have not granted any liens or security interests on the Ovid Technology; 

(f)Ovid and its Affiliates have not received any written notice from a Third Party that the Development of any Product conducted by Ovid prior to the Effective Date has infringed any Patents of any Third Party; 

(g)Ovid and  its Affiliates have not as of the Effective Date, and will not during the Term, grant any right to any Third Party under the Ovid Technology that would conflict with or derogate the licenses or other rights granted to Licensee hereunder;

(h)no claim or action has been brought or, to Ovid’s knowledge, threatened in writing, by any Third Party alleging that the Ovid Patents are invalid or unenforceable, and no Ovid Patent is the subject of any interference, opposition, cancellation, or other protest proceeding; 

(i)to Ovid’s knowledge, no Third Party is infringing or misappropriating or has materially infringed or misappropriated the Ovid Technology in the Licensee Territory;

(j)to Ovid’s knowledge, all research and Development of the Product conducted by or on behalf of Ovid prior to the Effective Date has been conducted in compliance with all Applicable Laws;

(k)to Ovid’s knowledge, it has disclosed to Licensee the clinical and non-clinical data in Ovid’s Control that is material to the evaluation of the safety, efficacy, and manufacturing process of the Product; 

(l)to Ovid’s knowledge, there are no issues or information, which to Ovid’s knowledge and reasonable opinion, are reasonably likely to have a material impact on the Development of the Product that have not been fully disclosed to Licensee in the course of Licensee’s due diligence;

(m)to Ovid’s knowledge, the Ovid Technology includes all intellectual property rights which are reasonably necessary for the Development, registration, manufacture, use and Commercialization of the Product in the Licensee Territory as contemplated by the terms of this Agreement;

54

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(n)no litigation has been brought against Ovid or any of its Affiliate, or threatened in writing, which would adversely affect the rights granted to Licensee under the Ovid Technology;

(o)neither Ovid nor any of its Affiliates has granted to any Third Party any right (including any license or option or other right to obtain a license) to develop or commercialize Product in the Field in the Licensee Territory that would conflict with the rights granted to Licensee under this Agreement;

(p)as set forth above, Ovid has not granted any Third Party any license, option or other right under or with respect to the Ovid Technology that would conflict with or derogate from the licenses, options and other rights granted to Licensee hereunder;

(q)Ovid has the right to grant the License under Ovid Know-How specified herein free and clear of any liens or encumbrances which would have prevent or impair the grant of such rights;

(r)as set forth above, to Ovid’s knowledge,  it has the right to grant the License specified in Section 2.1 free and clear of any liens or encumbrances which would prevent or impair the grant of such rights;

(s)as set forth above, to its knowledge, Ovid has not and will not enter into any agreement that is or would be inconsistent with the obligations, rights and licenses granted to Licensee in this Agreement.

(t)it will use Ovid Commercially Reasonable Efforts in the conduct of the Development and Commercialization of the Compound and/or Product under this Agreement and in compliance with Applicable Law; and

(u)as set forth above, it has to not and will not enter into any agreement that is or would be inconsistent with the obligations, rights and licenses granted to Licensee under this Agreement.

(v)Ovid: (i) has provided or made available to Licensee all material relevant documents and written communications and materials in its and its Affiliates’ possession or Control from and to any Regulatory Authority in the Licensee Territory related to the Product; (ii) as of the Effective Date, Ovid and its Affiliates have not received any oral or written communication (including any notice of inspection, deficiency letter, warning letter or similar notice) from any Regulatory Authority alleging that the Development of Product by or on behalf of Ovid and its Affiliates is not currently materially in compliance with any and all applicable laws or regulations implemented by any Regulatory Authority; and (iii) to Ovid’s knowledge, Ovid and its Affiliates have not made, with respect to the Product, any untrue statement of material fact to any Regulatory Authority, or failed to disclose a material fact required to be disclosed to such Regulatory Authority.

11.4Ovid Covenants Regarding the Lundbeck License Agreement.  Ovid shall make any and all payments that become due under the Lundbeck License Agreement as a result of any 

55

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

activity under this Agreement, whether by or on behalf of Ovid or by Licensee or its Affiliate or Sublicensee, in each case in accordance with the terms of the Upstream License Agreement.

(a)Ovid is in compliance in all material respects with the Lundbeck License Agreement, and, to Licensor’s knowledge, the other party to the Lundbeck License Agreement is not in breach or default in any respect of the Lundbeck License Agreement pertaining to the Product.

(b)In the event that Ovid receives a notice or other communication alleging it is in breach (including a notice or other communication threatening termination) of the Lundbeck License Agreement, Ovid shall promptly provide Licensee with a copy of such notice.

(c)Ovid shall not agree to any amendment or other modification (including termination) to the Lundbeck License Agreement in a manner that materially adversely affects the rights sublicensed to Licensee under this Agreement without Licensee’s prior written consent, such consent not to be unreasonably withheld or delayed. 

(d)Ovid and Licensee have negotiated with Lundbeck a technology transfer agreement (the “Technology Transfer Agreement”) for the transfer from Lundbeck to Licensee of Know-How, information, and data owned or controlled by Lundbeck that is necessary or reasonably useful for the manufacture of the Compound and Drug Product in or for the Licensee Territory and according to the technology transfer  plan (the “Technology Transfer Plan”) as attached to the Technology Transfer Agreement. Such Technology Transfer Agreement shall provide such transfer to be finalized over a period of [***] starting from the Effective Date, provided that such time period shall be extended to the extent of any delay caused by Licensee or any other factor outside Ovid’s reasonable control, including delays caused by any force majeure event as described in Section 16.8 of the Agreement.

 

11.5Additional Licensee Representations, Warranties, and Covenants.  Licensee represents, warrants, and covenants to Ovid that, as of the Effective Date, Licensee has not granted, and will not grant during the Term, any right to any Third Party under the Licensee Technology that would conflict with the rights granted to Ovid hereunder.  Licensee further represents, warrants, and covenants to Ovid that, as of the Effective Date, Licensee does not own or control any Licensee Patents.  Licensee further represents, warrants, and covenants to Ovid that Licensee has the personnel, expertise, capacity, resources, equipment, and facilities necessary to implement the Technology Transfer Plan in accordance with the timelines specified therein so that such plan can be completed over a period of [***] following the date such technology transfer is commenced. 

11.6Disclaimer.  Except as expressly set forth in this Agreement, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED “AS IS” AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.  Without limiting the foregoing, (a) neither Party represents or warrants that any data obtained from conducting Clinical 

56

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Trials in one country or jurisdiction will comply with the laws and regulations of any other country or jurisdiction, and (b) neither Party represents or warrants the success of any study or test conducted pursuant to this Agreement or the safety or usefulness for any purpose of the technology it provides hereunder.

	
12.
	
Indemnification

12.1Indemnification by Ovid.  Ovid hereby agrees to defend, indemnify, and hold harmless Licensee and its Affiliates and their respective directors, officers, employees, and agents (each, a “Licensee Indemnitee”) from and against any and all liabilities, expenses, and losses including any product liability, personal injury, property damage, including reasonable legal expenses and attorneys’ fees (collectively, “Losses”) to which any Licensee Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of or result from: (a) the Development, use, handling, storage, Commercialization, or other disposition of any Compound or Product by Ovid or its Affiliates or licensees or the contractors of any of them (excluding any activities by or on behalf of Licensee or its Affiliates or Sublicensees), (b) the negligence or willful misconduct of any Ovid Indemnitee, or (c) the breach by Ovid of any warranty, representation, covenant, or agreement made by Ovid in this Agreement; except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Licensee is obligated to indemnify any Ovid Indemnitee(s) under Section 12.2.

12.2Indemnification by Licensee.  Licensee hereby agrees to defend, indemnify, and hold harmless Ovid, its Affiliates, and licensees and their respective directors, officers, employees, and agents (each, a “Ovid Indemnitee”) from and against any and all Losses to which any Ovid Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of: (a) the Development, use, handling, storage, Commercialization, or other disposition of any Compound or Product by Licensee or its Affiliates or Sublicensees or the contractor of any of them, (b) the negligence or willful misconduct of any Licensee Indemnitee, or (c) the breach by Licensee of any warranty, representation, covenant, or agreement made by Licensee in this Agreement; except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Ovid is obligated to indemnify any Licensee Indemnitee(s) under Section 12.1.

12.3Procedure. A party that intends to claim indemnification under this Article 12 (the “Indemnitee”) shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third Party claim, demand, action, or other proceeding (each, a “Claim”) in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof.  The Indemnitee may participate at its expense in the Indemnitor’s defense of and settlement negotiations for any Claim with counsel of the Indemnitee’s own choice.  The indemnity arrangement in this Article 12 shall not apply to amounts paid in settlement of any action with respect to a Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.  The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 12 if and to the extent the Indemnitor is actually prejudiced thereby.  The Indemnitee shall cooperate fully with the Indemnitor and its legal 

57

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

representatives in the investigation of any action with respect to a Claim covered by this indemnification. 

12.4Insurance.  Each Party, at its own expense, hereby agrees and undertakes to maintain insurance policies with respect to the activities to be made by and obligations assumed by each of the Party in accordance to the provisions of this Agreement. In this respect the Parties agree to carry out at their sole expense and with a commercially reasonable insurance company, the following liability policies, in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term:

(a)Clinical Trial liability policies reasonable for each specific phase and country in which a Party is conducting activities under this Agreement, with limits and warranties no less than those required by Applicable Law; and

(b)product liability policies with limits at a minimum equivalent to [***] per each occurrence and per year.

The Public and Product liability policies above shall start from the Effective Date and last for a period of [***] after the expiration or the earlier termination of the Agreement. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverages to the other Party upon request.  It is understood that such policies shall not be construed to create any limit of either Party’s obligations or liabilities with respect to its indemnification obligations hereunder.  In the event of use by either Party of subcontractors, sublicensees, or any Third Party in the performance of such Party’s obligations under the Agreement, such Party shall ensure that its subcontractor, sublicensee, or Third Party has a proper and adequate general liability or professional liability insurance to cover its risks with respect to the other Party for damages mentioned above.

12.5Limitation of Liability.  NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; provided, however, that this Section 12.5 shall not be construed to limit either Party’s indemnification obligations under this Article 12 or damages available as a result of a breach of a Party’s EXCLUSIVITY obligations under SECTION 2.8 or CONFIDENTIALITY OBLIGATIONS UNDER Article 13.  

	
13.
	
Confidentiality

13.1Confidential Information.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [***] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to the remainder of this Article 13, shall not publish or otherwise disclose 

58

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

the terms of this Agreement.  Each Party may use the other Party’s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.  Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the Confidential Information of the other Party.  Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.

13.2Exceptions.  The obligations of confidentiality and restriction on use under Section 13.1 will not apply to any information that the receiving Party can prove by competent written evidence: (a) is at the time of disclosure, or thereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; (b) is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; (c) is disclosed to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto; or (d) is independently discovered or developed by the receiving Party without the use of or reference to the Confidential Information belonging to the disclosing Party.

13.3Authorized Disclosure.  Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:

(a)filing, prosecuting, and maintaining Patents as permitted by this Agreement;

(b)submitting and maintaining Regulatory Filings for Products that such Party has a license or right to Develop or Commercialize under this Agreement in a given country or jurisdiction; 

(c)prosecuting and defending litigation as permitted by this Agreement; 

(d)complying with applicable court orders or governmental regulations, including regulations promulgated by securities exchanges; and 

(e)disclosure to its and its Affiliates’ employees, consultants, contractors, agents, licensees, and sublicensees, in each case on a need-to-know basis in connection with the Development, manufacture, or Commercialization of the Compound and Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein;

(f)disclosure to actual and bona fide potential investors, acquirors, licensees, and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, collaboration, or other business relationship, in each case under written obligations of confidentiality and non-use at least as 

59

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

stringent as those herein, provided that the disclosing Party redacts the financial terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment, acquisition, collaboration, or business transaction which redaction shall be prepared in consultation with the other Party; and

(g)disclosure to Third Party licensors of intellectual property that is related to the Compound or any Product (e.g., the Third Party that is party to the Lundbeck License Agreement) for the purpose of meeting reporting obligations under such Third Party agreement.

Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Section 13.3(c) or 13.3(d), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure, and to the extent possible, at least [***] notice, and use the same diligent efforts to secure confidential treatment of such Confidential Information as such Party would use to protect its own confidential information, but in no event less than reasonable efforts.  In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.  Any information disclosed pursuant to Section 13.3 shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Section 13.

13.4Publications.  

(a)Ovid shall have the right to review and comment on any material proposed for disclosure or publication by Licensee regarding results of and other information regarding Licensee’s Development activities during the Term with respect to the Compound and Product, whether by oral presentation, manuscript, or abstract.  Before any such material is submitted for publication, or presentation of any such material is made, Licensee shall deliver a complete copy of the material proposed for disclosure to Ovid at least [***] prior to submitting the material to a publisher or initiating any other disclosure, or as close to these time frames as reasonably possible.  Ovid shall review any such material and give its comments to Licensee within [***] of the receipt of such material.  With respect to oral presentation materials and abstracts, Ovid shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to Licensee with comments, if any.  Subject to Section 13.4(b), following the expiration of the applicable time period for review, Licensee shall be free to submit such proposed manuscript for publication or presentation materials for public disclosure, and does not need to follow this process for subsequent publications or presentations of the same data.    

(b)If Ovid notifies Licensee within the applicable time period set forth in Section 13.4(a) that such publication or presentation, in Ovid’s reasonable judgment: 

(i)contains an invention for which Ovid desires to obtain patent protection, Licensee shall delay such publication or presentation for a period of up to [***] (or such other time period agreed by the Parties in writing) to permit the preparation and filing of a patent application for such invention, or

(ii)contains any Confidential Information of Ovid, or could be expected to have an adverse effect on the commercial value of any Confidential Information disclosed by 

60

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Ovid to Licensee, the Parties shall attempt to agree on revisions to the applicable disclosure so as to preserve both the commercial value of such Confidential Information and the scientific merit of such disclosure, provided that if and to the extent the Parties are unable to agree, Licensee shall delete such Confidential Information from the proposed publication or presentation.

13.5Publicity; Public Disclosures and Public Announcements. Save as permitted in this Section 13.5, neither Party shall make any public announcement or statement to the public containing Confidential Information of the other Party without the prior consent of such other Party. On or promptly after the Effective Date, the Parties shall issue a joint public announcement, or either Party may issue its own public announcement, regarding the execution of this Agreement with information substantially consistent with the information contained in the form of press release attached hereto as Exhibit D.  It is understood that each Party may desire or be required to issue subsequent press releases relating to this Agreement or activities hereunder.  The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, to the extent practicable, and in the case of any press release Licensee wishes to issue, Licensee shall first obtain Ovid’s written approval of such release.  Notwithstanding the foregoing, neither Party may unreasonably withhold, condition, or delay consent to such releases by more than [***], and either Party may issue such press releases or make such disclosures to the SEC or other applicable agency as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or for appropriate market disclosure.  Each Party shall provide the other Party with advance notice of legally required disclosures to the extent practicable, and to the extent possible, at least [***] prior to such disclosure.  The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or as otherwise required by Applicable Laws; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws.  In addition, following the initial joint press release announcing this Agreement, either Party shall be free to disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party, and those terms of the Agreement which have already been publicly disclosed in accordance with. 

13.6Prior Confidentiality Agreement.  As of the Effective Date, the terms of this Article 13 shall supersede any prior non-disclosure, secrecy, or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including the Confidentiality Agreement.  Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information under this Agreement.

13.7Equitable Relief.  Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 13.  In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 13.

	
14.
	
Term and Termination

14.1Term.  This Agreement shall commence on the Effective Date and shall continue until terminated as provided in this Article 14 (the “Term”).  Notwithstanding anything herein, on 

61

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

a Product-by-Product and country-by-country basis, upon the expiration of the Royalty Term the licenses granted to Licensee in Section 2.1 shall become perpetual  and fully paid-up with respect to such Product in such country, subject to Licensee’s payment obligations under Article 8 during the Extended Commercialization Term, but thereafter shall be on a non-exclusive basis.  

14.2Termination for Cause.

(a)Material Breach.  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within [***] after notice of such breach from the non-breaching Party.  In the event of any dispute, the Agreement shall remain in place during the pendency of any such dispute.  

(b)Insolvency Event. 

(i)Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files a petition for relief in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes the involuntary subject of any proceeding or action of the type described above and such proceeding or action remains un-dismissed or un-stayed for a period of more than [***].  

(ii)All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code and other similar laws in any other jurisdiction outside of the Territory (collectively, the “Bankruptcy Laws”), licenses of rights to “intellectual property” as defined under the Bankruptcy Laws.  If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is rejected as provided pursuant to such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee) shall perform all of the obligations in this Agreement intended to be performed by such Party.  If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as provided for under the Bankruptcy Laws, and the non-bankrupt Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall provide to the non-bankrupt Party copies of all Patents and Information necessary for the non-bankrupt Party to [***] enjoy its rights under the terms of this Agreement.  All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws.  [***].

(c)Patent Challenge.  Ovid shall have the right to terminate this Agreement immediately in its entirety upon written notice to Licensee if Licensee or any of its 

62

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Affiliates or Sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Ovid Patent.  

14.3Termination without Cause.

(a)Prior to the First Commercial Sale.  Prior to the First Commercial Sale of the Product in the Licensee Territory, Licensee shall have the right to terminate this Agreement in its entirety without cause [***].

(b)After the First Commercial Sale.  Following the First Commercial Sale of the Product in the Licensee Territory, Licensee shall have the right to terminate this Agreement in its entirety without cause [***].

14.4Effects of Termination.  Upon any termination of this Agreement by either Party, the following Sections 14.4(a) through 14.4(g) will apply.  For clarity, during the pendency of any termination notice period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  

(a)Licenses.  Except in the event of (i) termination by Licensee for  an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason, the licenses granted by Licensee to Ovid shall survive such termination and shall automatically become worldwide.   All of the licenses granted by Ovid to Licensee shall be automatically terminated.

(b)Regulatory Materials; Data.  Except in the event of (i) termination by Licensee for an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), within [***] after the effective date of such termination, Licensee shall transfer and assign to Ovid, at no cost to Ovid, all Regulatory Filings and Regulatory Approvals for the Products, Data from all pre-clinical, non-clinical, and clinical studies of the Product conducted by or on behalf of Licensee, its Affiliates, or Sublicensees, and all pharmacovigilance data (including all adverse event data) on the Products.  In addition, at Ovid’s request, Licensee shall provide Ovid with reasonable assistance with any inquiries and correspondence with Regulatory Authorities regarding the Product in the Licensee Territory, such assistance shall be limited to a period of [***] after such termination. 

(c)Development Wind-Down. Except in the event of (i) termination by Licensee for an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Licensee shall either, as directed by Ovid, (i) wind-down any ongoing Development activities (including any Clinical Trials) of Licensee or its Affiliates and Sublicensees with respect to any Product in the Licensee Territory in an orderly fashion or (ii) promptly transfer such 

63

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

Development activities to Ovid or its designee, in each case in compliance with all Applicable Laws.  

(d)Cost of Ongoing Trials. Except in the event of (i) termination by Licensee for  an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason, if there is any ongoing Clinical Trial of the Product under the Development Plan for which the Parties are sharing costs, then Licensee shall continue to share the cost of such Clinical Trial until the effective date of termination.   

(e)Commercial Wind-Down. Except in the event of (i) termination by Licensee for  an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Licensee shall, as directed by Ovid, (A) continue certain ongoing Commercial activities of Licensee and its Affiliates and Sublicensees with respect to any Product in the Licensee Territory for a period of up to [***] after the effective date of termination, as determined by Ovid, and (B) handoff such Commercial activities to Ovid or its designee, on a timetable to be set by Ovid, not to exceed [***] after the effective date of termination, and in compliance with all Applicable Laws.  During such commercial wind-down period, Licensee shall continue to book sales and pay royalties to Ovid in accordance with Section 8.5.  Except as necessary to conduct the foregoing activities as directed by Ovid, Licensee shall immediately discontinue its (and shall ensure that its Affiliates and Sublicensees immediately discontinue their) promotion, marketing, offering for sale, and servicing of the Product and its use of all Product Marks.  In addition, Licensee shall immediately deliver to Ovid (at Licensee’s expense) all samples, demonstration equipment, sales materials, catalogs, and literature of Ovid in Licensee’s possession or control.   

(f)Transition Assistance. Except in the event of (i) termination by Licensee for  an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Licensee shall, at no cost to Ovid, provide reasonable consultation and assistance for a period of no more than [***] after the effective date of termination for the purpose of transferring or transitioning to Ovid all Licensee Know-How not already in Ovid’s possession and, at Ovid’s request, all then-existing commercial arrangements, customer lists, and similar information relating to the Products that Licensee is able, using Commercially Reasonable Efforts, to transfer or transition to Ovid or its designee, in each case, to the extent reasonably necessary for Ovid to continue the Development or Commercialization of the Compound and Products in the Licensee Territory.  If any such contract between Licensee and a Third Party is not assignable to Ovid or its designee (whether by such contract’s terms or because such contract does not relate specifically to the Products) but is otherwise reasonably necessary for Ovid to continue the Development or Commercialization of the Compound and Products in the Licensee Territory, or if Licensee is performing such work for the Compound and Product itself (and thus there is no contract to assign), then Licensee shall reasonably cooperate with Ovid to negotiate for the continuation of such services for Ovid from such entity, or Licensee shall continue to perform such work for Ovid, as applicable, for a reasonable period (not to exceed [***]) after the effective date of termination at Ovid’s cost until Ovid establishes an alternate, validated source of such services.  

64

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

(g)Remaining Inventories. Except in the event of (i) termination by Licensee for an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or (iii) Ovid’s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Ovid shall have the right, at its discretion, to obtain from Licensee any or all of the inventory of the Products held by Licensee as of the date of termination, free of charge.  Ovid shall notify Licensee within [***] after the effective date of termination whether Ovid elects to exercise such right.

14.5Licensee Continuation. If (a) Licensee has the right to terminate this Agreement in its entirety for an uncured material breach by Ovid, but elects to continue this Agreement in its entirety as modified by this Section 14.5, or (b) Licensee has the right to terminate in the circumstances set forth in Section 14.2(b)(i), but elects to continue this Agreement as modified by this Section 14.5, or (c) Ovid elects to terminate this Agreement in its entirety for Safety Reason, but Licensee elects to continue this Agreement as modified by this Section 14.5, then, except as provided below, effective as of the date Licensee delivers notice of such election to Ovid, the following shall apply: 

	
 
	
i.
	
Licensee shall have the right to terminate the Supply Agreement, and if Licensee terminates the Supply Agreement, Ovid shall cooperate with Licensee for smooth technology transfer of the manufacturing process if termination occurs prior to the Technology Transfer Completion Date.

	
 
	
ii.
	
Notwithstanding anything contained in this Agreement to the contrary, Ovid shall cease any and all Development/Regulatory activities with respect to the Product in the Field in the Licensee Territory (other than the Ovid Ongoing Trials if still ongoing);

	
 
	
iii.
	
All Licensee payment obligations provided in this Agreement shall continue, including those that are accrued and unpaid as of the date of such election by Licensee, [***];

	
 
	
iv.
	
After the effective date of such election by Licensee, the licenses granted by Ovid to Licensee in Section 2.1 under the Product Marks, Ovid Know-How and Ovid Patents for the research, the Development, the use, and the Commercialization of the Product in the Field in the Licensee Territory shall continue and the Licensee shall have such rights to Develop, Manufacture and Commercialize any Product in the Field in the Licensee Territory at Licensee’s sole discretion;

	
 
	
v.
	
The CGB shall coordinate the wind-down of Ovid’s efforts under this Agreement, and Ovid, as soon as reasonably practical after the effective date of such election, shall provide to Licensee, as applicable and to the extent permitted under any applicable Third Party contract, (1) any information, including copies of all Clinical Trial data and results, and the like developed by or for the benefit of Ovid for a Product in the Field in the Licensee Territory; and (2) other documents to the extent relating to the Products that are necessary for the continued Development, Commercialization and Manufacture of the Product (including material documents and agreements relating to the sourcing and Manufacture of a Product for sale, promotion, distribution, or use of a Product) in the Field throughout the Licensee Territory. Ovid will cooperate with Licensee to 

65

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

	
 
		
provide a transfer of such material information and documents.  At Licensee’s request, Ovid shall use reasonable efforts to assign to Licensee any and all agreements to which Ovid, or its Affiliate, and a Third Party are parties, and that solely cover or govern the Development, Commercialization and Manufacturing activities conducted in connection with a Product in the Field in the Territory prior to such election by Licensee, or if such assignment is not permitted under the relevant agreement, (A) grant to Licensee other reasonable rights to provide to Licensee the benefit of such non-assignable agreement, at Licensee’s expense, to the extent permitted under the terms of such non-assignable agreement; or (B) to the extent not permitted under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable Licensee to receive, at Licensee’s expense, the benefit of the terms of such non-assignable agreement. Ovid shall take such other reasonable actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights to such Product(s) as described in this Section 14.5(v) hereunder to Licensee;

	
 
	
vi.
	
Ovid shall transfer to Licensee any and all Regulatory Materials directly and solely related to the Product in the Field in the Licensee Territory, and, upon Licensee’s request, shall make available to Licensee any other relevant information reasonably requested by Licensee related to such Regulatory Materials;

	
 
	
vii.
	
As long as Licensee is not in breach of this Agreement or the Lundbeck License Agreement at the effective date of such election, Licensee shall have the rights of a non-breaching sublicensee set forth in the Lundbeck License Agreement (as amended by the Lundbeck Sublicense Amendment) from and after such election;

	
 
	
viii.
	
Licensee shall have no further obligation to use Angelini Commercially Reasonable Efforts with respect to its obligations hereunder;

	
 
	
ix.
	
Ovid shall be obliged to bear the costs of the Ovid Ongoing Trials, if still ongoing; and

	
 
	
x.
	
In lieu of Section 12.1 and Section 12.2, the following shall apply: Licensee hereby agrees to defend, indemnify, and hold harmless the Ovid Indemnitees from and against any and all Losses to which any Ovid Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of: (A) Licensee’s decision to continue the Development, Manufacture and Commercialization of Product following Ovid’s cessation of such activities for Safety Reason, (B)  any Development, use, handling, storage, manufacture, Commercialization, or other disposition of any Compound or Product by Licensee or its Affiliates or Sublicensees or the contractor of any of them, (C) the negligence or willful misconduct of any Licensee Indemnitee or Licensee’s Affiliates or Sublicensees, or (D) the breach by Licensee of any warranty, representation, covenant, or agreement made by Licensee in this Agreement. 

14.6Confidential Information.  Upon expiration or termination of this Agreement in its entirety, except to the extent that a Party obtains or retains the right to use the other Party’s Confidential Information, each Party shall promptly return to the other Party, or delete or destroy, 

66

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

all relevant records and materials in such Party’s possession or control containing Confidential Information of the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject to continuing confidentiality obligations.  All Licensee Data and Regulatory Filings assigned to Ovid upon termination of this Agreement will be deemed Ovid’s Confidential Information and no longer Licensee’s Confidential Information.

14.7Survival.  Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.  Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement.

14.8Exercise of Right to Terminate.  All rights and obligations of a Party accrued prior to the effective date of a termination (including the rights to receive reimbursement for costs incurred prior to the effective date of such termination and payments accrued or due prior to the effective date of such termination) shall survive such termination.

	
15.
	
Dispute Resolution 

15.1General.  Except as provided in Sections 3.4 and 9.4, any dispute between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a “Dispute”) shall be resolved pursuant to this Section 15.

15.2Executive Officers.  Any Dispute shall first be referred to the Executive Officers of the Parties, who shall confer in good faith on the resolution of the issue.  Any final decision mutually agreed to by the Executive Officers shall be conclusive and binding on the Parties.

15.3Intellectual Property Disputes.  If the Executive Officers are not able to agree on the resolution of a Dispute within thirty (30) days (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them and such Dispute is with respect to the validity, scope, enforceability, inventorship, or ownership of any Patent, trademark, or other intellectual property right (“IP Dispute”), then, if a Party wishes to pursue further resolution of such IP Dispute, an action, claim, or proceeding to resolve such IP Dispute shall be brought in any court of competent jurisdiction in any country or jurisdiction in which such intellectual property rights apply.  

15.4Arbitration.  If the Executive Officers are not able to agree on the resolution of a Dispute within thirty (30) days (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then, except as otherwise set forth in Section 15.3, if a Party wishes to pursue further resolution of such Dispute, such Dispute shall be finally resolved by binding arbitration in accordance with this Section 15.4.  Such Dispute shall be referred to and finally resolved by arbitration under the International Chamber of Commerce (“ICC”) Rules, as then in effect, by a tribunal of three (3) arbitrators.  The seat and legal place of the arbitration shall be [***].  Each Party shall nominate one arbitrator and the third arbitrator shall be nominated by the two Party-nominated arbitrators within [***] after the second arbitrator’s appointment.  If a Party does not nominate its arbitrator within [***] following the expiry of the allotted period, then such arbitrator shall be appointed by the ICC in accordance with its rules.  Any arbitrator appointed by the ICC shall have at least [***] experience in the pharmaceutical 

67

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

industry.  The arbitration shall be conducted, and all documents submitted to the arbitrators shall be, in English.  Each Party shall bear its own legal costs for its counsel and other expenses, and the Parties shall equally share the costs of the arbitration; provided that the arbitral tribunal shall have the discretion to provide that the losing party is responsible for all or a portion of such arbitration and legal costs, in such case the arbitral award will so provide.  The arbitrators shall have no power to award damages excluded pursuant to Section 12.5.  In no event shall the arbitrators assign a value to any issue greater than the greatest value for such issue claimed by either Party or less than the smallest value for such issue for such item claimed by either Party.  The award shall be final and binding upon the Parties and the Parties undertake to carry out any award without delay.  Judgment on the award may be entered in any court of competent jurisdiction.  Except to the extent necessary to confirm, enforce, or challenge an award of the arbitration, to protect or pursue a legal right, or as otherwise required by Applicable Law or regulation or securities exchange, neither Party nor any arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties.  Notwithstanding anything to the contrary in the foregoing, in no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy, or claim would be barred by the applicable New York statute of limitations.  Any disputes concerning the propriety of the commencement of the arbitration shall be finally settled by the arbitral tribunal.  

15.5Interim Relief.  Notwithstanding anything herein to the contrary, nothing in this Article 15 shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction, or other interim equitable relief concerning a Dispute in any court of competent jurisdiction before or after the initiation of an arbitration as set forth in Section 15.4, if necessary to protect the interests of such Party.  This Section 15.5 shall be specifically enforceable.

	
16.
	
General Provisions

16.1Governing Law.  This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles.  

16.2Entire Agreement; Modification.  This Agreement, including the exhibits, is both a final expression of the Parties’ agreement and a complete and exclusive statement with respect to all of its terms.  This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein.  This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.

16.3Relationship Between the Parties.  The Parties’ relationship, as established by this Agreement, is solely that of independent contractors.  This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties, including for all tax purposes.  Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. The Parties (and any successor, assignee, transferee, 

68

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

or Affiliate of a Party) shall (a) use commercially reasonable efforts to structure the arrangement and activities contemplated by this Agreement to avoid the arrangement contemplated by this Agreement being treated as a partnership that is engaged in a “United States trade or business” for United States tax purposes and (b) not treat or report the relationship between the Parties arising under this Agreement as a partnership for United States tax purposes, without the prior written consent of the other Party unless required by a final “determination” as defined in Section 1313 of the United States Internal Revenue Code of 1986, as amended. 

16.4Non-Waiver.  The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance.  Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.

16.5Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, such consent not to be unreasonably withheld. Any successor or assignee of rights and obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and obligations. Notwithstanding the foregoing, either Party may assign this Agreement and its rights and obligations hereunder without the other Party’s consent: 

(a) in connection with the transfer or sale, through whatever means, of all or substantially all of its assets or the business of such Party to which this Agreement relates (whatever by assignment, conveyance, reorganization, merger, assumption, purchase and sale of stock, by contract or by operation of law, provided that the intellectual property rights of the acquiring party to such transaction (if other than one of the Parties) shall not be included in the technology licensed under this Agreement; or

(b)to an Affiliate, provided that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, the Agreement shall be automatically assigned back to the assigning Party or its successor.  

Any permitted assignment shall be binding on the successors and the permitted assigns of a Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 16.5 shall be null, void and of no legal effects. 

16.6Severability.  If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.  All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable, or illegal part.  

16.7Notices.  Any notice to be given under this Agreement must be in writing and delivered either in person, by (a) air mail (postage prepaid) requiring return receipt, (b) overnight courier, or (c) facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at 

69

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 16.7.  Notice shall be deemed sufficiently given for all purposes upon the earliest of:  (i) the date of actual receipt, (ii) if air mailed, five (5) days after the date of postmark, (iii) if delivered by overnight courier, the next day the overnight courier regularly makes deliveries, or (iv) if sent by facsimile, the date of confirmation of receipt if during the recipient’s normal business hours, otherwise the next business day.

If to Licensee, notices must be addressed to:

Angelini Pharma Rare Diseases AG 

Consulting GmbH Sumpfstrasse 26 6312 

Steinhausen, Zurich

Switzerland
Attention: Chief Executive Officer

With a copy to:

Angelini Pharma S.p.A.
Viale Amelia 70, 00181

Roma, Italy

Attention: Enza Maria Cristina Onnis, Global Pharma General Counsel
mail: [***]

If to Ovid, notices must be addressed to:

Ovid Therapeutics

1460 Broadway, Suite 15021

New York, NY 10036
USA
Attention:  Chief Executive Officer

And a copy to:

Attention:  General Counsel

With a copy to (which shall not constitute notice):

Cooley LLP
3175 Hanover Street
Palo Alto, CA 94304
USA
Attention: Laura Berezin

16.8Force Majeure.  Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (other than failure to make payment when due) by reason of any event beyond such Party’s reasonable control including Acts of God, fire, flood, explosion, earthquake, pandemic (including the COVID-19 pandemic), quarantine or similar restrictions, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction 

70

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

or other casualty, any lack or failure of transportation facilities, any injunction, order, proclamation, demand, or requirement of any Governmental Authority [***], any lack or failure of supply of raw materials, or any other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur and uses reasonable efforts to overcome such event.  Notice of a Party’s failure or delay in performance due to force majeure must be given to the other Party within [***] after its occurrence.  All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.  In no event shall any Party be required to prevent or settle any labor disturbance or dispute.

16.9Interpretation.  The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.  All references in this Agreement to the singular shall include the plural where applicable.  Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.  The word “including” and similar words means including without limitation.  The word “or” means “and/or” unless the context dictates otherwise because the subjects of the conjunction are, or are intended to be, mutually exclusive.  The words “herein”, “hereof”, and “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.  All references to days in this Agreement mean calendar days, unless otherwise specified.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  This Agreement has been prepared in the English language and the English language shall control its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.

16.10Counterparts; Electronic or Facsimile Signatures.  This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party. 

{Signature Page Follows}

71

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

In Witness Whereof, the Parties hereto have caused this Collaboration and License Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.

		
	
 

Ovid Therapeutics Inc.

 

By:  /s/ Jeremy Levin

Name:  Jeremy Levin

Title:  Chief Executive Officer
	
 

Angelini Pharma Rare Diseases AG  

 

By:  /s/ Pierluigi Antonelli

Name:  Pierluigi Antonelli

Title:  Chairman of the BoD

 

 

 

 

 

 

 

 

72

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

List of Exhibits and Schedules

Exhibit A: Compound

Exhibit B: Ovid Patents

Exhibit C: Development Plan

Exhibit D: Press Release

Exhibit E: Technology Transfer Plan

Exhibit F: Documents to be transferred according to Section 8.1(b)(i)

Exhibit G: Other Documents to be transferred

Exhibit H: Description of Additional Pivotal Trial

Exhibit I: Current Licensee Pipeline Products

Exhibit J: Descriptions of Elara Trial, Neptune Trial, and Rocket Trial

Exhibit K: Supply Agreement

Exhibit L: Finished Product Documentation

73

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit A

Compound

 

 

 

 

 

 

 

 

74

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit B

Ovid Patents

[***]

 

 

 

75

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit C

Development Plan

 

[***]

76

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit D

Press Release

 

             

 

Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe

 

	
 
	
•
	
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, Switzerland, Turkey and the United Kingdom

 

	
 
	
•
	
Ovid Therapeutics will receive an upfront payment of $20 million and additional payments of up to $212.5 million upon the achievement of development, manufacturing and sales milestones, in addition to double-digit royalties on net sales if successfully commercialized

 

	
 
	
•
	
Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG

 

NEW YORK and ROME, July XX, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID, hereinafter “Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, and Angelini Pharma S.p.A. (hereinafter “Angelini Pharma”), an Italian family-owned pharmaceutical company committed to helping patients with a constant and prevalent focus on Mental Health, Rare Diseases and Consumer Health, announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries in the European Economic Area, Switzerland, Turkey and United Kingdom.  Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG. OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in development, and is currently being evaluated in the pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020.

 

Under the terms of the agreement, Ovid will receive an upfront payment of $20 million and is eligible to receive up to an additional $212.5 million in payments upon the achievement of development, 

77

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

manufacturing and sales milestones for the initial indication (Angelman syndrome), as well as double-digit royalties on net sales if OV101 is successfully commercialized. Ovid will retain all U.S. and rest-of-world commercial rights to OV101.

 

“We are excited to enter into a strategic collaboration with Angelini Pharma with the goal of bringing OV101, if approved, to the Angelman community in Europe as quickly as possible. Angelini Pharma is an ideal partner for Europe as they have deep regional knowledge, an established infrastructure with a history of successful product launches, and a commitment to improving the quality of life of the patient communities they serve,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “Finding the right partners to bring OV101 to the Angelman community as rapidly as possible is a core part of our global strategy. We believe this partnership with Angelini will help to maximize the potential commercial value of OV101 and achieve our strategic objectives in this important geography."

 

“Today is a day that we will remember. Through our collaboration with Ovid Therapeutics, we are laying the foundation to developing innovative health solutions for rare diseases, in line with Angelini Pharma’s new strategy,” said Pierluigi Antonelli, Angelini Pharma CEO. “The new business unit Angelini Pharma Rare Diseases AG will contribute to the development, registration, production and, if approved, commercialization in Europe of OV101, Ovid Therapeutics’ very promising drug being evaluated in a Phase 3 clinical trial for the treatment of Angelman syndrome. As of now, there is no effective treatment for this rare genetic disease, characterized by severe psychomotor disability, which manifests itself from childhood. Delivering on our commitment makes us proud both from a scientific perspective and its social impact”. 

 

"As shareholders and executives of Angelini Holding we continue to invest in the pharma area, which today represents half of our Group's turnover,” commented the executive vice president Thea Paola Angelini and the CEO Sergio Marullo di Condojanni. “Our global development and internationalization strategy focuses on business areas with high growth potential. Particularly, we look closely at all the opportunities that can open up, not only in healthcare, but also in the consumer and machinery sector."

 

About Angelman Syndrome 

Angelman syndrome is a rare genetic condition that is characterized by a variety of signs and symptoms. Characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. Individuals with Angelman syndrome typically have normal lifespans but are unable to live independently. Therefore, they require constant support from a network of specialists and caregivers. Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 people globally.

 

There are no approved therapies by the U.S. Food and Drug Administration (FDA), European Medicines Agency or rest–of-world for Angelman syndrome, and treatment primarily consists of behavioral interventions and pharmacologic management of symptoms.

 

Angelman syndrome is associated with a reduction in tonic inhibition, a function of the delta (δ)-selective GABAA receptor that allows a human brain to decipher excitatory and inhibitory neurological 

78

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

signals correctly without being overloaded. If tonic inhibition is reduced, the brain becomes inundated with signals and loses the ability to separate background noise from critical information.

 

About OV101 (gaboxadol)

OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of certain neurodevelopmental disorders. OV101 has demonstrated in laboratory studies and animal models to selectively activate the δ-subunit of GABAA receptors, which are found in the extrasynaptic space (outside of the synapse), and thereby impact neuronal activity through modulation of tonic inhibition.

 

Ovid is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and thereby address several core symptoms of these conditions. In both these syndromes, the underlying pathophysiology includes disruption of tonic inhibition modulated through the δ-subunit of GABAA receptors. In preclinical studies, it was observed that OV101 improved symptoms of Angelman syndrome and Fragile X syndrome. This compound has also previously been tested in more than 4,000 patients (more than 1,000 patient-years of exposure) and was observed to have favorable safety and bioavailability profiles. Ovid is conducting a pivotal Phase 3 clinical trial with OV101 in Angelman syndrome (NEPTUNE) and has completed a Phase 2 signal-finding clinical trial with OV101 in Fragile X syndrome (ROCKET).

 

OV101 has received Rare Pediatric Disease Designation from the FDA for the treatment of Angelman syndrome. The FDA has also granted Orphan Drug and Fast Track designations for OV101 for both the treatment of Angelman syndrome and Fragile X syndrome. In addition, the European Commission (EC) has granted orphan drug designation to OV101 for the treatment of Angelman syndrome. The U.S. Patent and Trademark Office has granted Ovid patents directed to methods of treating Angelman syndrome and Fragile X syndrome using OV101. The issued patents expire in 2035 without regulatory extensions.

 

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit www.ovidrx.com.

 

About Angelini Pharma

Angelini Pharma, owned by Angelini Holding, is a pharmaceutical Company committed to helping patients with a constant and prevalent focus on Mental Health, including Pain, Rare Diseases and Consumer Health. Angelini Pharma has an extensive and recognized R&D programs, "World Class" production plants and international commercialization activities of active ingredients and market-leading drugs. For further information, please visit www.angelinipharma.com

 

About Angelini Holding

79

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Angelini Holding is the parent company of an international group operating in the pharmaceutical and consumer goods sectors. Founded in Italy in 1919, today Angelini group operates in 17 countries with a staff of 5,600 and a turnover of €1,7 billion. In addition to the Pharmaceutical sector, Angelini group operates in Personal and Home Care business area through Fater, a joint venture with Procter & Gamble, in the Machinery field, again in joint venture with P&G, with the group operating in automation and robotics for the consumer goods industry Fameccanica, in Perfumery and Skincare and Suncare with Angelini Beauty and in the Wine sector through Bertani Domains. Angelini Holding has recently entered the Baby food market as well through MadreNatura, a joint venture with Hero Group, which offers 100% organic baby food products.

 

 

Ovid Therapeutics Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: advancing development of and commercializing OV101, the potential benefits and value of OV101; the anticipated reporting schedule of clinical data for OV101; and the potential benefits and outcome from this collaboration. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Ovid Therapeutics Contacts

 

Investors and Media:

Ovid Therapeutics Inc.

Investor Relations & Public Relations

irpr@ovidrx.com 

 

Or

 

Investors: 

Steve Klass

Burns McClellan, Inc.

sklass@burnsmc.com 

(212) 213-0006

80

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

Media:
Katie Engleman
1AB
katie@1abmedia.com

 

Angelini Pharma Contact:

Daniela Poggio

Head of Global Communications Angelini Pharma 

+39 348 6558882

daniela.poggio@angelinipharma.com

 

Angelini Holding Contact:

Institutional & External Relations Director Angelini Holding 

+39 348 6707240

alessandra.favilli@angeliniholding.com 

 

 

 

 

 

81

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

Exhibit E

Technology Transfer Plan

 

[***]

 

82

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

Exhibit F

Documents to be transferred according to Section 8.1(b)(i)

 

[***]

83

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

Exhibit G

Other Documents to be transferred

[***]

 

 

84

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

 

Exhibit H
Description of Additional Pivotal Trial

 

[To be completed if and when the Additional Pivotal Trial is required by the EMA or by Licensee at its own discretion.] 

85

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit I 
Current Licensee Pipeline Products

 

 

[***]

 

86

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

Exhibit J
Descriptions of Elara Trial, Neptune Trial, and Rocket Trial

 

 

 

 

87

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

88

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit K
Supply Agreement

[***]

 

 

			
	
 
	
 

	
 
	
 

89

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

List of Exhibits

Exhibit A:The Compound

Exhibit B:Mandatory Estimated Forecast

Exhibit C:Initial Purchase Order for Allocated Quantity of Compound

90

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit A:The Compound

 

91

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit B:Mandatory Estimated Forecast 

 

[***]

 

 

92

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

Exhibit C:Initial Purchase Order for Allocated Quantity of Compound

 

[***]

 

 

 

 

 

 

93

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

 

 

 

Exhibit L

Finished Product Documentation

[***]

 

 

94

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.Exhibit 4.11

 

FIFTH SUPPLEMENTAL INDENTURE

 

FIFTH SUPPLEMENTAL INDENTURE, dated as of
March 15, 2021 (this “Supplemental Indenture”), by and between SANTANDER UK GROUP HOLDINGS PLC, a public limited
company incorporated in England and Wales (the “Issuer”) and CITIBANK, N.A., a national banking association
incorporated in the United States, as trustee (the “Trustee”), having its Corporate Trust Office at 388 Greenwich
Street, New York, New York 10013.

 

W I T N E S S E T H:

 

WHEREAS, the Issuer and Wells Fargo
Bank, National Association (the “Former Trustee”) have executed and delivered an Amended and Restated Indenture
dated as of April 18, 2017 (as supplemented and amended by a first supplemental indenture entered into between the Issuer and the
Former Trustee on November 3, 2017 and a fourth supplemental indenture entered into between the Issuer and the Former Trustee on
August 21, 2020, the “Base Indenture” and, together with this Supplemental Indenture, the “Indenture”);

 

WHEREAS, Section 6.11(a) of the Base
Indenture provides that any successor trustee appointed with respect to all Senior Debt Securities shall, in accordance with the
Base Indenture execute, acknowledge and deliver to the Issuer and to the retiring trustee an instrument accepting such appointment
under the Base Indenture, and thereupon the resignation of the retiring trustee shall become effective and such successor trustee,
without any further act, deed or conveyance, shall become vested with all rights, powers, duties and obligations of the retiring
trustee;

 

WHEREAS, in satisfaction of Section
6.11(a) of the Base Indenture, the Issuer, the Former Trustee and the Trustee entered into an Agreement of Resignation, Appointment
and Acceptance, dated as of March 4, 2021, whereby the Former Trustee resigned as trustee, and the Trustee was appointed, and accepted
its appointment, as trustee under the Indenture;

 

WHEREAS, Section 9.01(f) of the Base
Indenture provides that the Issuer and the Trustee may enter into a supplemental indenture to establish the forms or terms of the
Senior Debt Securities of any series without the consent of Holders as permitted under Sections 2.01 or 3.01 of the Base Indenture;

 

WHEREAS, the Issuer desires to issue
$1,400,000,000 1.089% Fixed Rate/Floating Rate Notes due 2025 (such series of Senior Debt Securities, the “2025 Notes”)
and $600,000,000 2.896% Fixed Rate/Floating Rate Notes due 2032 (such series of Senior Debt Securities, the “2032 Notes”,
and, together with the 2025 Notes, the “Notes”) pursuant to the Base Indenture (as supplemented and amended
by this Supplemental Indenture);

 

WHEREAS, all conditions and requirements
necessary to make this Supplemental Indenture a valid and binding instrument in accordance with the terms of the Indenture have
been performed and fulfilled and the execution and delivery hereof have been in all respects duly authorized;

 

NOW, THEREFORE, each party agrees
as follows for the benefit of the other parties and the equal and ratable benefit of the Holders of the Notes.

 

     

     

    

 

Article
1

DEFINITIONS

 

Section 1.01.         
Definition of Terms. For all purposes of this Supplemental Indenture:

 

(a)           
capitalized terms used herein but not otherwise defined shall have the meanings assigned to them in the Base Indenture;

 

(b)          
all other terms used herein that are defined in the Trust Indenture Act, either directly or by reference therein, have the
meanings assigned to them therein;

 

(c)           
the terms defined in this Article have the meanings assigned to them in this Article and include the plural as well as the
singular;

 

(d)           
the section headings herein are for convenience only and shall not affect the construction of this Supplemental Indenture;
and

 

(e)           
the words “herein,” “hereof” and “hereunder” and other words of
similar import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision.

 

Section 1.02.         
Supplemental Definitions. The following definitions shall apply to the Notes only:

 

(a)           
“2025 Notes” has the meaning set forth in the recitals to this Supplemental Indenture.

 

(b)           
“2025 Notes Fixed Rate Period” has the meaning set forth in Section 3.01(a) of this Supplemental
Indenture.

 

(c)           
“2025 Notes Floating Rate” has the meaning set forth in Section 3.01(a) of this Supplemental Indenture.

 

(d)          
 “2025 Notes Floating Rate Period” has the meaning set forth in Section 3.01(a) of this Supplemental
Indenture.

 

(e)           
“2025 Notes Floating Rate Period Interest Payment Date” means each of June 15, 2024, September 15, 2024,
December 15, 2024 and the 2025 Notes Maturity Date.

 

(f)            
“2025 Notes Initial Interest Rate” has the meaning set forth in Section 3.01(a) of this Supplemental
Indenture.

 

(g)           
“2025 Notes Margin” has the meaning set forth in Section 3.01(a) of this Supplemental Indenture.

 

(h)           
“2025 Notes Maturity Date” has the meaning set forth in Section 2.01(c) of this Supplemental Indenture.

 

(i)            
“2032 Notes” has the meaning set forth in the recitals to this Supplemental Indenture.

 

(j)            
“2032 Notes Fixed Rate Period” has the meaning set forth in Section 3.01(b) of this Supplemental
Indenture.

 

(k)           
“2032 Notes Floating Rate” has the meaning set forth in Section 3.01(b) of this Supplemental Indenture.

 

    2

     

    

 

(l)            
 “2032 Notes Floating Rate Period” has the meaning set forth in Section 3.01(b) of this Supplemental
Indenture.

 

(m)          
 “2032 Notes Floating Rate Period Interest Payment Date” means each of June 15, 2031, September 15, 2031,
December 15, 2031 and the 2032 Notes Maturity Date.

 

(n)           
“2032 Notes Initial Interest Rate” has the meaning set forth in Section 3.01(b) of this Supplemental
Indenture.

 

(o)           
“2032 Notes Margin” has the meaning set forth in Section 3.01(b) of this Supplemental Indenture.

 

(p)           
“2032 Notes Maturity Date” has the meaning set forth in Section 2.02(c) of this Supplemental Indenture.

 

(q)           
“Base Indenture” has the meaning set forth in the recitals to this Supplemental Indenture.

 

(r)            
“Benchmark” has the meaning set forth in Section 3.03(a) of this Supplemental Indenture.

 

	(s)            “Benchmark Replacement” means the first alternative set forth in the order below that can be determined by the Issuer or its designee (in consultation with the Issuer) as of the Benchmark Replacement Date:
	(1)    the sum of: (a) the alternate rate of interest that has been selected or recommended by the Relevant Governmental Body as the replacement for the then-current Benchmark for the applicable Corresponding Tenor (if any) and (b) the Benchmark Replacement Adjustment;
	(2)    the sum of: (a) the ISDA Fallback Rate and (b) the Benchmark Replacement Adjustment; and
	(3)    the sum of: (a) the alternate rate of interest that has been selected by the Issuer or the Issuer’s designee (in consultation with the Issuer) as the replacement for the then-current Benchmark for the applicable Corresponding Tenor giving due consideration to any industry-accepted rate of interest as a replacement for the then-current Benchmark for U.S. dollar-denominated floating rate notes at such time and (b) the Benchmark Replacement Adjustment.
	(t)            “Benchmark Replacement Adjustment” means the first alternative set forth in the order below that can be determined by the Issuer or its designee (in consultation with the Issuer) as of the Benchmark Replacement Date:
	(1)    the spread adjustment (which may be a positive or negative value or zero) that has been (i) selected or recommended by the Relevant Governmental Body or (ii) determined by the Issuer or its designee (in consultation with the Issuer) in accordance with the method for calculating or determining such spread adjustment that has been selected or recommended by the Relevant Governmental Body, in each case for the applicable Unadjusted Benchmark Replacement;
	(2)    if the applicable Unadjusted Benchmark Replacement is equivalent to the ISDA Fallback Rate, then the ISDA Fallback Adjustment;

 

    3

     

    

 

	(3)    the spread adjustment (which may be a positive or negative value or zero) that has been selected by the Issuer or its designee (in consultation with the Issuer) giving due consideration to industry-accepted spread adjustments (if any), or method for calculating or determining such spread adjustment, for the replacement of the then-current Benchmark with the applicable Unadjusted Benchmark Replacement for U.S. dollar-denominated floating rate notes at such time.

(u)           
“Benchmark Replacement Conforming Changes” has the meaning
set forth in Section 3.05(b) of this Supplemental Indenture.

 

(v)           
“Benchmark Replacement Date” means the earliest to occur of
the following events with respect to the then-current Benchmark:

 

(1)   
in the case of clause (1) or (2) of the definition of “Benchmark Transition Event,” the later of (A) the date
of the public statement or publication of information referenced therein and (B) the date on which the administrator of the Benchmark
permanently or indefinitely ceases to provide the Benchmark; or

 

(2)   
in the case of clause (3) of the definition of “Benchmark Transition Event,” the date of the public statement
or publication of information referenced therein.

 

For the avoidance of doubt, if the
event giving rise to the Benchmark Replacement Date occurs on the same day as, but earlier than, the Reference Time in respect
of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference Time for such determination.

 

(w)          
“Benchmark Transition Event” means the occurrence of one or
more of the following events with respect to the then-current Benchmark:

 

(1)   
a public statement or publication of information by or on behalf of the administrator of the Benchmark announcing that such
administrator has ceased or will cease to provide the Benchmark, permanently or indefinitely, provided that, at the time
of such statement or publication, there is no successor administrator that will continue to provide the Benchmark;

 

(2)   
a public statement or publication of information by the regulatory supervisor for the administrator of the Benchmark, the
central bank for the currency of the Benchmark, an insolvency official with jurisdiction over the administrator for the Benchmark,
a resolution authority with jurisdiction over the administrator for the Benchmark or a court or an entity with similar insolvency
or resolution authority over the administrator for the Benchmark, which states that the administrator of the Benchmark has ceased
or will cease to provide the Benchmark permanently or indefinitely, provided that, at the time of such statement or publication,
there is no successor administrator that will continue to provide the Benchmark; or

 

(3)   
a public statement or publication of information by the regulatory supervisor for the administrator of the Benchmark announcing
that the Benchmark is no longer representative;

 

(x)           
“Benchmark Transition Provisions” has the meaning set forth in Section 3.05 of this Supplemental
Indenture;

 

(y)           
“Business Day” means any day, other than a Saturday or Sunday, that is neither a legal holiday nor a
day on which banking institutions in the City of New York or London, England are authorized or required by law, regulation or executive
order to close.

 

    4

     

    

 

(z)            
 “Calculation Agent” means Citibank, N.A., or its successor appointed by the Issuer.

 

(aa)         
“Capital Rules” means at any time the regulations, requirements, guidelines and policies relating to
capital resources requirements or capital adequacy then in effect and applicable to the Group (including, without limitation, any
regulations, requirements, guidelines and policies of the Regulator as may from time to time be applicable to the Group).

 

(bb)        
“Compounded SOFR Index Rate” has the meaning set forth in Section 3.03(b) of this Supplemental
Indenture.

 

(cc)         
“Corresponding Tenor” with respect to a Benchmark Replacement means a tenor (including overnight) having
approximately the same length (disregarding business day adjustments) as the applicable tenor for the then-current Benchmark.

 

(dd)         
 “designee” means an Affiliate or any other agent of the Issuer.

 

(ee)         
“Fixed Rate Period Interest Payment Date” means each March 15 and September 15, commencing September
15, 2021.

 

(ff)          
“Floating Rate Interest Period” means, during each of the 2025 Notes Floating Rate Period and the 2032
Note Floating Rate Period, the period beginning on (and including) a Floating Rate Period Interest Payment Date and ending on (but
excluding) the next succeeding Floating Rate Period Interest Payment Date; provided that the first Floating Rate Interest Period
in respect of the 2025 Notes will begin on (and include) March 15, 2024 and will end on (but exclude) the first 2025 Notes Floating
Rate Period Interest Payment Date and the first Floating Rate Interest Period in respect of the 2032 Notes will begin on (and include)
March 15, 2031 and will end on (but exclude) the first 2032 Notes Floating Rate Period Interest Payment Date.

 

(gg)        
“Floating Rate Period Interest Payment Date” means any of the 2025 Notes Floating Rate Period Interest
Payment Dates or the 2032 Notes Floating Rate Period Interest Payment Dates, as applicable.

 

(hh)        
“Former Trustee” has the meaning set forth in the recitals to this Supplemental Indenture.

 

(ii)           
“Group” means the Issuer and each other entity which is part of the UK prudential consolidation group
(as that term, or its successor, is used in the Capital Rules) of which the Issuer is part from time to time.

 

(jj)           
 “Indenture” has the meaning set forth in the recitals to this Supplemental Indenture.

 

(kk)         
“Interest Determination Date” means the second Business Day preceding the applicable Floating Rate Period
Interest Payment Date.

 

(ll)           
“Interest Payment Date” means any of the Fixed Rate Period Interest Payment Dates or the Floating Rate
Period Interest Payment Dates, as applicable.

 

(mm)       
“ISDA Definitions” means the 2006 ISDA Definitions published by the International Swaps and Derivatives
Association, Inc. (“ISDA”) or any successor thereto, as amended or supplemented from time to time, or any successor
definitional booklet for interest rate derivatives published from time to time.

 

    5

     

    

 

(nn)        
 “ISDA Fallback Adjustment” means the spread adjustment (which may be a positive or negative value or
zero) that would apply for derivatives transactions referencing the ISDA Definitions to be determined upon the occurrence of an
index cessation event with respect to the Benchmark for the applicable tenor.

 

(oo)        
“ISDA Fallback Rate” means the rate that would apply for derivatives transactions referencing the ISDA
Definitions to be effective upon the occurrence of an index cessation date with respect to the Benchmark for the applicable tenor
excluding the applicable ISDA Fallback Adjustment.

 

(pp)        
“Issue Date” has the meaning set forth in Section 2.01(c) of this Supplemental Indenture.

 

(qq)        
 “Issuer” has the meaning set forth in the introduction to this Supplemental Indenture.

 

(rr)          
“Loss Absorption Disqualification Event” means:

 

(1)   
at the time that any Loss Absorption Regulation becomes effective after the date of issuance of a given series of Senior
Debt Securities, and as a result of such Loss Absorption Regulation becoming so effective, in each case with respect to the Issuer
and/or the Group, such Senior Debt Securities are not or will not be eligible to qualify in full towards the Issuer’s and/or
the Group’s minimum requirements for (A) own funds and eligible liabilities and/or (B) loss absorbing capacity instruments;
or

 

(2)   
as a result of any amendment to, or change in, any Loss Absorption Regulation, or any change in the application or official
interpretation of any Loss Absorption Regulation, in any such case becoming effective on or after the date of issuance of a given
series of Senior Debt Securities, such Senior Debt Securities are or will be fully or partially excluded from the Issuer’s
and/or the Group’s minimum requirements for (A) own funds and eligible liabilities and/or (B) loss absorbing capacity instruments,

 

in each case as such minimum requirements
are applicable to the Issuer and/or the Group and determined in accordance with, and pursuant to, the relevant Loss Absorption
Regulations; provided that a Loss Absorption Disqualification Event shall not occur where the exclusion of such Senior Debt Securities
from the relevant minimum requirement(s) is due to the remaining maturity of such Senior Debt Securities being less than any period
prescribed by any applicable eligibility criteria for such minimum requirements under the relevant Loss Absorption Regulations
effective with respect to the Issuer and/or the Group on the date of issuance of such Senior Debt Securities.

 

(ss)         
“Loss Absorption Disqualification Event Call Option” means the Issuer’s option, subject to the
satisfaction of the Regulatory Redemption Conditions, to redeem in whole, but not in part, any series of Senior Debt Securities
at any time at a redemption price equal to 100% of the principal amount, together with accrued but unpaid interest, if any, in
respect of such series of Senior Debt Securities to (but excluding) the Loss Absorption Disqualification Redemption Date, upon
the occurrence of a Loss Absorption Disqualification Event which is continuing.

 

(tt)          
“Loss Absorption Disqualification Redemption Date” means the date fixed for redemption pursuant to an
exercise by the Issuer of the Loss Absorption Disqualification Event Call Option.

 

(uu)         “Loss
Absorption Regulations” means, at any time, the laws, regulations, requirements, guidelines, rules, standards and
policies relating to minimum requirements for own funds and eligible liabilities and/or loss absorbing capacity instruments
of the United Kingdom, the PRA, the United Kingdom resolution authority, the Financial Stability Board and/or of the European
Parliament or of the Council of the European Union then in effect in the United Kingdom.

 

    6

     

    

 

(vv)         
 “Notes” has the meaning set forth in the recitals to this Supplemental Indenture.

 

(ww)       
“NY Federal Reserve’s website” means the website of the Federal Reserve Bank of New York (the “NY
Federal Reserve”), currently at http://www.newyorkfed.org, or any successor website of the NY Federal Reserve or the website
of any successor administrator of the Secured Overnight Financing Rate.

 

(xx)          
“Observation Period” has the meaning set forth in Section 3.03(b) of this Supplemental Indenture.

 

(yy)         
 “PRA” means the Prudential Regulation Authority of the United Kingdom.

 

(zz)          
“Reference Time” means (1) if the Benchmark is Compounded SOFR Index Rate, the SOFR Determination
Time, and (2) if the Benchmark is not Compounded SOFR Index Rate, the time determined by the Issuer or the Issuer’s
designee (in consultation with the Issuer) in accordance with the Benchmark Replacement Conforming Changes.

 

(aaa)       
 “Regular Record Date” means the fifteenth calendar day, whether or not a Business Day, that precedes
the related Interest Payment Date.

 

(bbb)      
“Regulator” means (i) the Bank of England, in its capacity as the PRA, or such successor or other authority
having primary responsibility for the prudential supervision of the Issuer and the Group; and/or (ii) the Bank of England or such
other successor or other authority designated as the United Kingdom resolution authority or otherwise having primary responsibility
for the resolution of financial institutions in the United Kingdom, as applicable in accordance with the Capital Rules.

 

(ccc)       
“Regulatory Approval” means, at any time, such approval, consent or prior permission by, or notification
required within prescribed periods to, the Regulator, or such waiver of the then prevailing Loss Absorption Regulations from the
Regulator, as is required under the then prevailing Loss Absorption Regulations at such time.

 

(ddd)      
“Regulatory Preconditions” means if, at the time of a redemption or purchase, the prevailing Loss Absorption
Regulations permit the redemption or purchase after compliance with any pre-conditions, the Issuer having complied with such pre-conditions.

 

(eee)       
“Regulatory Redemption Conditions” means (1) the Issuer has obtained Regulatory Approval and (2) the
Issuer is in compliance with the Regulatory Preconditions.

 

(fff)         
“Relevant Governmental Body” means the Federal Reserve and/or the Federal Reserve Bank of New York (“NY
Federal Reserve”), or a committee officially endorsed or convened by the Federal Reserve and/or the NY Federal Reserve
or any successor thereto.

 

(ggg)      
 “SOFR” has the meaning set forth in Section 3.03(b) of this Supplemental Indenture.

 

(hhh)      
“SOFR Administrator” has the meaning set forth in Section 3.03(b) of this Supplemental Indenture.

 

(iii)          
“SOFR Administrator’s Website” has the meaning set forth in Section 3.03(b) of this Supplemental
Indenture.

 

    7

     

    

 

(jjj)          
 “SOFR Determination Time” has the meaning set forth in Section 3.03(b) of this Supplemental Indenture.

 

(kkk)       
“SOFR Index” has the meaning set forth in Section 3.03(b) of this Supplemental Indenture.

 

(lll)            
“SOFR Indexend” has the meaning set forth in Section 3.03(b) of this Supplemental Indenture.

 

(mmm)    
“SOFR Indexstart” has the meaning set forth in Section 3.03(b) of this Supplemental
Indenture.

 

(nnn)      
“Trustee” has the meaning set forth in the introduction to this Supplemental Indenture.

 

(ooo)      
“Unadjusted Benchmark Replacement” means the Benchmark Replacement excluding the Benchmark Replacement
Adjustment.

 

(ppp)      
“U.S. Government Securities Business Day” has the meaning set forth in Section 3.03(b) of this
Supplemental Indenture.

 

Section 1.03.         
A reference in this Supplemental Indenture or the Base Indenture to a provision of any law, regulation or directive of the
European Union shall be construed as including a reference to such provision as the same may have been implemented, transposed,
enacted or retained under the laws of the United Kingdom.

 

Article
2 

THE NOTES

 

Section 2.01.         
The following terms relating to the 2025 Notes are hereby established:

 

(a)           
The title of the 2025 Notes shall be “1.089% Fixed Rate/Floating Rate Notes due 2025”;

 

(b)          
The principal amount of the 2025 Notes that may be authenticated and delivered under the Indenture shall not initially exceed
$1,400,000,000 (except as otherwise provided in the Indenture);

 

(c)           
The 2025 Notes shall be issued on March 15, 2021 (the “Issue Date”) and the principal on the 2025 Notes
shall be payable on March 15, 2025 (the “2025 Notes Maturity Date”);

 

(d)           
During the 2025 Notes Fixed Rate Period, interest on the 2025 Notes shall be payable at the 2025 Notes Initial Interest
Rate and semi-annually in arrear on each Fixed Rate Period Interest Payment Date. During the 2025 Notes Floating Rate Period, interest
on the 2025 Notes shall be payable at a rate per annum determined in accordance with Article Three of this Supplemental
Indenture and quarterly in arrear on each 2025 Notes Floating Rate Period Interest Payment Date. Accrual and computation of interest
on the 2025 Notes shall be determined in accordance with Article Three of this Supplemental Indenture;

 

(e)           
No premium, upon redemption or otherwise, shall be payable by the Issuer on the 2025 Notes;

 

(f)            
Principal of, and any interest on, the 2025 Notes shall be paid to the Holder through the Trustee, having offices in New
York, New York;

 

    8

     

    

 

(g)           
 The 2025 Notes shall not be redeemable except as provided in (i) Section 11.08 of the Base Indenture (as amended hereby),
(ii) Section 11.09 of the Base Indenture (as amended hereby) and (iii) in Section 11.10 of the Base Indenture (as amended hereby),
or on the 2025 Notes Maturity Date. The 2025 Notes shall not be redeemable at the option of the Holders at any time;

 

(h)           
The Issuer shall have no obligation to redeem or purchase the 2025 Notes pursuant to any sinking fund or analogous provision;

 

(i)            
The 2025 Notes shall be issued only in denominations of $200,000 and integral multiples of $1,000 in excess thereof;

 

(j)            
The 2025 Notes shall be denominated in U.S. dollars;

 

(k)           
The payment of principal of, and interest on, the 2025 Notes shall be payable only in the coin or currency in which the
2025 Notes are denominated which, pursuant to clause (j) above, shall be U.S. dollars;

 

(l)            
The 2025 Notes will be subject to, and each Holder (including each holder of a beneficial interest in the 2025 Notes) acknowledges,
accepts, agrees and consents that the Notes will be subject to, the exercise of any UK Bail-in Power by the Relevant UK Resolution
Authority. Each Holder of Notes (including each holder of a beneficial interest in the Notes) acknowledges, accepts, agrees to
be bound by and consents to (i) the effect of the exercise of any UK Bail-in Power by the Relevant UK Resolution Authority and
(ii) the variation, if necessary, of the terms of the Notes to give effect to the exercise of any UK Bail-in Power by the Relevant
UK Resolution Authority, pursuant to Article Twelve of the Base Indenture;

 

(m)          
The 2025 Notes will be issued in the form of one or more Global Securities in registered form, without coupons attached,
and the initial Holder with respect to each such Global Security shall be Cede & Co., as nominee of DTC;

 

(n)           
Except in limited circumstances, the 2025 Notes will not be issued in definitive form; and

 

(o)          
The form of the 2025 Notes shall be evidenced by one or more Global Securities in registered form substantially in the form
of Exhibit A to this Supplemental Indenture.

 

Section 2.02.         
The following terms relating to the 2032 Notes are hereby established:

 

(a)           
The title of the 2032 Notes shall be “2.896% Fixed Rate/Floating Rate Notes due 2032”;

 

(b)          
The principal amount of the 2032 Notes that may be authenticated and delivered under the Indenture shall not initially exceed
$600,000,000 (except as otherwise provided in the Indenture);

 

(c)           
The 2032 Notes shall be issued on the Issue Date and the principal on the 2032 Notes shall be payable on March 15, 2032
(the “2032 Notes Maturity Date”);

 

(d)          
During the 2032 Notes Fixed Rate Period, interest on the 2032 Notes shall be payable at the 2032 Notes Initial Interest
Rate and semi-annually in arrear on each Fixed Rate Period Interest Payment Date. During the 2032 Notes Floating Rate Period, interest
on the 2032 Notes shall be payable at a rate per annum determined in accordance with Article Three and quarterly in arrear
on each 2032 Notes Floating Rate Period Interest Payment Date. Accrual and computation of interest on the 2032 Notes shall be determined
in accordance with Article Three of this Supplemental Indenture.

 

    9

     

    

 

(e)           
 No premium, upon redemption or otherwise, shall be payable by the Issuer on the 2032 Notes;

 

(f)            
Principal of, and any interest on, the 2032 Notes shall be paid to the Holder through the Trustee, having offices in New
York, New York;

 

(g)          
The 2032 Notes shall not be redeemable except as provided in (i) Section 11.08 of the Base Indenture (as amended hereby),
(ii) Section 11.09 of the Base Indenture (as amended hereby) and (iii) in Section 11.10 of the Base Indenture (as amended hereby),
or on the 2032 Notes Maturity Date. The 2032 Notes shall not be redeemable at the option of the Holders at any time;

 

(h)           
The Issuer shall have no obligation to redeem or purchase the 2032 Notes pursuant to any sinking fund or analogous provision;

 

(i)            
The 2032 Notes shall be issued only in denominations of $200,000 and integral multiples of $1,000 in excess thereof;

 

(j)            
The 2032 Notes shall be denominated in U.S. dollars;

 

(k)           
The payment of principal of, and interest on, the 2032 Notes shall be payable only in the coin or currency in which the
2032 Notes are denominated which, pursuant to clause (j) above, shall be U.S. dollars;

 

(l)            
The 2032 Notes will be subject to, and each Holder (including each holder of a beneficial interest in the Notes) acknowledges,
accepts, agrees and consents that the Notes will be subject to, the exercise of any UK Bail-in Power by the Relevant UK Resolution
Authority. Each Holder of Notes (including each holder of a beneficial interest in the Notes) acknowledges, accepts, agrees to
be bound by and consents to (i) the effect of the exercise of any UK Bail-in Power by the Relevant UK Resolution Authority and
(ii) the variation, if necessary, of the terms of the Notes to give effect to the exercise of any UK Bail-in Power by the Relevant
UK Resolution Authority, pursuant to Article Twelve of the Base Indenture;

 

(m)          
The 2032 Notes will be issued in the form of one or more Global Securities in registered form, without coupons attached,
and the initial Holder with respect to each such Global Security shall be Cede & Co., as nominee of DTC;

 

(n)           
Except in limited circumstances, the 2032 Notes will not be issued in definitive form; and

 

(o)           
The form of the 2032 Notes shall be evidenced by one or more Global Securities in registered form substantially in the form
of Exhibit B to this Supplemental Indenture.

 

Article
3

INTEREST CALCULATIONS IN RESPECT OF THE NOTES

 

Section 3.01.         
Interest Rates on the Notes.

 

(a)           
With respect to the 2025 Notes:

 

(1)   
From (and including) the Issue Date to (but excluding) March 15, 2024 (the “2025 Notes Fixed Rate Period”),
interest on the 2025 Notes will be payable at a rate of 1.089% per annum (the “2025 Notes Initial Interest Rate”);
and

 

    10

     

    

 

(2)   
 From (and including) March 15, 2024 to (but excluding) the 2025 Notes Maturity Date (the “2025 Notes Floating
Rate Period”), the interest rate on the 2025 Notes will be equal to the Benchmark plus 0.787% per annum (the “2025
Notes Margin”) (the “2025 Notes Floating Rate”). The 2025 Notes Floating Rate will be calculated quarterly
on each Interest Determination Date.

 

    11

     

    

 

 

 

 

(b)               
With respect to the 2032 Notes:

 

(1)   
From (and including) the Issue Date to (but excluding) March 15, 2031 (the “2032 Notes Fixed Rate Period”),
interest on the 2032 Notes will be payable at a rate of 2.896% per annum (the “2032 Notes Initial Interest Rate”);
and

 

(2)   
From (and including) March 15, 2031 to (but excluding) the 2032 Notes Maturity Date (the “2032 Notes Floating Rate
Period”), the interest rate on the 2032 Notes will be equal to the Benchmark plus 1.475% per annum (the “2032
Notes Margin”) (the “2032 Notes Floating Rate”). The 2032 Notes Floating Rate will be calculated quarterly
on each Interest Determination Date.

 

Section 3.02.         
Interest Rate Calculations and Interest Payments on the Notes.

 

(a)               
During each of the 2025 Notes Fixed Rate Period and the 2032 Notes Fixed Rate Period, as applicable:

 

(1)   
Each of the 2025 Notes Initial Interest Rate and the 2032 Notes Initial Interest Rate will be calculated on the basis of
twelve 30-day months or, in the case of an incomplete month, the actual number of days elapsed, in each case assuming a 360-day
year.

 

(2)   
If any scheduled Fixed Rate Period Interest Payment Date is not a Business Day, such Fixed Rate Period Interest Payment
Date will be postponed to the next day that is a Business Day, but interest on that payment will not accrue during the period from
and after the scheduled Fixed Rate Period Interest Payment Date.

 

(b)               
During each of the 2025 Notes Floating Rate Period and the 2032 Notes Floating Rate Period, as applicable:

 

(1)   
Interest on the 2025 Notes and the 2032 Notes, respectively, during each of the 2025 Notes Floating Rate Period and the
2032 Notes Floating Rate Period will be calculated on the basis of the actual number of days in each Floating Rate Interest Period,
assuming a 360-day year.

 

(2)   
If any scheduled Floating Rate Period Interest Payment Date (other than the 2025 Notes Maturity Date or the 2032 Notes Maturity
Date, as applicable) is not a Business Day, such Floating Rate Period Interest Payment Date will be postponed to the next day that
is a Business Day; provided that if that Business Day falls in the next succeeding calendar month, such Floating Rate Period Interest
Payment Date will be the immediately preceding Business Day. If any such Floating Rate Period Interest Payment Date (other than
the 2025 Notes Maturity Date or the 2032 Notes Maturity Date, as the case may be) is postponed or brought forward as described
above, the payment of interest due on such postponed or brought forward Floating Rate Period Interest Payment Date will include
interest accrued to but excluding such postponed or brought forward Floating Rate Period Interest Payment Date.

 

(c)               
The regular record dates for interest on the Notes will be the fifteenth calendar day preceding each Interest Payment Date,
whether or not a Business Day.

 

    12

     

    

 

(d)               
 If the 2025 Notes Maturity Date or the 2032 Notes Maturity Date, as the case may be, or date of redemption or repayment
of the 2025 Notes or the 2032 Notes, as applicable, is not a Business Day, the Issuer may pay interest and principal on the next
succeeding Business Day, but interest on that payment will not accrue during the period from and after the 2025 Notes Maturity
Date or the 2032 Notes Maturity Date, as applicable, or date of redemption or repayment of the 2025 Notes or the 2032 Notes.

 

(e)               
If a date of redemption or repayment of the 2025 Notes falls within the 2025 Notes Floating Rate Period or a date of redemption
or repayment of the 2032 Notes falls within the 2032 Notes Floating Rate Period, as applicable, but does not occur on a Floating
Rate Period Interest Payment Date, (i) the related Interest Determination Date shall be deemed to be the date that is two Business
Days prior to such date of redemption or repayment, (ii) the related Observation Period shall be deemed to end on (but exclude)
the last U.S. Government Securities Business Day falling prior to the Interest Determination Date for such date of redemption or
repayment, (iii) the Floating Rate Interest Period will be deemed to be shortened accordingly and (iv) corresponding adjustments
will be deemed to be made to the Compounded SOFR Index Rate formula.

 

Section 3.03.         
Calculation of the Benchmark

 

(a)               
The “Benchmark” means, initially, Compounded SOFR Index Rate; provided that if a Benchmark Transition
Event and related Benchmark Replacement Date have occurred with respect to SOFR or the then-current Benchmark, then “Benchmark”
means the applicable Benchmark Replacement.

 

(b)               
“Compounded SOFR Index Rate” means in relation to a Floating Rate Interest Period, the rate computed
by the Calculation Agent in accordance with the following formula (and the resulting percentage will be rounded if necessary to
the nearest seventh decimal place, with 0.00000005 being rounded upwards):

 

 

Where:

 

“d” is the number of calendar
days from (and including) SOFR IndexStart to (but excluding) SOFR IndexEnd (being the number of calendar
days in the Observation Period);

 

“SOFR IndexStart”
is the SOFR Index value for the day which is two U.S. Government Securities Business Days preceding the first date of the relevant
Floating Rate Interest Period;

 

“SOFR IndexEnd”
is the SOFR Index value for the day which is two U.S. Government Securities Business Days preceding the Floating Rate Period Interest
Payment Date relating to such Floating Rate Interest Period;

 

“SOFR Index” means, with
respect to any U.S. Government Securities Business Day:

 

(1)   
the SOFR Index value as published by the SOFR Administrator as such index appears on the SOFR Administrator’s Website
at the SOFR Determination Time; provided that:

 

(2)    if
a SOFR Index value does not so appear as specified in (1) above at the SOFR Determination Time, then (i) if a
Benchmark Transition Event and its related Benchmark Replacement Date have not occurred with respect to SOFR, then Compounded
SOFR Index Rate shall be the rate determined pursuant to the “SOFR Index Unavailability” provisions below or
(ii) if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred in respect of SOFR, then
Compounded SOFR Index Rate shall be the rate determined pursuant to the “Benchmark Transition Provisions”
below.

 

    13

     

    

 

“SOFR” means, with respect
to any U.S. Government Securities Business Day, the rate determined by the Calculation Agent in accordance with the following provisions:

 

(1)   
the Secured Overnight Financing Rate published for such U.S. Government Securities Business Day as such rate appears on
the NY Federal Reserve’s website on the immediately following U.S. Government Securities Business Day at the SOFR Determination
Time.

 

(2)   
if the rate does not so appear, the Secured Overnight Financing Rate published on the NY Federal Reserve’s website
for the first preceding U.S. Government Securities Business Day for which the Secured Overnight Financing Rate was published on
the NY Federal Reserve’s website.

 

“NY Federal Reserve’s website”
means the website of the Federal Reserve Bank of New York (the “NY Federal Reserve”), currently at http://www.newyorkfed.org,
or any successor website of the NY Federal Reserve or the website of any successor administrator of the Secured Overnight Financing
Rate.

 

“Observation Period” means,
in respect of each Floating Rate Interest Period, means the period from (and including) the day falling two U.S. Government Securities
Business Days prior to the first day of the relevant Floating Rate Interest Period to (but excluding) the day falling two U.S.
Government Securities Business Days prior to the relevant Floating Rate Period Interest Payment Date for such Floating Rate Interest
Period.

 

“SOFR Administrator” means
the Federal Reserve Bank of New York (or a successor administrator of SOFR).

 

“SOFR Administrator’s Website”
means the website of the Federal Reserve Bank of New York, currently at http://www.newyorkfed.org, or any successor source.

 

“SOFR Determination Time”
means, with respect to any U.S. Government Securities Business Day, 3:00 p.m. (New York City time) on such U.S. Government
Securities Business Day.

 

“U.S. Government Securities Business
Day” means any day except for a Saturday, Sunday or a day on which the Securities Industry and Financial Markets Association
(SIFMA) recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in U.S.
government securities.

 

(c)               
Notwithstanding clauses (1) and (2) of the definition of “SOFR” above, if the Issuer or the Issuer’s
designee (in consultation with the Issuer) determines on or prior to the relevant Interest Determination Date that a Benchmark
Transition Event and related Benchmark Replacement Date have occurred with respect to SOFR, then Section 3.05 of this Supplemental
Indenture will thereafter apply to all determinations of the rate of interest payable on the notes during each of the 2025 Notes
Floating Rate Period and 2032 Notes Floating Rate Period, respectively.

 

(d)                In
accordance with and subject to Section 3.05 of this Supplemental Indenture, after a Benchmark Transition Event and
related Benchmark Replacement Date have occurred, the amount of interest that will be payable for each interest period on the
2025 Notes and the 2032 Notes during the 2025 Notes Floating Rate Period will be determined by reference to a rate per annum
equal to the Benchmark Replacement plus the 2025 Notes Margin and the amount of interest that will be payable for each
interest period on the 2032 Notes during the 2032 Notes Floating Rate Period will be determined by reference to a rate per
annum equal to the Benchmark Replacement plus the 2032 Notes Margin.

 

    14

     

    

 

Section 3.04.         
SOFR Index Unavailability

 

(a)               
If SOFR IndexStart or SOFR IndexEnd is not published on the relevant Interest Determination Date and
a Benchmark Transition Event and its related Benchmark Replacement Date have not occurred with respect to SOFR, “Compounded
SOFR Index Rate” will mean, for the relevant interest period for which such index is not available, the rate of return on
a daily compounded interest investment calculated in accordance with the formula for SOFR Averages, and definitions required for
such formula, published on the SOFR Administrator’s Website at https:// www.newyorkfed.org/markets/treasury repo reference
rates information (or such successor website).

 

(b)               
For the purposes of this provision, references in the SOFR Averages compounding formula and related definitions to “calculation
period” shall be replaced with “Observation Period” and the words “that is, 30-, 90-, or 180- calendar
days” shall be removed. If the daily SOFR (“SOFRi”) does not so appear for any day, “i”
in the Observation Period, SOFRi for such day “i” shall be SOFR published in respect of the first preceding
U.S. Government Securities Business Day for which SOFR was published on the SOFR Administrator’s Website.

 

Section 3.05.         
Benchmark Transition Provisions

 

(a)               
If the Issuer or the Issuer’s designee (in consultation with the Issuer) determines that a Benchmark Transition Event
and related Benchmark Replacement Date have occurred prior to the applicable Reference Time in respect of any determination of
the Benchmark on any date, the applicable Benchmark Replacement will replace the then current Benchmark for all purposes relating
to the 2025 Notes during the 2025 Notes Floating Rate Period and the 2032 Notes during the 2032 Notes Floating Rate Period, as
applicable, in respect of such determination on such date and all determinations on all subsequent dates; provided that, if the
Issuer or its designee (in consultation with the Issuer) are unable to or do not determine a Benchmark Replacement in accordance
with the provisions below prior to 5:00 p.m. (New York time) on the relevant Interest Determination Date, the interest rate for
the related Floating Rate Interest Period will be equal to the interest rate in effect for the immediately preceding Floating Rate
Interest Period or, in the case of the Interest Determination Date prior to the first Floating Rate Period Interest Payment Date,
the 2025 Notes Initial Interest Rate or the 2032 Notes Initial Interest Rate, as applicable.

 

(b)               
In connection with the implementation of a Benchmark Replacement, the Issuer or the Issuer’s designee (in consultation
with the Issuer) will have the right to make changes to (1) any Interest Determination Date, Floating Rate Period Interest
Payment Date, Reference Time, business day convention or Floating Rate Interest Period, (2) the manner, timing and frequency
of determining the rate and amounts of interest that are payable on the 2025 Notes during the 2025 Notes Floating Rate Period and
the 2032 Notes during the 2032 Notes Floating Rate Period, as applicable, and the conventions relating to such determination and
calculations with respect to interest, (3) rounding conventions, (4) tenors and (5) any other terms or provisions
of the 2025 Notes during the 2025 Notes Floating Rate Period and the 2032 Notes during the 2032 Notes Floating Rate Period, as
applicable, in each case that the Issuer or its designee (in consultation with the Issuer) determines, from time to time, to be
appropriate to reflect the determination and implementation of such Benchmark Replacement in a manner substantially consistent
with market practice (or, if the Issuer or its designee (in consultation with the Issuer) decide that implementation of any portion
of such market practice is not administratively feasible or determine that no market practice for use of the Benchmark Replacement
exists, in such other manner as the Issuer or its designee (in consultation with the Issuer) determine is appropriate (acting in
good faith)) (the “Benchmark Replacement Conforming Changes”). Any Benchmark Replacement Conforming Changes
will apply to the 2025 Notes and/or the 2032 Notes for all future Floating Rate Interest Periods, as applicable.

 

    15

     

    

 

(c)               
 The Issuer will promptly give notice of the determination of the Benchmark Replacement, the Benchmark Replacement Adjustment
and any Benchmark Replacement Conforming Changes to the Trustee, the Paying Agent, the Calculation Agent and the Holders; provided
that failure to provide such notice will have no impact on the effectiveness of, or otherwise invalidate, any such determination.

 

(d)               
All determinations, decisions, elections and any calculations made by the Issuer or the Issuer’s designee for the
purposes of determining the Benchmark Replacement, the Benchmark Replacement Adjustment and any Benchmark Replacement Conforming
Changes will be conclusive and binding on the Holders, the Issuer, the Calculation Agent, the Trustee and the Paying Agent, absent
manifest error. If made by the Issuer’s designee, such determinations, decisions, elections and calculations will be made
after consulting with the Issuer, and the Issuer’s designees will not make any such determination, decision, election or
calculation to which the Issuer objects. Notwithstanding anything to the contrary in the Indenture or the Notes, any determinations,
decisions, calculations or elections made in accordance with this provision will become effective without consent from the Holders
or any other party.

 

(e)               
Any determination, decision or election relating to the Benchmark will be made by the Issuer on the basis described above.
The Calculation Agent shall have no liability for not making any such determination, decision or election. In addition, the Issuer
may designate an entity (which may be the Issuer’s Affiliate) to make any determination, decision or election that the Issuer
has the right to make in connection with the determination of the Benchmark.

 

(f)                
Notwithstanding any other provision of “Benchmark Transition Provisions” set forth above, no Benchmark Replacement
will be adopted, nor will the applicable Benchmark Replacement Adjustment be applied, nor will any Benchmark Replacement Conforming
Changes be made, if in the Issuer’s determination, the same could reasonably be expected to prejudice the qualification of
the Notes as eligible liabilities or loss absorbing capacity instruments for the purposes of the Capital Rules.

 

(g)               
By its acquisition of the Notes, each Holder (which, for these purposes, includes each beneficial owner) (i) acknowledges,
accepts, consents and agrees to be bound by the Company’s or its designee’s determination of a Benchmark Transition
Event, a Benchmark Replacement Date, the Benchmark Replacement, the Benchmark Replacement Adjustment and any Benchmark Replacement
Conforming Changes, including as may occur without any prior notice from the Company and without the need for the Issuer to obtain
any further consent from such Holder, (ii) waives any and all claims, in law and/or in equity, against the Trustee, the Paying
Agent and the Calculation Agent or the Issuer’s designee for, agrees not to initiate a suit against the Trustee, the Paying
Agent and the Calculation Agent or the Issuer’s designee in respect of, and agrees that none of the Trustee, the Paying Agent
or the Calculation Agent or the Issuer’s designee will be liable for, the determination of or the failure to determine any
Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement Adjustment and
any Benchmark Replacement Conforming Changes, and any losses suffered in connection therewith and (iii) agrees that none of the
Trustee, the Paying Agent or the Calculation Agent or the Issuer’s designee will have any obligation to determine any Benchmark
Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement Adjustment and any Benchmark
Replacement Conforming Changes (including any adjustments thereto), including in the event of any failure by the Issuer to determine
any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement Adjustment
and any Benchmark Replacement Conforming Changes.

 

(h)                All
percentages resulting from any calculation of any interest rate for the Notes will be rounded, if necessary, to the nearest
one hundred thousandth of a percentage point, with five one-millionths of a percentage point rounded upward
(e.g., 9.876545% (or .09876545) would be rounded to 9.87655% (or .0987655)), and all dollar amounts would be rounded to
the nearest cent, with one-half cent being rounded upward.

 

    16

     

    

 

Article
 4

AMENDMENTS TO THE BASE INDENTURE APPLICABLE TO THE NOTES ONLY

 

Section 4.01.         
Article 11 of the Base Indenture is hereby amended as follows:

 

(a)               
Section 11.08 of the Base Indenture is hereby amended and restated in its entirety, as follows:

 

Section 11.08. 
Optional Redemption Due to Changes in Tax Treatment.   Unless otherwise provided in the Senior Debt Securities of
any series and subject to the satisfaction of the Regulatory Redemption Conditions, the Issuer will have the option to redeem the
Senior Debt Securities of any series in whole as contemplated by Section 3.01 with respect to any series of Senior Debt Securities
on not less than 30 nor more than 60 days’ notice, on any Interest Payment Date, at a redemption price equal to 100% of the
principal amount, together with accrued but unpaid interest, if any, in respect of such series of Senior Debt Securities to the
date fixed for redemption (or, in the case of Original Issue Discount Securities, the accreted face amount thereof, together with
accrued interest, if any), if, at any time, the Issuer shall determine that as a result of a change in or amendment to the laws
or regulations of the Taxing Jurisdiction (including any treaty to which such Taxing Jurisdiction is a party) or any change in
the official application or interpretation of such laws or regulations (including a decision of any court or tribunal) which change
or amendment becomes effective on or after a date included in the terms of such series of Senior Debt Securities pursuant to Section 3.01:

 

(a)          
in making payment under the Senior Debt Securities in respect of principal or premium, if any, or interest, if any, it has or will
or would on the next Interest Payment Date become obligated to pay Additional Amounts;

 

(b) any payment of Interest on
an Interest Payment Date in respect of the Senior Debt Securities has been treated as a “distribution”, or the
payment of interest on the next Interest Payment Date in respect of any of the Senior Debt Securities would be treated as a “distribution,”
in each case within the meaning of Section 1000 of the Corporation Tax Act 2010 of the United Kingdom (or any statutory modification
or re-enactment thereof for the time being); or

 

(c) on an Interest Payment Date
the Issuer was not entitled, or on the next Interest Payment Date the Issuer would not be entitled, to claim a deduction in respect
of such payment of interest in computing its United Kingdom taxation liabilities (or the value of such deduction to the Issuer
would be materially reduced).

 

In any case where the Issuer
shall determine that as a result of any change in the official application or interpretation of any laws or regulations it is entitled
to redeem the Senior Debt Securities of any series, the Issuer shall be required to deliver to the Trustee prior to the giving
of any notice of redemption a written legal opinion of independent United Kingdom counsel of recognized standing (selected by the
Issuer) in a form reasonably satisfactory to the Trustee confirming that the relevant change in the official application or interpretation
of such laws or regulations has occurred and that the Issuer is entitled to exercise its right of redemption.

 

    17

     

    

 

(b)               
Sections 11.09, 11.10 and 11.11 are hereby added at the end of Article 11 of the Base Indenture as follows:

 

Section 11.09. Optional Redemption
upon a Loss Absorption Disqualification Event. If a Loss Absorption Disqualification Event has occurred and is continuing,
the Issuer may exercise the Loss Absorption Disqualification Event Call Option, having given not less than 30 nor more than 60
days’ notice to the Trustee, the Paying Agent, the Holders and the Registrar (which notice shall be irrevocable and shall
specify the Loss Absorption Disqualification Redemption Date). Upon the expiry of such notice the Issuer shall be bound to redeem
such Senior Debt Securities accordingly.

 

In any case where the Issuer
shall determine that as a result of the occurrence of a Loss Absorption Disqualification Event it is entitled to exercise the Loss
Absorption Disqualification Event Call Option in respect of any series of Senior Debt Securities, the Issuer shall be required
to deliver to the Trustee an Officer’s Certificate stating that the relevant requirement or circumstance referred to in this
Section 11.09 applies.

 

Section 11.10. Issuer’s
Optional Redemption. The Issuer will have the option, subject to the satisfaction of the Regulatory Redemption Conditions,
to redeem the Senior Debt Securities, in whole, but not in part, on March 15, 2024, in the case of the 2025 Notes, and March 15,
2031, in the case of the 2032 Notes, at a redemption price equal to 100% of the principal amount of the applicable series of Senior
Debt Securities, plus accrued and unpaid interest thereon to, but excluding, the Redemption Date, on not less than 30 nor more
than 60 days’ notice.

 

Section 11.11. Redemption
Subject to Satisfaction of Regulatory Redemption Conditions. Notwithstanding any provision or statement to the contrary in
this Senior Debt Securities Indenture or the Senior Debt Securities, if required pursuant to any Loss Absorption Regulation, the
Issuer may only redeem or repurchase any Senior Debt Securities prior to the 2025 Notes Maturity Date in the case of the 2025 Notes,
or the 2032 Notes Maturity Date in the case of the 2032 Notes, if it has satisfied the Regulatory Redemption Conditions.

 

Article
5

MISCELLANEOUS

 

Section 5.01.      
Effect of this Supplemental Indenture; Ratification and Integral Part. This Supplemental Indenture shall become effective
upon its execution and delivery.

 

Except as hereby expressly amended with
respect to the Notes only, the Base Indenture is in all respects ratified and confirmed and all the terms, provisions and conditions
thereof shall be and remain in full force and effect. This Supplemental Indenture shall be deemed an integral part of the Base
Indenture in the manner and to the extent herein and therein provided.

 

Section 5.02.         
Responsibility for Recitals, Etc. The recitals herein shall be taken as the statements of the Issuer, and the Trustee assumes
no responsibility for the correctness thereof. The Trustee makes no representations as to the validity or sufficiency of this Supplemental
Indenture.

 

Section 5.03.         
Priority. This Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the extent herein
and therein provided. The provisions of this Supplemental Indenture shall, with respect to the Notes and subject to the terms hereof,
supersede the provisions of the Base Indenture to the extent the Base Indenture is inconsistent herewith.

 

Section 5.04.         
Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State
of New York, except that the authorization and execution of this Supplemental Indenture shall be governed (in addition to the laws
of the State of New York relevant to execution) by the respective jurisdictions of the Issuer and the Trustee, as the case may
be.

 

    18

     

    

 

Section 5.05.      
Execution and Counterparts. This Supplemental Indenture shall be valid, binding, and enforceable against a party when executed
and delivered by an authorized individual on behalf of the party by means of (i) an original manual signature, (ii) a faxed, scanned,
or photocopied manual signature or (iii) any other electronic signature permitted by the federal Electronic Signatures in Global
and National Commerce Act, the New York State Electronic Signatures and Records Act or any other state enactments of the Uniform
Electronic Transactions Act, and/or any other relevant electronic signatures law, in each case to the extent applicable. Each
faxed, scanned, or photocopied manual signature, or other electronic signature, shall for all purposes have the same validity,
legal effect, and admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively
rely upon, and shall have no liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic
signature, of any other party and shall have no duty to investigate, confirm or otherwise verify the validity or authenticity
thereof. This Supplemental Indenture may be executed in any number of counterparts, each of which shall be deemed to be an original,
but such counterparts shall, together, constitute one and the same instrument. The exchange of copies of this Supplemental Indenture
and of signature pages by facsimile, email or other electronic format (i.e., “pdf,” “tif” or “jpg”)
transmission or other electronically-imaged signature (including, without limitation, DocuSign or AdobeSign) or transmission shall
constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of
the original Supplemental Indenture and signature pages for all purposes.

 

Section 5.06.      
Entire Agreement. This Supplemental Indenture constitutes the entire agreement of the parties hereto with respect to the
amendments to the Base Indenture set forth herein.

 

[Remainder of page intentionally
left blank]

 

    19

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Supplemental Indenture to be duly executed, all as of the day and year first above written.

 	 	SANTANDER UK GROUP HOLDINGS PLC
	 	 
	 	By:	/s/ Joanne Wainwright
	 	 	Name: Joanne Wainwright 
	 	 	Title: Authorized Signatory
	 	 	 
	 	CITIBANK, N.A., as Trustee
	 	 
	 	By:	/s/ Danny Lee 
	 	 	Name: Danny Lee
	 	 	Title: Senior Trust Officer

 

    20

     

    

 

 

EXHIBIT A

 

FORM OF 1.089% FIXED RATE/FLOATING RATE
NOTE DUE 2025

 

This Senior Debt Security is in global
form within the meaning of the Senior Debt Securities Indenture hereinafter referred to and is registered in the name of The Depository
Trust Company, a New York corporation (“DTC”), or a nominee of DTC, which may be treated by the Issuer, the
Trustee and any agent thereof as owner and holder of this Senior Debt Security for all purposes.

 

Notwithstanding any other term of the
Senior Debt Securities represented by this Global Security or the Senior Debt Securities Indenture (as defined herein) or any other
agreements, arrangements or understandings between the Issuer and any Holder, by its acquisition of the Senior Debt Securities,
each Holder of the Senior Debt Securities (including for these purposes each holder of a beneficial interest in the Senior Debt
Securities) acknowledges, accepts, agrees to be bound by and consents to: (a) the effect of the exercise of any UK Bail-in Power
(as defined herein) by the Relevant UK Resolution Authority (as defined herein) arising in respect of the Senior Debt Securities,
whether or not imposed with prior notice, that may include and result in: (i) the reduction of all, or a portion, of the Amounts
Due (as defined herein); (ii) the conversion of all, or a portion, of the Amounts Due on the Senior Debt Securities into shares,
other securities or other obligations of the Issuer or another Person (and the issue to or conferral on the Holders of the Senior
Debt Securities of such shares, securities or obligations)), including by means of an amendment, modification or variation of the
terms of the Senior Debt Securities; (iii) the cancellation of the Senior Debt Securities including any other Amounts Due on the
Senior Debt Securities; (iv) the amendment or alteration of the maturity of the Senior Debt Securities or amendment of the amount
of interest payable on the Senior Debt Securities, or the date on which the interest becomes payable, including by suspending payment
for a temporary period; and (b) the variation, if necessary, of the terms of the Senior Debt Securities Indenture or the Senior
Debt Securities as may be deemed necessary by the Relevant UK Resolution Authority to give effect to the exercise of the UK Bail-in
Power by the Relevant UK Resolution Authority.

 

Unless this certificate is presented
by an authorized representative of DTC to the Issuer or its agent for registration of transfer, exchange or payment, and any certificate
issued is registered in the name of Cede & Co. or in such other name as is requested by an authorized representative of DTC
(and any payment is made to Cede & Co. or to such other entity as is requested by an authorized representative of DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof,
Cede & Co., has an interest herein.

 

Unless and until it is exchanged in
whole or in part for Senior Debt Securities in definitive form in the limited circumstances referred to in the Senior Debt Securities
Indenture, this Global Security may not be transferred except as a whole by DTC to a nominee of DTC or by a nominee of DTC to
DTC or another nominee of DTC or by DTC or any such nominee to a successor depositary or a nominee of such successor depositary.

 

    A-1

     

    

 

	Registered No. [      ]	Principal Amount:  $[       ]
	
        CUSIP: 80281LAN5

        ISIN: US80281LAN55
	 
	 	 
	SANTANDER UK GROUP HOLDINGS PLC
	 
	1.089% Fixed Rate/Floating Rate Notes due 2025

 

Santander UK Group Holdings plc, a public
limited company incorporated in England and Wales (hereinafter called the “Issuer,” which term shall include
any successor entity under the Senior Debt Securities Indenture), for value received, hereby promises to pay to Cede & Co.,
as nominee for DTC, or registered assigns, upon presentation, the principal sum of [ ] DOLLARS ($[ ]) on March 15, 2025 (the “Maturity
Date”).

 

The Issuer hereby promises to pay interest
thereon:

 

(1)       from
(and including) March 15, 2021 to (but excluding) March 15, 2024 (the “Fixed Rate Period”) semi-annually in
arrear on March 15 and September 15 of each year (each, a “Fixed Rate Period Interest Payment Date”), beginning
on September 15, 2021, at a rate of 1.089% per annum (the “Initial Interest Rate”); and

 

(2)        from
(and including) March 15, 2024 to (but excluding) the Maturity Date, (the “Floating Rate Period”), quarterly
in arrear on June 15, 2024, September 15, 2024, December 15, 2024 and the Maturity Date (each a “Floating Rate Period
Interest Payment Date” and, together with each Fixed Rate Period Interest Payment Date, an “Interest Payment
Date”), at a floating rate equal to the Benchmark plus 0.787% per annum (the “Margin”) (the “Floating
Rate”). The interest rate during the Floating Rate Period on this Senior Debt Security will be calculated quarterly on
each Interest Determination Date.

 

The interest so payable, and punctually
paid or duly provided for on any Interest Payment Date will, as provided in the Senior Debt Securities Indenture, be paid to the
Person in whose name this Senior Debt Security is registered at the close of business on the Regular Record Date for such interest,
which shall be the fifteenth calendar day (whether or not a Business Day) preceding the related Interest Payment Date. Any such
interest not so punctually paid or duly provided for shall forthwith cease to be payable to the Holder on such Regular Record Date,
and may either be paid to the Person in whose name this Senior Debt Security is registered at the close of business on a Special
Record Date for the payment of Defaulted Interest to be fixed by the Issuer, or may be paid at any time in any other lawful manner
not inconsistent with the requirements of any securities exchange on which the Senior Debt Securities may be listed, and upon such
notice as may be required by such exchange, all as more fully provided in the Senior Debt Securities Indenture.

 

Payment of the principal of and interest
on and any Additional Amounts in respect of this Global Security will be paid to DTC for the purpose of permitting DTC to credit
the principal and interest received by it in respect of this Global Security to the accounts of the beneficial owners thereof;
provided, however, that if this Senior Debt Security is not a Global Security, payment of the principal of, interest on and Additional
Amounts, if any, in respect of this Senior Debt Security will be made at the office or agency of the Trustee in The City of New
York, or elsewhere as provided in the Senior Debt Securities Indenture, in such coin or currency of the United States of America
as at the time of payment is legal tender for payment of public and private debts; and provided, further, that at the option of
the Issuer payment of interest may be made by (a) check mailed to the address of the Person entitled thereto as such address shall
appear in the Register or (b) transfer to an account of the Person entitled thereto located inside the United States.

 

    A-2

     

    

 

If a Fixed Rate Period Interest Payment
Date or a Redemption Date, as the case may be, would fall on a day that is not a Business Day, then the Interest Payment Date,
or Redemption Date, as the case may be, will be postponed to the next succeeding Business Day, but no additional interest shall
be paid unless the Issuer fails to make payment on such next succeeding Business Day.

 

If any Floating Rate Interest Payment Date
(other than the Maturity Date or a Redemption Date) would fall on a day that is not a Business Day, then the Interest Payment Date,
will be postponed to the next succeeding Business Day and interest thereon will continue to accrue to but excluding such succeeding
Business Day, except that if that Business Day falls in the next succeeding calendar month, the Interest Payment Date will be the
immediately preceding Business Day and interest thereon will accrue to but excluding such preceding Business Day. If the Maturity
Date or Redemption Date would fall on a day that is not a Business Day, then the payment of interest and principal will be made
on the next succeeding but no additional interest shall be paid unless the Issuer fails to make payment on such next succeeding
Business Day.

 

All amounts of principal, and premium, if
any, and interest, on the Senior Debt Securities will be paid by the Issuer without deduction or withholding for, or on account
of, any and all present and future income, stamp and other taxes, levies, imposts, duties, charges, fees, deductions or withholdings
(“Taxes”) now or hereafter imposed, levied, collected, withheld or assessed by or on behalf of the country in
which the Issuer is organized or any political subdivision or authority thereof or therein having the power to tax (the “Taxing
Jurisdiction”), unless such deduction or withholding is required by fiscal or other laws, regulations and directives.
For the purposes of this Senior Debt Security, the phrase “fiscal or other laws, regulations and directives” shall
include any obligation of the Issuer to withhold or deduct from a payment pursuant to an agreement described in Section 1471(b)
of the Internal Revenue Code of 1986, as amended (the “Code”) or otherwise imposed pursuant to Sections 1471
through 1474 of the Code, any regulations thereunder or official interpretations thereof or any law implementing an intergovernmental
approach thereto (collectively, “FATCA”). If deduction or withholding of any such Taxes shall at any time be
required by the Taxing Jurisdiction, the Issuer will pay such additional amounts of, or in respect of, the principal amount of,
premium, if any, and interest, on the Senior Debt Securities (“Additional Amounts”) as may be necessary in order
that the net amounts paid to the Holders of the Senior Debt Securities, after such deduction or withholding, shall equal the respective
amounts of principal, premium, if any, and interest, which would have been payable in respect of the Senior Debt Securities had
no such deduction or withholding been required; provided, however, that the foregoing will not apply to any such Tax which would
not have been payable or due but for the fact that:

 

(i) the Holder or the beneficial owner of
this Senior Debt Security is a domiciliary, national or resident of, or engaging in business or maintaining a permanent establishment
or physically present in, the Taxing Jurisdiction or otherwise has some connection with the Taxing Jurisdiction other than the
holding or ownership of this Senior Debt Security, or the collection of any payment of (or in respect of) principal of, premium,
if any, or interest, on this Senior Debt Security;

 

(ii) except in the case of a winding-up
of the Issuer in the United Kingdom, this Senior Debt Security is presented (where presentation is required) for payment in the
United Kingdom;

 

(iii) this Senior Debt Security is presented
(where presentation is required) for payment more than 30 days after the date payment became due or was provided for, whichever
is later, except to the extent that the Holder would have been entitled to such Additional Amount on presenting (where presentation
is required) the same for payment at the close of such 30 day period;

 

(iv) the Holder or the beneficial
owner of this Senior Debt Security or the beneficial owner of any payment of (or in respect of) principal of, premium, if
any, or interest on, this Senior Debt Security failed to comply with a request of the Issuer or its liquidator or other
authorized person addressed to the Holder (x) to provide information concerning the nationality, residence or identity of the
Holder or such beneficial owner or (y) to make any declaration or other similar claim to satisfy any information requirement,
which in the case of (x) or (y), is required or imposed by a statute, treaty, regulation or administrative practice of the
Taxing Jurisdiction as a precondition to exemption from all or part of such tax, assessment or other governmental charge;
or

 

    A-3

     

    

 

(v) any combination of sub-clauses (i) through
(iv) above;

 

nor shall Additional Amounts be paid with
respect to the principal of, premium, if any, and interest on, the Senior Debt Securities to any holder who is a fiduciary or partnership
or settlor with respect to such fiduciary or a member of such partnership other than the sole beneficial owner of such payment
to the extent such payment would be required by the laws of any Taxing Jurisdiction to be included in the income for tax purposes
of a beneficiary or partner or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner who
would not have been entitled to such Additional Amounts, had it been the holder. For the avoidance of doubt, all payments in respect
of the Senior Debt Securities will be made subject to any withholding or deduction required pursuant to any fiscal or other laws,
regulations and directives, including FATCA, and the Issuer shall not be required to pay Additional Amounts with respect to the
principal of, interest and any other payments on, the Senior Debt Securities on account of any such deduction or withholding required
pursuant to FATCA.

 

Whenever in this Senior Debt Security there
is mentioned, in any context, the payment of the principal of (and premium, if any) or interest, on, or in respect of, the Senior
Debt Securities such mention shall be deemed to include mention of the payment of Additional Amounts provided for herein to the
extent that, in such context, Additional Amounts are, were or would be payable in respect thereof pursuant to the provisions hereof
and as if express mention of the payment of Additional Amounts (if applicable) were made in any provisions hereof where such express
mention is not made.

 

A “Business Day” is any
day, other than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions in the City of New
York or London, England are authorized or required by law, regulation or executive order to close.

 

Additional provisions of this Senior Debt
Security are set forth following the signature page hereof, which provisions shall for all purposes have the same effect as if
set forth at this place.

 

Unless the certificate of authentication
hereon has been executed by or on behalf of the Trustee referred to on the reverse hereof by manual signature, this Senior Debt
Security shall not be entitled to any benefit under the Senior Debt Securities Indenture or be valid or obligatory for any purpose.

 

[The remainder of this
page has been left blank intentionally]

 

    A-4

     

    

 

IN WITNESS WHEREOF, the Issuer has caused
this instrument to be duly executed this [ ] day of March 2021.

 

	 	SANTANDER UK GROUP HOLDINGS PLC
	 	 
	 	By:	
	 	Name:
	 	Title:

 

CERTIFICATE OF AUTHENTICATION

 

This is one of the Senior Debt Securities of the series designated herein referred to in the within-mentioned Senior Debt Securities
Indenture.

 

	Dated:	 
	 	 
	CITIBANK, N.A., as Trustee	 
	 	 
	By:		 
	 	Authorized Signatory	 

 

    A-5

     

    

 

1.089% Fixed Rate/Floating Rate Notes
due 2025

 

This Senior Debt Security is one or all
of a duly authorized issue of securities of the Issuer (herein called the “Senior Debt Securities”), initially
limited in aggregate principal amount to $1,400,000,000 issued and to be issued in one or more series under an Amended and Restated
Indenture, dated as of April 18, 2017, between the Issuer and Citibank, N.A., as trustee (the “Trustee,” which
term includes any successor trustee under the Senior Debt Securities Indenture (as defined below), as successor to Wells Fargo
Bank, National Association pursuant to an Agreement of Resignation, Appointment and Acceptance dated as of March 4, 2021 among
the Issuer, the Trustee and Wells Fargo Bank, National Association), as supplemented and amended by the First Supplemental Indenture
dated as of November 3, 2017 and the Fourth Supplemental Indenture dated as of August 21, 2020 (as supplemented and amended, the
 “Original Senior Debt Securities Indenture”), as supplemented and amended by the Fifth Supplemental Indenture,
dated as of March 15, 2021 (the “Fifth Supplemental Indenture” and, together with the Original Securities Indenture,
the “Senior Debt Securities Indenture”) between the Issuer and the Trustee to which Senior Debt Securities Indenture
and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitation of rights,
duties and immunities thereunder of the Issuer, the Trustee and the Holders of the Senior Debt Securities and of the terms upon
which the Senior Debt Securities are, and are to be, authenticated and delivered. This Senior Debt Security is one or all of the
series designated as the “1.089% Fixed Rate/Floating Rate Notes due 2025.” All terms used in this Senior Debt Security
that are defined in the Senior Debt Securities Indenture and not otherwise defined herein shall have the meanings assigned to them
in the Senior Debt Securities Indenture.

 

During the Floating Rate Period, the calculation
agent, who shall be Citibank, N.A., or its successor appointed by the Issuer, will determine the Floating Rate by reference to
the Benchmark on the second Business Day preceding the applicable Floating Rate Period Interest Payment Date (each, an “Interest
Determination Date”). Promptly upon such determination, the calculation agent will notify the Issuer and the Trustee
(if the calculation agent is not the same entity as the Trustee) of the new interest rate.

 

The “Benchmark” means,
initially, Compounded SOFR Index Rate; provided that if a Benchmark Transition Event and related Benchmark Replacement Date have
occurred with respect to SOFR or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement
as provided in and determined in accordance with the Senior Debt Securities Indenture.

 

“Compounded SOFR Index Rate”
means in relation to a Floating Rate Interest Period, the rate computed by the Calculation Agent in accordance with the following
formula (and the resulting percentage will be rounded if necessary to the nearest seventh decimal place, with 0.00000005 being
rounded upwards):

 

 

Where:

 

“d” is the number of
calendar days from (and including) SOFR IndexStart to (but excluding) SOFR IndexEnd (being the number of
calendar days in the Observation Period);

 

“SOFR IndexStart”
is the SOFR Index value for the day which is two U.S. Government Securities Business Days preceding the first date of the relevant
Floating Rate Interest Period;

 

    A-6

     

    

 

“SOFR IndexEnd”
is the SOFR Index value for the day which is two U.S. Government Securities Business Days preceding the Floating Rate Period Interest
Payment Date relating to such Floating Rate Interest Period;

 

“SOFR Index” means,
with respect to any U.S. Government Securities Business Day:

 

(1)   
the SOFR Index value as published by the SOFR Administrator as such index appears on the SOFR Administrator’s Website
at the SOFR Determination Time; provided that:

 

(2)   
if a SOFR Index value does not so appear as specified in (1) above at the SOFR Determination Time, then (i) if
a Benchmark Transition Event and its related Benchmark Replacement Date have not occurred with respect to SOFR, then Compounded
SOFR Index Rate shall be the rate determined pursuant to the “SOFR Index Unavailability” provisions below or (ii) if
a Benchmark Transition Event and its related Benchmark Replacement Date have occurred in respect of SOFR, then Compounded SOFR
Index Rate shall be the rate determined pursuant to the “Benchmark Transition Provisions” below.

 

“SOFR” means, with
respect to any U.S. Government Securities Business Day, the rate determined by the Calculation Agent in accordance with the following
provisions:

 

(1)   
the Secured Overnight Financing Rate published for such U.S. Government Securities Business Day as such rate appears on
the NY Federal Reserve’s website on the immediately following U.S. Government Securities Business Day at the SOFR Determination
Time.

 

(2)   
if the rate does not so appear, the Secured Overnight Financing Rate published on the NY Federal Reserve’s website
for the first preceding U.S. Government Securities Business Day for which the Secured Overnight Financing Rate was published on
the NY Federal Reserve’s website.

 

“NY Federal Reserve’s website”
means the website of the Federal Reserve Bank of New York (the “NY Federal Reserve”), currently at http://www.newyorkfed.org,
or any successor website of the NY Federal Reserve or the website of any successor administrator of the Secured Overnight Financing
Rate.

 

“Observation Period”
means, in respect of each Floating Rate Interest Period, means the period from (and including) the day falling two U.S. Government
Securities Business Days prior to the first day of the relevant Floating Rate Interest Period to (but excluding) the day falling
two U.S. Government Securities Business Days prior to the relevant Floating Rate Period Interest Payment Date for such Floating
Rate Interest Period.

 

“SOFR Administrator”
means the Federal Reserve Bank of New York (or a successor administrator of SOFR).

 

“SOFR Administrator’s Website”
means the website of the Federal Reserve Bank of New York, currently at http://www.newyorkfed.org, or any successor source.

 

“SOFR Determination Time”
means, with respect to any U.S. Government Securities Business Day, 3:00 p.m. (New York City time) on such U.S. Government
Securities Business Day.

 

“U.S. Government Securities Business
Day” means any day except for a Saturday, Sunday or a day on which the Securities Industry and Financial Markets Association
(SIFMA) recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in U.S.
government securities.

 

    A-7

     

    

 

Notwithstanding clauses (1) and (2) of
the definition of “SOFR” above, if the Issuer or the Issuer’s designee (in consultation with the Issuer) determines
on or prior to the relevant Interest Determination Date that a Benchmark Transition Event and related Benchmark Replacement Date
have occurred with respect to SOFR, then Section 3.05 of the Fifth Supplemental Indenture will thereafter apply to all determinations
of the rate of interest payable on the Senior Debt Securities during the Floating Rate Period.

 

In accordance with and subject to Section
3.05 of the Fifth Supplemental Indenture, after a Benchmark Transition Event and related Benchmark Replacement Date have occurred,
the amount of interest that will be payable for each interest period on the Senior Debt Securities during the Floating Rate Period
will be determined by reference to a rate per annum equal to the Benchmark Replacement plus the Margin.

 

By its acquisition of the Senior Debt Securities,
each Holder (including each holder of a beneficial interest in the Senior Debt Securities) (i) will acknowledge, accept, consent
and agree to be bound by the Issuer or its designee’s determination of a Benchmark Transition Event, a Benchmark Replacement
Date, the Benchmark Replacement, the Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes, including
as may occur without any prior notice from the Issuer and without the need for the Issuer to obtain any further consent from such
Holder, (ii) will waive any and all claims, in law and/or in equity, against the Trustee, the Paying Agent and the calculation
agent or the Issuer’s designee for, agree not to initiate a suit against the Trustee, the Paying Agent and the calculation
agent or the Issuer’s designee in respect of, and agree that none of the Trustee, the Paying Agent or the calculation agent
or the Issuer’s designee will be liable for, the determination of or the Issuer’s failure or delay to determine any
Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement Adjustment and
any Benchmark Replacement Conforming Changes, and any losses suffered in connection therewith and (iii) will agree that none of
the Trustee, the Paying Agent or the calculation agent or the Issuer’s designee will have any obligation to determine, confirm
or verify any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement
Adjustment and any Benchmark Replacement Conforming Changes (including any adjustments thereto), including in the event of any
failure or delay by the Issuer to determine any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement,
any Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes.

 

Subject to the provisions of the Senior
Debt Securities Indenture and the satisfaction of the Regulatory Redemption Conditions (as defined below), the Issuer may redeem
the Senior Debt Securities, at its option, in whole, but not in part, on March 15, 2024 at a Redemption Price equal to 100% of
the principal amount of the Senior Debt Securities, plus accrued and unpaid interest thereon to, but excluding, the Redemption
Date.

 

As provided in and subject to the provisions
of the Senior Debt Securities Indenture, subject to the satisfaction of the Regulatory Redemption Conditions the Issuer will also
have the option to redeem the Senior Debt Securities in whole on any Interest Payment Date, at a Redemption Price equal to 100%
of the principal amount, together with accrued but unpaid interest, if any, in respect of the Senior Debt Securities to the date
fixed for redemption, if, at any time, the Issuer shall determine (such view being confirmed by a written legal opinion of independent
United Kingdom counsel of recognized standing as set forth in the Senior Debt Securities Indenture) that as a result of a change
in or amendment to the laws or regulations of the Taxing Jurisdiction (including any treaty to which such Taxing Jurisdiction is
a party) (as defined below), any change in the official application or interpretation of such laws or regulations (including a
decision of any court or tribunal) which change or amendment becomes effective on or after a date included in the terms of such
Senior Debt Securities:

 

(a) in making payment under the Senior Debt
Securities in respect of principal or premium, if any, or interest, if any, it has or will or would on the next Interest Payment
Date become obligated to pay Additional Amounts;

 

    A-8

     

    

 

(b) any payment of Interest on an Interest
Payment Date in respect of the Senior Debt Securities has been treated as a “distribution,” or the payment of interest
on the next Interest Payment Date in respect of any of the Senior Debt Securities would be treated as a “distribution,”
in each case within the meaning of Section 1000 of the Corporation Tax Act 2010 of the United Kingdom (or any statutory modification
or re-enactment thereof for the time being); or

 

(c) on an Interest Payment Date the Issuer
was not entitled, or on the next Interest Payment Date the Issuer would not be entitled, to claim a deduction in respect of such
payment of interest in computing its United Kingdom taxation liabilities (or the value of such deduction to the Issuer would be
materially reduced).

 

As provided in and subject to the provisions
of the Senior Debt Securities Indenture, if a Loss Absorption Disqualification Event has occurred and is continuing, the Issuer
may exercise the Loss Absorption Disqualification Event Call Option, having given not less than 30 nor more than 60 days’
notice to the Trustee, the Paying Agent, the Holders and the Registrar (which notice shall be irrevocable and shall specify the
Loss Absorption Disqualification Redemption Date). Upon the expiry of such notice the Issuer shall be bound to redeem the Senior
Debt Securities accordingly.

 

In any case where the Issuer shall determine
that as a result of the occurrence of a Loss Absorption Disqualification Event it is entitled to exercise the Loss Absorption Disqualification
Event Call Option in respect of the Senior Debt Securities, the Issuer shall be required to deliver to the Trustee an Officer’s
Certificate stating that the relevant requirement or circumstance referred to herein applies.

 

For the purposes of the Senior Debt Securities:

 

“Capital Rules”
means at any time the regulations, requirements, guidelines and policies relating to capital resources requirements or capital
adequacy then in effect and applicable to the Group (including, without limitation, any regulations, requirements, guidelines and
policies of the Regulator as may from time to time be applicable to the Group).

 

“Group” means
the Issuer and each other entity which is part of the UK prudential consolidation group (as that term, or its successor, is used
in the Capital Rules) of which the Issuer is part from time to time.

 

“Loss Absorption Disqualification
Event” means:

 

		(i)	at the time that any Loss Absorption Regulation becomes effective after the date of issuance of the Senior Debt Securities,
and as a result of such Loss Absorption Regulation becoming so effective, in each case with respect to the Issuer and/or the Group,
the Senior Debt Securities are not or will not be eligible to qualify in full towards the Issuer’s and/or the Group’s
minimum requirements for (A) own funds and eligible liabilities and/or (B) loss absorbing capacity instruments; or

 

		(ii)	as a result of any amendment to, or change in, any Loss Absorption Regulation, or any change in the application or
                                                                official interpretation of any Loss Absorption Regulation, in any such case becoming effective on or after the date of
                                                                issuance of the Senior Debt Securities, such Senior Debt Securities are or will be fully or partially excluded from the
                                                                Issuer’s and/or the Group’s minimum requirements for (A) own funds and eligible liabilities and/or (B) loss
                                                                absorbing capacity instruments, in each case as such minimum requirements are applicable to the Issuer of such Senior Debt
                                                                Securities and/or the Group and determined in accordance with, and pursuant to, the relevant Loss Absorption Regulations;
                                                                provided that a Loss Absorption Disqualification Event shall not occur where the exclusion of the Senior Debt Securities from
                                                                the relevant minimum requirement(s) is due to the remaining maturity of the Senior Debt Securities being less than any period
                                                                prescribed by any applicable eligibility criteria for such minimum requirements under the relevant Loss Absorption
                                                                Regulations effective with respect to the Issuer and/or the Group on the date of issuance of the Senior Debt Securities. 

 

    A-9

     

    

 

“Loss Absorption Disqualification
Event Call Option” means the Issuer’s option, subject to the satisfaction of the Regulatory Redemption Conditions,
to redeem in whole, but not in part, the Senior Debt Securities at any time at a redemption price equal to 100% of the principal
amount, together with accrued but unpaid interest, if any, in respect of the Senior Debt Securities to (but excluding) the Loss
Absorption Disqualification Redemption Date, upon the occurrence of a Loss Absorption Disqualification Event which is continuing.

 

“Loss Absorption Disqualification
Redemption Date” means the date fixed for redemption pursuant to an exercise by the Issuer of the Loss Absorption Disqualification
Event Call Option.

 

“Loss Absorption Regulations”
means, at any time, the laws, regulations, requirements, guidelines, rules, standards and policies relating to minimum requirements
for own funds and eligible liabilities and/or loss absorbing capacity instruments of the United Kingdom, the PRA, the United Kingdom
resolution authority, the Financial Stability Board and/or of the European Parliament or of the Council of the European Union then
in effect in the United Kingdom including, without limitation to the generality of the foregoing, any delegated or implementing
acts (such as regulatory technical standards) adopted by the European Commission which are applicable to the United Kingdom and
any regulations, requirements, guidelines, rules, standards and policies relating to minimum requirements for own funds and eligible
liabilities and/or loss absorbing capacity instruments adopted by the PRA and/or the United Kingdom resolution authority from time
to time (whether or not such regulations, requirements, guidelines, rules, standards or policies are applied generally or specifically
to the Issuer or to the Group).

 

“PRA” means
the Prudential Regulation Authority of the United Kingdom.

 

“Regulator”
means (i) the Bank of England, in its capacity as the PRA, or such successor or other authority having primary responsibility for
the prudential supervision of the Issuer and the Group; and/or (ii) the Bank of England or such other successor or other authority
designated as the United Kingdom resolution authority or otherwise having primary responsibility for the resolution of financial
institutions in the United Kingdom, as applicable in accordance with the Capital Rules.

 

“Regulatory Approval”
means, at any time, such approval, consent or prior permission by, or notification required within prescribed periods to, the Regulator,
or such waiver of the then prevailing Loss Absorption Regulations from the Regulator, as is required under the then prevailing
Loss Absorption Regulations at such time.

 

“Regulatory Preconditions”
means if, at the time of a redemption or purchase, the prevailing Loss Absorption Regulations permit the redemption or purchase
after compliance with any pre-conditions, the Issuer having complied with such pre-conditions.

 

“Regulatory Redemption
Conditions” means: (a) the Issuer has obtained Regulatory Approval; and (b) the Issuer is in compliance with the Regulatory
Preconditions.

 

    A-10

     

    

 

 

Notwithstanding any other term of the Senior
Debt Securities represented by this Global Security or the Senior Debt Securities Indenture, if required pursuant to any Loss Absorption
Regulation the Issuer may only redeem or repurchase the notes prior to the Maturity Date if it has satisfied the Regulatory Redemption
Conditions.

 

In the event of a redemption as described
in the paragraphs above, unless otherwise specified notice of such redemption to the Holders of the Senior Debt Securities of any
series to be redeemed in whole but not in part at the option of the Issuer shall be given by mailing notice of such redemption
by first class mail, postage prepaid, at least 30 days and not more than 60 days prior to the date fixed for redemption to such
Holders of the Senior Debt Securities of such series at their last addresses as they shall appear upon the Register of the Issuer.

 

The Senior Debt Securities Indenture contains
provisions for satisfaction and discharge of the Senior Debt Securities Indenture applicable to the Issuer upon compliance by the
Issuer with certain conditions set forth in the Senior Debt Securities Indenture, which provisions apply to this Senior Debt Security.

 

If an Event of Default with respect to the
Senior Debt Securities of this series shall occur and be continuing, the principal of the Senior Debt Securities of this series
may be declared due and payable in the manner and with the effect provided in the Senior Debt Securities Indenture.

 

As provided in and subject to the provisions
of the Senior Debt Securities Indenture, if an Event of Default occurs and is continuing with respect to the Senior Debt Securities
of this series (except in any such case for a solvent winding-up solely for the purpose of a merger, reconstruction or amalgamation
of us, the terms of which reorganization, reconstruction or amalgamation (i) have previously been approved in writing by a majority
of Holders and (ii) do not provide that the Senior Debt Securities shall thereby become redeemable or repayable in accordance with
the terms of the Senior Debt Securities), the Trustee may, and if so requested by the Holders of not less than 25% in principal
amount of the outstanding Senior Debt Securities of such series will, declare the principal amount together with accrued interest,
if any, with respect to the Senior Debt Securities of this series due and payable immediately, by a notice in writing to the Issuer
(and to the Trustee if given by the Holder or Holders), and upon any such declaration such principal amount (or specified amount)
shall become immediately due and payable.

 

The Holder of this Senior Debt
Security shall not have the right to institute any proceeding with respect to the Senior Debt Securities Indenture or for the
appointment of an administrator, receiver or trustee or for any other remedy thereunder, unless such Holder has previously
given written notice to the Trustee of a continuing Event of Default or Default with respect to such Senior Debt Security
specifying such Event of Default or Default and stating that such notice is a “Notice of Default” under
the Senior Debt Securities Indenture; the Holders of not less than 25% in aggregate principal amount of such Senior Debt
Security shall have made written request to the Trustee to institute proceedings in respect of such Event of Default or
Default in its own name, as Trustee hereunder; such Holders have offered to the Trustee reasonable indemnity or security
satisfactory to it against the costs, expenses and liabilities to be incurred in compliance with such request; the Trustee
for 60 days after its receipt of such notice, request and offer of indemnity or security has failed to institute any such
proceeding; and no direction inconsistent with such written request has been given to the Trustee during such 60-day period
by the Holders of a majority in principal amount of such Senior Debt Security; it being understood and intended that no one
or more Holders of this series shall have any right in any manner whatsoever by virtue of, or by availing of, any provision
of the Senior Debt Securities Indenture or the Senior Debt Securities to affect, disturb or prejudice the rights of any other
such Holders or holders, or to obtain or to seek to obtain priority or preference over any other such Holders or holders or
to enforce any right under the Senior Debt Securities Indenture, except in the manner herein provided and for the equal and
ratable benefit of all Holders of this series. The foregoing shall not apply to any suit instituted by the Holder of this
Senior Debt Security for the enforcement of any payment of principal hereof or interest hereon on or after the respective due
dates expressed herein.

 

    A-11

     

    

 

The Senior Debt Securities Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Issuer
and the rights of the Holders of the Senior Debt Securities under the Senior Debt Securities Indenture at any time by the Issuer
and the Trustee with the consent of the Holders of not less than a majority in principal amount of the outstanding Senior Debt
Securities affected by such amendment. The Senior Debt Securities Indenture also contains provisions permitting the Holders of
specified percentages in principal amount of the Senior Debt Securities at the time outstanding, on behalf of the Holders of all
Senior Debt Securities, to waive compliance by the Issuer with certain provisions of the Senior Debt Securities Indenture and certain
past defaults under the Senior Debt Securities Indenture and their consequences. Any such consent or waiver by the Holder of this
Senior Debt Security shall be conclusive and binding upon such Holder and upon all future Holders of this Senior Debt Security
and of any Senior Debt Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether
or not notation of such consent or waiver is made upon this Senior Debt Security.

 

No reference herein to the Senior Debt Securities
Indenture and no provision of this Senior Debt Security or of the Senior Debt Securities Indenture shall alter or impair the obligation
of the Issuer, which is absolute and unconditional, to pay the principal of and interest on this Senior Debt Security at the times,
place and rate, and in the coin or currency, herein prescribed.

 

The Issuer may, from time to time, without
the consent of the Holders of the Senior Debt Securities, issue additional Senior Debt Securities of this series having the same
ranking and same interest rate, stated maturity, redemption terms and other terms, except for the price to the public and issue
date and first Interest Payment Date, as this Senior Debt Security; provided however that such additional Senior Debt Securities
shall be issued under a separate CUSIP, Common Code and/or ISIN number unless the additional Senior Debt Securities are issued
pursuant to a “qualified reopening” of the original series, are otherwise treated as part of the same “issue”
of debt instruments as the original series, or the original series was issued with no more than a de minimis amount of original
issue discount and the additional Senior Debt Securities are issued with no more than a de minimis amount of original issue
discount, in each case for U.S. federal income tax purposes. Any such additional Senior Debt Securities, together with this Senior
Debt Security, will constitute a single series of Senior Debt Securities under the Senior Debt Securities Indenture.

 

As provided in the Senior Debt Securities
Indenture and subject to certain limitations therein set forth, the transfer of this Senior Debt Security is registrable in the
Register, upon surrender of this Senior Debt Security for registration of transfer at the office or agency of the Issuer in any
place of payment where the principal of and interest on this Senior Debt Security are payable, duly endorsed by, or accompanied
by a written instrument of transfer in form satisfactory to the Issuer and the Registrar duly executed by the registered Holder
hereof or his attorney duly authorized in writing, and thereupon one or more new Senior Debt Securities of this series, of authorized
denominations containing identical terms and provisions, of a like aggregate principal amount, will be issued to the designated
transferee or transferees.

 

The Senior Debt Securities of this series
are issuable only in registered form without coupons in denominations of $200,000 and integral multiples of $1,000 in excess thereof.
As provided in the Senior Debt Securities Indenture and subject to certain limitations set forth therein, Senior Debt Securities
of this series are exchangeable for a like aggregate principal amount of Senior Debt Securities of this series of a different authorized
denomination, as requested by the Holder surrendering the same.

 

No service charge shall be made for any
such registration of transfer or exchange, but, subject to certain exceptions set forth in the Senior Debt Securities Indenture,
the Issuer may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.

 

    A-12

     

    

 

Prior to due presentment of this Senior
Debt Security for registration of transfer, the Issuer, the Trustee and any agent of the Issuer or the Trustee may treat the Person
in whose name this Senior Debt Security is registered as the owner hereof for all purposes, whether or not this Senior Debt Security
be overdue, and none of the Issuer, the Trustee or any such agent shall be affected by notice to the contrary.

 

The obligations of the Issuer under the
Senior Debt Securities Indenture and this Senior Debt Security and all documents delivered in the name of the Issuer in connection
herewith and therewith do not and shall not constitute personal obligations of the directors, officers, employees, agents or shareholders
of the Issuer or any of them, and shall not involve any claim against or personal liability on the part of any of them, and all
persons including the Trustee shall look solely to the assets of the Issuer for the payment of any claim thereunder or for the
performance thereof and shall not seek recourse against such directors, officers, employees, agents or shareholders of the Issuer
or any of them or any of their personal assets for such satisfaction. The performance of the obligations of the Issuer under the
Senior Debt Securities Indenture and this Senior Debt Security and all documents delivered in the name of the Issuer in connection
therewith shall not be deemed a waiver of any rights or powers of the Issuer or its directors or shareholders under the Issuer’s
Memorandum and Articles of Association.

 

Notwithstanding any other term of the Senior
Debt Securities or the Senior Debt Securities Indenture or any other agreements, arrangements or understandings between the Issuer
and any Holder of the Senior Debt Securities (including for these purposes each holder of a beneficial interest in the Senior Debt
Securities), by its acquisition of the Senior Debt Securities, each Holder of the Senior Debt Securities acknowledges, accepts,
agrees to be bound by and consents to:

 

(a) the effect of the exercise of any UK
Bail-in Power by the Relevant UK Resolution Authority arising in respect of the Senior Debt Securities, whether or not imposed
with prior notice, that may include and result in: (i) the reduction of all, or a portion, of the Amounts Due; (ii) the conversion
of all, or a portion, of the Amounts Due on the Senior Debt Securities into shares, other securities or other obligations of the
Issuer or another Person (and the issue to or conferral on the Holders of the Senior Debt Securities of such shares, securities
or obligations), including by means of an amendment, modification or variation of the terms of the Senior Debt Securities; (iii)
the cancellation of the Senior Debt Securities including any other Amounts Due on the Senior Debt Securities; and/or (iv) the amendment
or alteration of the maturity of the Senior Debt Securities or amendment of the amount of interest payable on the Senior Debt Securities,
or the date on which the interest becomes payable, including by suspending payment for a temporary period; and

 

(b) the variation, if necessary, of the
terms of the Senior Debt Securities Indenture or the Senior Debt Securities to give effect to the exercise of the UK Bail-in Power
by the Relevant UK Resolution Authority.

 

No Amounts Due on the Senior Debt Securities
will become due and payable or be paid after the exercise of any UK Bail-in Power by the Relevant UK Resolution Authority if and
to the extent such Amounts Due have been reduced, converted, cancelled, amended or altered as a result of such exercise.

 

Notwithstanding any other provision of the
Senior Debt Securities Indenture or the Senior Debt Securities, neither a reduction or cancellation, in part or in full, of the
Amounts Due, the conversion thereof into another security or obligation of the Issuer or another Person, as a result of the exercise
of the UK Bail-in Power by the Relevant UK Resolution Authority with respect to the Issuer, nor the exercise of the UK Bail-in
Power by the Relevant UK Resolution Authority with respect to the Senior Debt Securities will be an Event of Default.

 

    A-13

     

    

 

By its acquisition of the Senior Debt Securities,
each Holder of the Senior Debt Securities (which for these purposes includes each holder of a beneficial interest in the Senior
Debt Securities):

 

(i) to the extent permitted by the Trust
Indenture Act, waives any and all claims, in law and/or in equity, against the Trustee for, agrees not to initiate a suit against
the Trustee in respect of, and agrees that the Trustee will not be liable for, any action that the Trustee takes, or abstains from
taking, in either case in accordance with the exercise of the UK Bail-in Power by the Relevant UK Resolution Authority with respect
to the Senior Debt Securities;

 

(ii) acknowledges and agrees that neither
a cancellation or deemed cancellation of the principal or interest (in each case, in whole or in part), nor the exercise of the
UK Bail-in Power by the Relevant UK Resolution Authority with respect to the Senior Debt Securities will give rise to a default
for purposes of Section 315(b) (Notice of Default) and Section 315(c) (Duties of the Trustee in Case of Default) of the Trust Indenture
Act; and

 

(iii) acknowledges and agrees that, upon
the exercise of the UK Bail-in Power by the Relevant UK Resolution Authority:

 

(A) the Trustee shall not be required to
take any further directions from the Holders of the Senior Debt Securities with respect to any portion of the Senior Debt Securities
that are written-down, converted to equity and/or cancelled under Section 5.12 of the Senior Debt Securities Indenture, and

 

(B) the Senior Debt Securities Indenture
shall not impose any duties upon the Trustee whatsoever with respect to the exercise of the UK Bail-in Power by the Relevant UK
Resolution Authority.

 

Notwithstanding clauses (i)-(iii) above,
if, following the completion of the exercise of the UK Bail-in Power by the Relevant UK Resolution Authority, the Senior Debt Securities
remain Outstanding (for example, if the exercise of the UK Bail-in Power results in only a partial write-down of the principal
of the Senior Debt Securities), then the Trustee’s duties under the Senior Debt Securities Indenture shall remain applicable
with respect to such Senior Debt Securities following such completion to the extent the Issuer and the Trustee shall agree pursuant
to a supplemental indenture or an amendment to the Senior Debt Securities Indenture; provided, however, that, notwithstanding the
exercise of the UK Bail-in Power by the Relevant UK Resolution Authority, so long as the Senior Debt Securities remain Outstanding,
there will at all times be a Trustee for the Senior Debt Securities in accordance with, Section 6.09 of the Senior Debt Securities
Indenture, and the resignation and/or removal of the Trustee and the appointment of a successor Trustee will continue to be governed
by Sections 6.10 and 6.11 of the Senior Debt Securities Indenture, respectively, including to the extent no additional supplemental
indenture or amendment is agreed upon in the event the Senior Debt Securities remain Outstanding following the completion of the
exercise of the UK Bail-in Power.

 

Upon the exercise of the UK Bail-in Power
by the Relevant UK Resolution Authority with respect to the Senior Debt Securities, the Issuer will provide a written notice to
DTC as soon as practicable regarding such exercise of the UK Bail-in Power for the purposes of notifying the Holders of such occurrence.
The Issuer will also deliver a copy of such notice to the Trustee for information purposes. Each Holder of the Senior Debt Securities
(including for these purposes each holder of a beneficial interest in the Senior Debt Securities) shall be deemed to have authorized,
directed and requested DTC and any direct participant in DTC or other intermediary through which it holds the Senior Debt Securities
to take any and all necessary action, if required, to implement the exercise of the UK Bail-in Power with respect to the Senior
Debt Securities as it may be imposed, without any further action or direction on the part of such Holder or the Trustee.

 

“UK Bail-in Power”
means the powers under the UK Bail-in Legislation to cancel, transfer or dilute shares issued by a person that is a bank or
investment firm or affiliate of a bank or investment firm, to cancel, reduce, modify or change the form of a liability of
such a person or any contract or instrument under which that liability arises, to convert all or part of that liability into
shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to
have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability.

 

    A-14

     

    

 

“UK Bail-in Legislation”
means Part I of the UK Banking Act 2009 and any other law or regulation applicable in the UK relating to the resolution of unsound
or failing banks, investment firms or other financial institutions or their affiliates (otherwise than through liquidation, administration
or other insolvency proceedings).

 

“Relevant UK Resolution Authority”
means the Bank of England or any other authority with the ability to exercise a UK Bail-in Power.

 

“Amounts Due” means the
principal amount of, and accrued but unpaid interest, including any Additional Amounts due on, the Senior Debt Securities. References
to principal and interest will include payments of principal and interest that have become due and payable but which have not been
paid, prior to the exercise of any UK Bail-in Power by the Relevant UK Resolution Authority.

 

The Senior Debt Securities Indenture
and the Senior Debt Securities, including this Senior Debt Security, shall be governed by and construed in accordance with the
law of the State of New York.

 

Pursuant to a recommendation promulgated
by the Committee on Uniform Security Identification Procedures, the Issuer has caused “CUSIP” numbers to be
printed on the Senior Debt Securities as a convenience to the Holders of the Senior Debt Securities. No representation is made
as to the correctness or accuracy of such CUSIP numbers as printed on the Senior Debt Securities, and reliance may be placed only
on the other identification numbers printed hereon. 

 

    A-15

     

    

 

ASSIGNMENT FORM

 

FOR VALUE RECEIVED, the undersigned hereby

sells, assigns and transfers unto

 

PLEASE INSERT SOCIAL

SECURITY OR OTHER IDENTIFYING

NUMBER OF ASSIGNEE

 

	 	 	 

 

	 
	(Please Print or Typewrite Name and Address, including Zip Code, of Assignee)

 

	 
	the within Security of the company and                          hereby does irrevocably constitute and appoint

 

	 
	attorney to transfer said Security on the books of the within-named company with full power of substitution in the premises.

 

	Dated:	 

 

	Signature	 

 

NOTICE: The signature to this assignment must correspond with
the name as it appears on the first page of the within Security in every particular, without alteration or enlargement or any change
whatever.

 

	Signature Guaranteed:	 

 

NOTICE: Signature(s) must be guaranteed by an “eligible
guarantor institution” that is a member or participant in a “signature guarantee program” (e.g.,
the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the New York Stock Exchange Medallion
Program).

 

    A-16

     

    

 

 

EXHIBIT B

 

FORM OF 2.896% FIXED RATE/FLOATING RATE
NOTE DUE 2032

 

This Senior Debt Security is in global
form within the meaning of the Senior Debt Securities Indenture hereinafter referred to and is registered in the name of The Depository
Trust Company, a New York corporation (“DTC”), or a nominee of DTC, which may be treated by the Issuer, the
Trustee and any agent thereof as owner and holder of this Senior Debt Security for all purposes.

 

Notwithstanding any other term of the
Senior Debt Securities represented by this Global Security or the Senior Debt Securities Indenture (as defined herein) or any other
agreements, arrangements or understandings between the Issuer and any Holder, by its acquisition of the Senior Debt Securities,
each Holder of the Senior Debt Securities (including for these purposes each holder of a beneficial interest in the Senior Debt
Securities) acknowledges, accepts, agrees to be bound by and consents to: (a) the effect of the exercise of any UK Bail-in Power
(as defined herein) by the Relevant UK Resolution Authority (as defined herein) arising in respect of the Senior Debt Securities,
whether or not imposed with prior notice, that may include and result in: (i) the reduction of all, or a portion, of the Amounts
Due (as defined herein); (ii) the conversion of all, or a portion, of the Amounts Due on the Senior Debt Securities into shares,
other securities or other obligations of the Issuer or another Person (and the issue to or conferral on the Holders of the Senior
Debt Securities of such shares, securities or obligations)), including by means of an amendment, modification or variation of the
terms of the Senior Debt Securities; (iii) the cancellation of the Senior Debt Securities including any other Amounts Due on the
Senior Debt Securities; (iv) the amendment or alteration of the maturity of the Senior Debt Securities or amendment of the amount
of interest payable on the Senior Debt Securities, or the date on which the interest becomes payable, including by suspending payment
for a temporary period; and (b) the variation, if necessary, of the terms of the Senior Debt Securities Indenture or the Senior
Debt Securities as may be deemed necessary by the Relevant UK Resolution Authority to give effect to the exercise of the UK Bail-in
Power by the Relevant UK Resolution Authority.

 

Unless this certificate is presented
by an authorized representative of DTC to the Issuer or its agent for registration of transfer, exchange or payment, and any certificate
issued is registered in the name of Cede & Co. or in such other name as is requested by an authorized representative of DTC
(and any payment is made to Cede & Co. or to such other entity as is requested by an authorized representative of DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof,
Cede & Co., has an interest herein.

 

Unless and until it is exchanged in whole
or in part for Senior Debt Securities in definitive form in the limited circumstances referred to in the Senior Debt Securities
Indenture, this Global Security may not be transferred except as a whole by DTC to a nominee of DTC or by a nominee of DTC to DTC
or another nominee of DTC or by DTC or any such nominee to a successor depositary or a nominee of such successor depositary. 

 

    B-1

     

    

 

	Registered No. [      ]	Principal Amount:  $[       ]
	
        CUSIP: 80281LAP0

        ISIN: US80281LAP04
	 
	 	 
	SANTANDER UK GROUP HOLDINGS PLC
	2.896% Fixed Rate/Floating Rate Notes due 2032
	 

Santander UK Group Holdings plc, a public
limited company incorporated in England and Wales (hereinafter called the “Issuer,” which term shall include
any successor entity under the Senior Debt Securities Indenture), for value received, hereby promises to pay to Cede & Co.,
as nominee for DTC, or registered assigns, upon presentation, the principal sum of [ ] DOLLARS ($[ ]) on March 15, 2032 (the “Maturity
Date”).

 

The Issuer hereby promises to pay interest
thereon:

 

(1)       from
(and including) March 15, 2021 to (but excluding) March 15, 2031 (the “Fixed Rate Period”) semi-annually in
arrear on March 15 and September 15 of each year (each, a “Fixed Rate Period Interest Payment Date”), beginning
on September 15, 2021, at a rate of 2.896% per annum (the “Initial Interest Rate”); and

 

(2)        from
(and including) March 15, 2031 to (but excluding) the Maturity Date, (the “Floating Rate Period”), quarterly
in arrear on June 15, 2031, September 15, 2031, December 15, 2031 and the Maturity Date (each a “Floating Rate Period
Interest Payment Date” and, together with each Fixed Rate Period Interest Payment Date, an “Interest Payment
Date”), at a floating rate equal to the Benchmark plus 1.475% per annum (the “Margin”) (the “Floating
Rate”). The interest rate during the Floating Rate Period on this Senior Debt Security will be calculated quarterly on
each Interest Determination Date.

 

The interest so payable, and punctually
paid or duly provided for on any Interest Payment Date will, as provided in the Senior Debt Securities Indenture, be paid to the
Person in whose name this Senior Debt Security is registered at the close of business on the Regular Record Date for such interest,
which shall be the fifteenth calendar day (whether or not a Business Day) preceding the related Interest Payment Date. Any such
interest not so punctually paid or duly provided for shall forthwith cease to be payable to the Holder on such Regular Record Date,
and may either be paid to the Person in whose name this Senior Debt Security is registered at the close of business on a Special
Record Date for the payment of Defaulted Interest to be fixed by the Issuer, or may be paid at any time in any other lawful manner
not inconsistent with the requirements of any securities exchange on which the Senior Debt Securities may be listed, and upon such
notice as may be required by such exchange, all as more fully provided in the Senior Debt Securities Indenture.

 

Payment of the principal of and interest
on and any Additional Amounts in respect of this Global Security will be paid to DTC for the purpose of permitting DTC to credit
the principal and interest received by it in respect of this Global Security to the accounts of the beneficial owners thereof;
provided, however, that if this Senior Debt Security is not a Global Security, payment of the principal of, interest on and Additional
Amounts, if any, in respect of this Senior Debt Security will be made at the office or agency of the Trustee in The City of New
York, or elsewhere as provided in the Senior Debt Securities Indenture, in such coin or currency of the United States of America
as at the time of payment is legal tender for payment of public and private debts; and provided, further, that at the option of
the Issuer payment of interest may be made by (a) check mailed to the address of the Person entitled thereto as such address shall
appear in the Register or (b) transfer to an account of the Person entitled thereto located inside the United States.

 

    B-2

     

    

 

If a Fixed Rate Period Interest Payment
Date or a Redemption Date, as the case may be, would fall on a day that is not a Business Day, then the Interest Payment Date,
or Redemption Date, as the case may be, will be postponed to the next succeeding Business Day, but no additional interest shall
be paid unless the Issuer fails to make payment on such next succeeding Business Day.

 

If any Floating Rate Interest Payment Date
(other than the Maturity Date or a Redemption Date) would fall on a day that is not a Business Day, then the Interest Payment Date,
will be postponed to the next succeeding Business Day and interest thereon will continue to accrue to but excluding such succeeding
Business Day, except that if that Business Day falls in the next succeeding calendar month, the Interest Payment Date will be the
immediately preceding Business Day and interest thereon will accrue to but excluding such preceding Business Day. If the Maturity
Date or Redemption Date would fall on a day that is not a Business Day, then the payment of interest and principal will be made
on the next succeeding but no additional interest shall be paid unless the Issuer fails to make payment on such next succeeding
Business Day.

 

All amounts of principal, and premium, if
any, and interest, on the Senior Debt Securities will be paid by the Issuer without deduction or withholding for, or on account
of, any and all present and future income, stamp and other taxes, levies, imposts, duties, charges, fees, deductions or withholdings
(“Taxes”) now or hereafter imposed, levied, collected, withheld or assessed by or on behalf of the country in
which the Issuer is organized or any political subdivision or authority thereof or therein having the power to tax (the “Taxing
Jurisdiction”), unless such deduction or withholding is required by fiscal or other laws, regulations and directives.
For the purposes of this Senior Debt Security, the phrase “fiscal or other laws, regulations and directives” shall
include any obligation of the Issuer to withhold or deduct from a payment pursuant to an agreement described in Section 1471(b)
of the Internal Revenue Code of 1986, as amended (the “Code”) or otherwise imposed pursuant to Sections 1471
through 1474 of the Code, any regulations thereunder or official interpretations thereof or any law implementing an intergovernmental
approach thereto (collectively, “FATCA”). If deduction or withholding of any such Taxes shall at any time be
required by the Taxing Jurisdiction, the Issuer will pay such additional amounts of, or in respect of, the principal amount of,
premium, if any, and interest, on the Senior Debt Securities (“Additional Amounts”) as may be necessary in order
that the net amounts paid to the Holders of the Senior Debt Securities, after such deduction or withholding, shall equal the respective
amounts of principal, premium, if any, and interest, which would have been payable in respect of the Senior Debt Securities had
no such deduction or withholding been required; provided, however, that the foregoing will not apply to any such Tax which would
not have been payable or due but for the fact that:

 

(i)                   the Holder or the beneficial owner of
this Senior Debt Security is a domiciliary, national or resident of, or engaging in business or maintaining a permanent establishment
or physically present in, the Taxing Jurisdiction or otherwise has some connection with the Taxing Jurisdiction other than the
holding or ownership of this Senior Debt Security, or the collection of any payment of (or in respect of) principal of, premium,
if any, or interest, on this Senior Debt Security;

 

(ii)                  except in the case of a winding-up
of the Issuer in the United Kingdom, this Senior Debt Security is presented (where presentation is required) for payment in the
United Kingdom;

 

(iii)                 this Senior Debt Security is presented
(where presentation is required) for payment more than 30 days after the date payment became due or was provided for, whichever
is later, except to the extent that the Holder would have been entitled to such Additional Amount on presenting (where presentation
is required) the same for payment at the close of such 30 day period;

 

(iv)                 the Holder or the beneficial
owner of this Senior Debt Security or the beneficial owner of any payment of (or in respect of) principal of, premium, if
any, or interest on, this Senior Debt Security failed to comply with a request of the Issuer or its liquidator or other
authorized person addressed to the Holder (x) to provide information concerning the nationality, residence or identity of the
Holder or such beneficial owner or (y) to make any declaration or other similar claim to satisfy any information requirement,
which in the case of (x) or (y), is required or imposed by a statute, treaty, regulation or administrative practice of the
Taxing Jurisdiction as a precondition to exemption from all or part of such tax, assessment or other governmental charge;
or

 

    B-3

     

    

 

(v)                  any combination of sub-clauses (i) through
(iv) above;

 

nor shall Additional Amounts be paid with
respect to the principal of, premium, if any, and interest on, the Senior Debt Securities to any holder who is a fiduciary or partnership
or settlor with respect to such fiduciary or a member of such partnership other than the sole beneficial owner of such payment
to the extent such payment would be required by the laws of any Taxing Jurisdiction to be included in the income for tax purposes
of a beneficiary or partner or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner who
would not have been entitled to such Additional Amounts, had it been the holder. For the avoidance of doubt, all payments in respect
of the Senior Debt Securities will be made subject to any withholding or deduction required pursuant to any fiscal or other laws,
regulations and directives, including FATCA, and the Issuer shall not be required to pay Additional Amounts with respect to the
principal of, interest and any other payments on, the Senior Debt Securities on account of any such deduction or withholding required
pursuant to FATCA.

 

Whenever in this Senior Debt Security there
is mentioned, in any context, the payment of the principal of (and premium, if any) or interest, on, or in respect of, the Senior
Debt Securities such mention shall be deemed to include mention of the payment of Additional Amounts provided for herein to the
extent that, in such context, Additional Amounts are, were or would be payable in respect thereof pursuant to the provisions hereof
and as if express mention of the payment of Additional Amounts (if applicable) were made in any provisions hereof where such express
mention is not made.

 

A “Business Day” is any
day, other than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions in the City of New
York or London, England are authorized or required by law, regulation or executive order to close.

 

Additional provisions of this Senior Debt
Security are set forth following the signature page hereof, which provisions shall for all purposes have the same effect as if
set forth at this place.

 

Unless the certificate of authentication
hereon has been executed by or on behalf of the Trustee referred to on the reverse hereof by manual signature, this Senior Debt
Security shall not be entitled to any benefit under the Senior Debt Securities Indenture or be valid or obligatory for any purpose.

 

[The remainder of this
page has been left blank intentionally]

 

    B-4

     

    

 

IN WITNESS WHEREOF, the Issuer has caused
this instrument to be duly executed this [ ] day of March 2021.

 

	 	SANTANDER UK GROUP HOLDINGS PLC
	 	 
	 	By:	          
	 	Name:
	 	Title:

 

 

CERTIFICATE OF AUTHENTICATION

This is one of the Senior Debt Securities of the series designated herein referred to in the within-mentioned Senior Debt Securities
Indenture.

 

	Dated:
	 
	CITIBANK, N.A.,
	as Trustee
	 
	 
	By:	        	 
	 	Authorized Signatory	 

 

    B-5

     

    

 

 

2.896% Fixed Rate/Floating Rate Notes
due 2032

 

This Senior Debt Security is one or all
of a duly authorized issue of securities of the Issuer (herein called the “Senior Debt Securities”), initially
limited in aggregate principal amount to $600,000,000 issued and to be issued in one or more series under an Amended and Restated
Indenture, dated as of April 18, 2017, between the Issuer and Citibank, N.A., as trustee (the “Trustee,” which
term includes any successor trustee under the Senior Debt Securities Indenture (as defined below), as successor to Wells Fargo
Bank, National Association pursuant to an Agreement of Resignation, Appointment and Acceptance dated as of March 4, 2021 among
the Issuer, the Trustee and Wells Fargo Bank, National Association), as supplemented and amended by the First Supplemental Indenture
dated as of November 3, 2017 and the Fourth Supplemental Indenture dated as of August 21, 2020 (as supplemented and amended, the
 “Original Senior Debt Securities Indenture”), as supplemented and amended by the Fifth Supplemental Indenture,
dated as of March 15, 2021 (the “Fifth Supplemental Indenture” and, together with the Original Securities Indenture,
the “Senior Debt Securities Indenture”) between the Issuer and the Trustee to which Senior Debt Securities Indenture
and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitation of rights,
duties and immunities thereunder of the Issuer, the Trustee and the Holders of the Senior Debt Securities and of the terms upon
which the Senior Debt Securities are, and are to be, authenticated and delivered. This Senior Debt Security is one or all of the
series designated as the “2.896% Fixed Rate/Floating Rate Notes due 2032.” All terms used in this Senior Debt Security
that are defined in the Senior Debt Securities Indenture and not otherwise defined herein shall have the meanings assigned to them
in the Senior Debt Securities Indenture.

 

During the Floating Rate Period, the calculation
agent, who shall be Citibank, N.A., or its successor appointed by the Issuer, will determine the Floating Rate by reference to
the Benchmark on the second Business Day preceding the applicable Floating Rate Period Interest Payment Date (each, an “Interest
Determination Date”). Promptly upon such determination, the calculation agent will notify the Issuer and the Trustee
(if the calculation agent is not the same entity as the Trustee) of the new interest rate.

 

The “Benchmark” means,
initially, Compounded SOFR Index Rate; provided that if a Benchmark Transition Event and related Benchmark Replacement Date have
occurred with respect to SOFR or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement
as provided in and determined in accordance with the Senior Debt Securities Indenture.

 

“Compounded SOFR Index Rate”
means in relation to a Floating Rate Interest Period, the rate computed by the Calculation Agent in accordance with the following
formula (and the resulting percentage will be rounded if necessary to the nearest seventh decimal place, with 0.00000005 being
rounded upwards):

 

 

Where:

 

“d” is the number of
calendar days from (and including) SOFR IndexStart to (but excluding) SOFR IndexEnd (being the number of
calendar days in the Observation Period);

 

“SOFR IndexStart”
is the SOFR Index value for the day which is two U.S. Government Securities Business Days preceding the first date of the relevant
Floating Rate Interest Period;

 

    B-6

     

    

 

“SOFR IndexEnd”
is the SOFR Index value for the day which is two U.S. Government Securities Business Days preceding the Floating Rate Period Interest
Payment Date relating to such Floating Rate Interest Period;

 

“SOFR Index” means,
with respect to any U.S. Government Securities Business Day:

 

(3)   
the SOFR Index value as published by the SOFR Administrator as such index appears on the SOFR Administrator’s Website
at the SOFR Determination Time; provided that:

 

(4)   
if a SOFR Index value does not so appear as specified in (1) above at the SOFR Determination Time, then (i) if
a Benchmark Transition Event and its related Benchmark Replacement Date have not occurred with respect to SOFR, then Compounded
SOFR Index Rate shall be the rate determined pursuant to the “SOFR Index Unavailability” provisions below or (ii) if
a Benchmark Transition Event and its related Benchmark Replacement Date have occurred in respect of SOFR, then Compounded SOFR
Index Rate shall be the rate determined pursuant to the “Benchmark Transition Provisions” below.

 

“SOFR” means, with
respect to any U.S. Government Securities Business Day, the rate determined by the Calculation Agent in accordance with the following
provisions:

 

(5)   
the Secured Overnight Financing Rate published for such U.S. Government Securities Business Day as such rate appears on
the NY Federal Reserve’s website on the immediately following U.S. Government Securities Business Day at the SOFR Determination
Time.

 

(6)   
if the rate does not so appear, the Secured Overnight Financing Rate published on the NY Federal Reserve’s website
for the first preceding U.S. Government Securities Business Day for which the Secured Overnight Financing Rate was published on
the NY Federal Reserve’s website.

 

“NY Federal Reserve’s website”
means the website of the Federal Reserve Bank of New York (the “NY Federal Reserve”), currently at http://www.newyorkfed.org,
or any successor website of the NY Federal Reserve or the website of any successor administrator of the Secured Overnight Financing
Rate.

 

“Observation Period”
means, in respect of each Floating Rate Interest Period, means the period from (and including) the day falling two U.S. Government
Securities Business Days prior to the first day of the relevant Floating Rate Interest Period to (but excluding) the day falling
two U.S. Government Securities Business Days prior to the relevant Floating Rate Period Interest Payment Date for such Floating
Rate Interest Period.

 

“SOFR Administrator”
means the Federal Reserve Bank of New York (or a successor administrator of SOFR).

 

“SOFR Administrator’s Website”
means the website of the Federal Reserve Bank of New York, currently at http://www.newyorkfed.org, or any successor source.

 

“SOFR Determination Time”
means, with respect to any U.S. Government Securities Business Day, 3:00 p.m. (New York City time) on such U.S. Government
Securities Business Day.

 

“U.S. Government Securities Business
Day” means any day except for a Saturday, Sunday or a day on which the Securities Industry and Financial Markets Association
(SIFMA) recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in U.S.
government securities.

 

    B-7

     

    

 

Notwithstanding clauses (1) and (2) of
the definition of “SOFR” above, if the Issuer or the Issuer’s designee (in consultation with the Issuer) determines
on or prior to the relevant Interest Determination Date that a Benchmark Transition Event and related Benchmark Replacement Date
have occurred with respect to SOFR, then Section 3.05 of the Fifth Supplemental Indenture will thereafter apply to all determinations
of the rate of interest payable on the Senior Debt Securities during the Floating Rate Period.

 

In accordance with and subject to Section
3.05 of the Fifth Supplemental Indenture, after a Benchmark Transition Event and related Benchmark Replacement Date have occurred,
the amount of interest that will be payable for each interest period on the Senior Debt Securities during the Floating Rate Period
will be determined by reference to a rate per annum equal to the Benchmark Replacement plus the Margin.

 

By its acquisition of the Senior Debt Securities,
each Holder (including each holder of a beneficial interest in the Senior Debt Securities) (i) will acknowledge, accept, consent
and agree to be bound by the Issuer or its designee’s determination of a Benchmark Transition Event, a Benchmark Replacement
Date, the Benchmark Replacement, the Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes, including
as may occur without any prior notice from the Issuer and without the need for the Issuer to obtain any further consent from such
Holder, (ii) will waive any and all claims, in law and/or in equity, against the Trustee, the Paying Agent and the calculation
agent or the Issuer’s designee for, agree not to initiate a suit against the Trustee, the Paying Agent and the calculation
agent or the Issuer’s designee in respect of, and agree that none of the Trustee, the Paying Agent or the calculation agent
or the Issuer’s designee will be liable for, the determination of or the Issuer’s failure or delay to determine any
Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement Adjustment and
any Benchmark Replacement Conforming Changes, and any losses suffered in connection therewith and (iii) will agree that none of
the Trustee, the Paying Agent or the calculation agent or the Issuer’s designee will have any obligation to determine, confirm
or verify any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement
Adjustment and any Benchmark Replacement Conforming Changes (including any adjustments thereto), including in the event of any
failure or delay by the Issuer to determine any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement,
any Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes.

 

Subject to the provisions of the Senior
Debt Securities Indenture and the satisfaction of the Regulatory Redemption Conditions (as defined below), the Issuer may redeem
the Senior Debt Securities, at its option, in whole, but not in part, on March 15, 2031 at a Redemption Price equal to 100% of
the principal amount of the Senior Debt Securities, plus accrued and unpaid interest thereon to, but excluding, the Redemption
Date.

 

As provided in and subject to the provisions
of the Senior Debt Securities Indenture, subject to the satisfaction of the Regulatory Redemption Conditions the Issuer will also
have the option to redeem the Senior Debt Securities in whole on any Interest Payment Date, at a Redemption Price equal to 100%
of the principal amount, together with accrued but unpaid interest, if any, in respect of the Senior Debt Securities to the date
fixed for redemption, if, at any time, the Issuer shall determine (such view being confirmed by a written legal opinion of independent
United Kingdom counsel of recognized standing as set forth in the Senior Debt Securities Indenture) that as a result of a change
in or amendment to the laws or regulations of the Taxing Jurisdiction (including any treaty to which such Taxing Jurisdiction is
a party) (as defined below), any change in the official application or interpretation of such laws or regulations (including a
decision of any court or tribunal) which change or amendment becomes effective on or after a date included in the terms of such
Senior Debt Securities:

 

(a)       in making payment under the Senior Debt
Securities in respect of principal or premium, if any, or interest, if any, it has or will or would on the next Interest Payment
Date become obligated to pay Additional Amounts;

 

    B-8

     

    

 

  

(b)      any payment of Interest on an Interest
Payment Date in respect of the Senior Debt Securities has been treated as a “distribution,” or the payment of interest
on the next Interest Payment Date in respect of any of the Senior Debt Securities would be treated as a “distribution,”
in each case within the meaning of Section 1000 of the Corporation Tax Act 2010 of the United Kingdom (or any statutory modification
or re-enactment thereof for the time being); or

 

(c)      on an Interest Payment Date the Issuer
was not entitled, or on the next Interest Payment Date the Issuer would not be entitled, to claim a deduction in respect of such
payment of interest in computing its United Kingdom taxation liabilities (or the value of such deduction to the Issuer would be
materially reduced).

 

As provided in and subject to the provisions
of the Senior Debt Securities Indenture, if a Loss Absorption Disqualification Event has occurred and is continuing, the Issuer
may exercise the Loss Absorption Disqualification Event Call Option, having given not less than 30 nor more than 60 days’
notice to the Trustee, the Paying Agent, the Holders and the Registrar (which notice shall be irrevocable and shall specify the
Loss Absorption Disqualification Redemption Date). Upon the expiry of such notice the Issuer shall be bound to redeem the Senior
Debt Securities accordingly.

 

In any case where the Issuer shall determine
that as a result of the occurrence of a Loss Absorption Disqualification Event it is entitled to exercise the Loss Absorption Disqualification
Event Call Option in respect of the Senior Debt Securities, the Issuer shall be required to deliver to the Trustee an Officer’s
Certificate stating that the relevant requirement or circumstance referred to herein applies.

 

For the purposes of the Senior Debt Securities:

 

“Capital Rules”
means at any time the regulations, requirements, guidelines and policies relating to capital resources requirements or capital
adequacy then in effect and applicable to the Group (including, without limitation, any regulations, requirements, guidelines and
policies of the Regulator as may from time to time be applicable to the Group).

 

“Group” means
the Issuer and each other entity which is part of the UK prudential consolidation group (as that term, or its successor, is used
in the Capital Rules) of which the Issuer is part from time to time.

 

“Loss Absorption Disqualification
Event” means:

 

		(iii)	at the time that any Loss Absorption Regulation becomes effective after the date of issuance of the Senior Debt Securities,
and as a result of such Loss Absorption Regulation becoming so effective, in each case with respect to the Issuer and/or the Group,
the Senior Debt Securities are not or will not be eligible to qualify in full towards the Issuer’s and/or the Group’s
minimum requirements for (A) own funds and eligible liabilities and/or (B) loss absorbing capacity instruments; or

  

		(iv)	as a result of any amendment to, or change in, any Loss Absorption Regulation, or any change in the application or
                                                                official interpretation of any Loss Absorption Regulation, in any such case becoming effective on or after the date of
                                                                issuance of the Senior Debt Securities, such Senior Debt Securities are or will be fully or partially excluded from the
                                                                Issuer’s and/or the Group’s minimum requirements for (A) own funds and eligible liabilities and/or (B) loss
                                                                absorbing capacity instruments, 

 

    B-9

     

    

  

in each case as such minimum requirements are applicable to the Issuer of such Senior Debt Securities and/or the Group and determined
in accordance with, and pursuant to, the relevant Loss Absorption Regulations; provided that a Loss Absorption Disqualification Event
shall not occur where the exclusion of the Senior Debt Securities from the relevant minimum requirement(s) is due to the remaining maturity
of the Senior Debt Securities being less than any period prescribed by any applicable eligibility criteria for such minimum requirements
under the relevant Loss Absorption Regulations effective with respect to the Issuer and/or the Group on the date of issuance of the Senior
Debt Securities.

 

“Loss Absorption Disqualification
Event Call Option” means the Issuer’s option, subject to the satisfaction of the Regulatory Redemption Conditions,
to redeem in whole, but not in part, the Senior Debt Securities at any time at a redemption price equal to 100% of the principal
amount, together with accrued but unpaid interest, if any, in respect of the Senior Debt Securities to (but excluding) the Loss
Absorption Disqualification Redemption Date, upon the occurrence of a Loss Absorption Disqualification Event which is continuing.

 

“Loss Absorption Disqualification
Redemption Date” means the date fixed for redemption pursuant to an exercise by the Issuer of the Loss Absorption Disqualification
Event Call Option.

 

“Loss Absorption Regulations”
means, at any time, the laws, regulations, requirements, guidelines, rules, standards and policies relating to minimum requirements
for own funds and eligible liabilities and/or loss absorbing capacity instruments of the United Kingdom, the PRA, the United Kingdom
resolution authority, the Financial Stability Board and/or of the European Parliament or of the Council of the European Union then
in effect in the United Kingdom including, without limitation to the generality of the foregoing, any delegated or implementing
acts (such as regulatory technical standards) adopted by the European Commission which are applicable to the United Kingdom and
any regulations, requirements, guidelines, rules, standards and policies relating to minimum requirements for own funds and eligible
liabilities and/or loss absorbing capacity instruments adopted by the PRA and/or the United Kingdom resolution authority from time
to time (whether or not such regulations, requirements, guidelines, rules, standards or policies are applied generally or specifically
to the Issuer or to the Group).

 

“PRA” means
the Prudential Regulation Authority of the United Kingdom.

 

“Regulator”
means (i) the Bank of England, in its capacity as the PRA, or such successor or other authority having primary responsibility for
the prudential supervision of the Issuer and the Group; and/or (ii) the Bank of England or such other successor or other authority
designated as the United Kingdom resolution authority or otherwise having primary responsibility for the resolution of financial
institutions in the United Kingdom, as applicable in accordance with the Capital Rules.

 

“Regulatory Approval”
means, at any time, such approval, consent or prior permission by, or notification required within prescribed periods to, the Regulator,
or such waiver of the then prevailing Loss Absorption Regulations from the Regulator, as is required under the then prevailing
Loss Absorption Regulations at such time.

 

“Regulatory Preconditions”
means if, at the time of a redemption or purchase, the prevailing Loss Absorption Regulations permit the redemption or purchase
after compliance with any pre-conditions, the Issuer having complied with such pre-conditions.

 

“Regulatory Redemption
Conditions” means: (a) the Issuer has obtained Regulatory Approval; and (b) the Issuer is in compliance with the Regulatory
Preconditions.

 

    B-10

     

    

 

Notwithstanding any other term of the Senior
Debt Securities represented by this Global Security or the Senior Debt Securities Indenture, if required pursuant to any Loss Absorption
Regulation the Issuer may only redeem or repurchase the notes prior to the Maturity Date if it has satisfied the Regulatory Redemption
Conditions.

 

In the event of a redemption as described
in the paragraphs above, unless otherwise specified notice of such redemption to the Holders of the Senior Debt Securities of any
series to be redeemed in whole but not in part at the option of the Issuer shall be given by mailing notice of such redemption
by first class mail, postage prepaid, at least 30 days and not more than 60 days prior to the date fixed for redemption to such
Holders of the Senior Debt Securities of such series at their last addresses as they shall appear upon the Register of the Issuer.

 

The Senior Debt Securities Indenture contains
provisions for satisfaction and discharge of the Senior Debt Securities Indenture applicable to the Issuer upon compliance by the
Issuer with certain conditions set forth in the Senior Debt Securities Indenture, which provisions apply to this Senior Debt Security.

 

If an Event of Default with respect to the
Senior Debt Securities of this series shall occur and be continuing, the principal of the Senior Debt Securities of this series
may be declared due and payable in the manner and with the effect provided in the Senior Debt Securities Indenture.

 

As provided in and subject to the provisions
of the Senior Debt Securities Indenture, if an Event of Default occurs and is continuing with respect to the Senior Debt Securities
of this series (except in any such case for a solvent winding-up solely for the purpose of a merger, reconstruction or amalgamation
of us, the terms of which reorganization, reconstruction or amalgamation (i) have previously been approved in writing by a majority
of Holders and (ii) do not provide that the Senior Debt Securities shall thereby become redeemable or repayable in accordance with
the terms of the Senior Debt Securities), the Trustee may, and if so requested by the Holders of not less than 25% in principal
amount of the outstanding Senior Debt Securities of such series will, declare the principal amount together with accrued interest,
if any, with respect to the Senior Debt Securities of this series due and payable immediately, by a notice in writing to the Issuer
(and to the Trustee if given by the Holder or Holders), and upon any such declaration such principal amount (or specified amount)
shall become immediately due and payable.

 

The Holder of this Senior Debt
Security shall not have the right to institute any proceeding with respect to the Senior Debt Securities Indenture or for the
appointment of an administrator, receiver or trustee or for any other remedy thereunder, unless such Holder has previously
given written notice to the Trustee of a continuing Event of Default or Default with respect to such Senior Debt Security
specifying such Event of Default or Default and stating that such notice is a “Notice of Default” under
the Senior Debt Securities Indenture; the Holders of not less than 25% in aggregate principal amount of such Senior Debt
Security shall have made written request to the Trustee to institute proceedings in respect of such Event of Default or
Default in its own name, as Trustee hereunder; such Holders have offered to the Trustee reasonable indemnity or security
satisfactory to it against the costs, expenses and liabilities to be incurred in compliance with such request; the Trustee
for 60 days after its receipt of such notice, request and offer of indemnity or security has failed to institute any such
proceeding; and no direction inconsistent with such written request has been given to the Trustee during such 60-day period
by the Holders of a majority in principal amount of such Senior Debt Security; it being understood and intended that no one
or more Holders of this series shall have any right in any manner whatsoever by virtue of, or by availing of, any provision
of the Senior Debt Securities Indenture or the Senior Debt Securities to affect, disturb or prejudice the rights of any other
such Holders or holders, or to obtain or to seek to obtain priority or preference over any other such Holders or holders or
to enforce any right under the Senior Debt Securities Indenture, except in the manner herein provided and for the equal and
ratable benefit of all Holders of this series. The foregoing shall not apply to any suit instituted by the Holder of this
Senior Debt Security for the enforcement of any payment of principal hereof or interest hereon on or after the respective due
dates expressed herein.

 

    B-11

     

    

 

The Senior Debt Securities Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Issuer
and the rights of the Holders of the Senior Debt Securities under the Senior Debt Securities Indenture at any time by the Issuer
and the Trustee with the consent of the Holders of not less than a majority in principal amount of the outstanding Senior Debt
Securities affected by such amendment. The Senior Debt Securities Indenture also contains provisions permitting the Holders of
specified percentages in principal amount of the Senior Debt Securities at the time outstanding, on behalf of the Holders of all
Senior Debt Securities, to waive compliance by the Issuer with certain provisions of the Senior Debt Securities Indenture and certain
past defaults under the Senior Debt Securities Indenture and their consequences. Any such consent or waiver by the Holder of this
Senior Debt Security shall be conclusive and binding upon such Holder and upon all future Holders of this Senior Debt Security
and of any Senior Debt Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether
or not notation of such consent or waiver is made upon this Senior Debt Security.

 

No reference herein to the Senior Debt Securities
Indenture and no provision of this Senior Debt Security or of the Senior Debt Securities Indenture shall alter or impair the obligation
of the Issuer, which is absolute and unconditional, to pay the principal of and interest on this Senior Debt Security at the times,
place and rate, and in the coin or currency, herein prescribed.

 

The Issuer may, from time to time, without
the consent of the Holders of the Senior Debt Securities, issue additional Senior Debt Securities of this series having the same
ranking and same interest rate, stated maturity, redemption terms and other terms, except for the price to the public and issue
date and first Interest Payment Date, as this Senior Debt Security; provided however that such additional Senior Debt Securities
shall be issued under a separate CUSIP, Common Code and/or ISIN number unless the additional Senior Debt Securities are issued
pursuant to a “qualified reopening” of the original series, are otherwise treated as part of the same “issue”
of debt instruments as the original series, or the original series was issued with no more than a de minimis amount of original
issue discount and the additional Senior Debt Securities are issued with no more than a de minimis amount of original issue
discount, in each case for U.S. federal income tax purposes. Any such additional Senior Debt Securities, together with this Senior
Debt Security, will constitute a single series of Senior Debt Securities under the Senior Debt Securities Indenture.

 

As provided in the Senior Debt Securities
Indenture and subject to certain limitations therein set forth, the transfer of this Senior Debt Security is registrable in the
Register, upon surrender of this Senior Debt Security for registration of transfer at the office or agency of the Issuer in any
place of payment where the principal of and interest on this Senior Debt Security are payable, duly endorsed by, or accompanied
by a written instrument of transfer in form satisfactory to the Issuer and the Registrar duly executed by the registered Holder
hereof or his attorney duly authorized in writing, and thereupon one or more new Senior Debt Securities of this series, of authorized
denominations containing identical terms and provisions, of a like aggregate principal amount, will be issued to the designated
transferee or transferees.

 

The Senior Debt Securities of this series
are issuable only in registered form without coupons in denominations of $200,000 and integral multiples of $1,000 in excess thereof.
As provided in the Senior Debt Securities Indenture and subject to certain limitations set forth therein, Senior Debt Securities
of this series are exchangeable for a like aggregate principal amount of Senior Debt Securities of this series of a different authorized
denomination, as requested by the Holder surrendering the same.

 

No service charge shall be made for any
such registration of transfer or exchange, but, subject to certain exceptions set forth in the Senior Debt Securities Indenture,
the Issuer may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.

 

    B-12

     

    

 

Prior to due presentment of this Senior
Debt Security for registration of transfer, the Issuer, the Trustee and any agent of the Issuer or the Trustee may treat the Person
in whose name this Senior Debt Security is registered as the owner hereof for all purposes, whether or not this Senior Debt Security
be overdue, and none of the Issuer, the Trustee or any such agent shall be affected by notice to the contrary.

 

The obligations of the Issuer under the
Senior Debt Securities Indenture and this Senior Debt Security and all documents delivered in the name of the Issuer in connection
herewith and therewith do not and shall not constitute personal obligations of the directors, officers, employees, agents or shareholders
of the Issuer or any of them, and shall not involve any claim against or personal liability on the part of any of them, and all
persons including the Trustee shall look solely to the assets of the Issuer for the payment of any claim thereunder or for the
performance thereof and shall not seek recourse against such directors, officers, employees, agents or shareholders of the Issuer
or any of them or any of their personal assets for such satisfaction. The performance of the obligations of the Issuer under the
Senior Debt Securities Indenture and this Senior Debt Security and all documents delivered in the name of the Issuer in connection
therewith shall not be deemed a waiver of any rights or powers of the Issuer or its directors or shareholders under the Issuer’s
Memorandum and Articles of Association.

 

Notwithstanding any other term of the Senior
Debt Securities or the Senior Debt Securities Indenture or any other agreements, arrangements or understandings between the Issuer
and any Holder of the Senior Debt Securities (including for these purposes each holder of a beneficial interest in the Senior Debt
Securities), by its acquisition of the Senior Debt Securities, each Holder of the Senior Debt Securities acknowledges, accepts,
agrees to be bound by and consents to:

 

(a) the effect of the exercise of any UK
Bail-in Power by the Relevant UK Resolution Authority arising in respect of the Senior Debt Securities, whether or not imposed
with prior notice, that may include and result in: (i) the reduction of all, or a portion, of the Amounts Due; (ii) the conversion
of all, or a portion, of the Amounts Due on the Senior Debt Securities into shares, other securities or other obligations of the
Issuer or another Person (and the issue to or conferral on the Holders of the Senior Debt Securities of such shares, securities
or obligations), including by means of an amendment, modification or variation of the terms of the Senior Debt Securities; (iii)
the cancellation of the Senior Debt Securities including any other Amounts Due on the Senior Debt Securities; and/or (iv) the amendment
or alteration of the maturity of the Senior Debt Securities or amendment of the amount of interest payable on the Senior Debt Securities,
or the date on which the interest becomes payable, including by suspending payment for a temporary period; and

 

(b) the variation, if necessary, of the
terms of the Senior Debt Securities Indenture or the Senior Debt Securities to give effect to the exercise of the UK Bail-in Power
by the Relevant UK Resolution Authority.

 

No Amounts Due on the Senior Debt Securities
will become due and payable or be paid after the exercise of any UK Bail-in Power by the Relevant UK Resolution Authority if and
to the extent such Amounts Due have been reduced, converted, cancelled, amended or altered as a result of such exercise.

 

Notwithstanding any other provision of the
Senior Debt Securities Indenture or the Senior Debt Securities, neither a reduction or cancellation, in part or in full, of the
Amounts Due, the conversion thereof into another security or obligation of the Issuer or another Person, as a result of the exercise
of the UK Bail-in Power by the Relevant UK Resolution Authority with respect to the Issuer, nor the exercise of the UK Bail-in
Power by the Relevant UK Resolution Authority with respect to the Senior Debt Securities will be an Event of Default.

 

By its acquisition of the Senior Debt Securities,
each Holder of the Senior Debt Securities (which for these purposes includes each holder of a beneficial interest in the Senior
Debt Securities):

 

    B-13

     

    

 

(i) to the extent permitted by the Trust
Indenture Act, waives any and all claims, in law and/or in equity, against the Trustee for, agrees not to initiate a suit against
the Trustee in respect of, and agrees that the Trustee will not be liable for, any action that the Trustee takes, or abstains from
taking, in either case in accordance with the exercise of the UK Bail-in Power by the Relevant UK Resolution Authority with respect
to the Senior Debt Securities;

 

(ii) acknowledges and agrees that neither
a cancellation or deemed cancellation of the principal or interest (in each case, in whole or in part), nor the exercise of the
UK Bail-in Power by the Relevant UK Resolution Authority with respect to the Senior Debt Securities will give rise to a default
for purposes of Section 315(b) (Notice of Default) and Section 315(c) (Duties of the Trustee in Case of Default) of the Trust Indenture
Act; and

 

(iii) acknowledges and agrees that, upon
the exercise of the UK Bail-in Power by the Relevant UK Resolution Authority:

 

(A) the Trustee shall not be required to
take any further directions from the Holders of the Senior Debt Securities with respect to any portion of the Senior Debt Securities
that are written-down, converted to equity and/or cancelled under Section 5.12 of the Senior Debt Securities Indenture, and

 

(B) the Senior Debt Securities Indenture
shall not impose any duties upon the Trustee whatsoever with respect to the exercise of the UK Bail-in Power by the Relevant UK
Resolution Authority.

 

Notwithstanding clauses (i)-(iii) above,
if, following the completion of the exercise of the UK Bail-in Power by the Relevant UK Resolution Authority, the Senior Debt Securities
remain Outstanding (for example, if the exercise of the UK Bail-in Power results in only a partial write-down of the principal
of the Senior Debt Securities), then the Trustee’s duties under the Senior Debt Securities Indenture shall remain applicable
with respect to such Senior Debt Securities following such completion to the extent the Issuer and the Trustee shall agree pursuant
to a supplemental indenture or an amendment to the Senior Debt Securities Indenture; provided, however, that, notwithstanding the
exercise of the UK Bail-in Power by the Relevant UK Resolution Authority, so long as the Senior Debt Securities remain Outstanding,
there will at all times be a Trustee for the Senior Debt Securities in accordance with, Section 6.09 of the Senior Debt Securities
Indenture, and the resignation and/or removal of the Trustee and the appointment of a successor Trustee will continue to be governed
by Sections 6.10 and 6.11 of the Senior Debt Securities Indenture, respectively, including to the extent no additional supplemental
indenture or amendment is agreed upon in the event the Senior Debt Securities remain Outstanding following the completion of the
exercise of the UK Bail-in Power.

 

Upon the exercise of the UK Bail-in Power
by the Relevant UK Resolution Authority with respect to the Senior Debt Securities, the Issuer will provide a written notice to
DTC as soon as practicable regarding such exercise of the UK Bail-in Power for the purposes of notifying the Holders of such occurrence.
The Issuer will also deliver a copy of such notice to the Trustee for information purposes. Each Holder of the Senior Debt Securities
(including for these purposes each holder of a beneficial interest in the Senior Debt Securities) shall be deemed to have authorized,
directed and requested DTC and any direct participant in DTC or other intermediary through which it holds the Senior Debt Securities
to take any and all necessary action, if required, to implement the exercise of the UK Bail-in Power with respect to the Senior
Debt Securities as it may be imposed, without any further action or direction on the part of such Holder or the Trustee.

 

“UK Bail-in Power”
means the powers under the UK Bail-in Legislation to cancel, transfer or dilute shares issued by a person that is a bank or
investment firm or affiliate of a bank or investment firm, to cancel, reduce, modify or change the form of a liability of
such a person or any contract or instrument under which that liability arises, to convert all or part of that liability into
shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to
have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability.

 

    B-14

     

    

 

“UK Bail-in Legislation”
means Part I of the UK Banking Act 2009 and any other law or regulation applicable in the UK relating to the resolution of unsound
or failing banks, investment firms or other financial institutions or their affiliates (otherwise than through liquidation, administration
or other insolvency proceedings).

 

“Relevant UK Resolution Authority”
means the Bank of England or any other authority with the ability to exercise a UK Bail-in Power.

 

“Amounts Due” means the
principal amount of, and accrued but unpaid interest, including any Additional Amounts due on, the Senior Debt Securities. References
to principal and interest will include payments of principal and interest that have become due and payable but which have not been
paid, prior to the exercise of any UK Bail-in Power by the Relevant UK Resolution Authority.

 

The Senior Debt Securities Indenture
and the Senior Debt Securities, including this Senior Debt Security, shall be governed by and construed in accordance with the
law of the State of New York.

 

Pursuant to a recommendation promulgated
by the Committee on Uniform Security Identification Procedures, the Issuer has caused “CUSIP” numbers to be
printed on the Senior Debt Securities as a convenience to the Holders of the Senior Debt Securities. No representation is made
as to the correctness or accuracy of such CUSIP numbers as printed on the Senior Debt Securities, and reliance may be placed only
on the other identification numbers printed hereon.

 

    B-15

     

    

 

ASSIGNMENT FORM

 

FOR VALUE RECEIVED, the undersigned hereby

sells, assigns and transfers unto

 

PLEASE INSERT SOCIAL

SECURITY OR OTHER IDENTIFYING

NUMBER OF ASSIGNEE

  

	 	 	         _________________________________

 

 

	 	 

(Please Print or Typewrite Name and Address, including Zip Code,
of Assignee)

 

	 	 

the within Security of the company and                         
hereby does irrevocably constitute and appoint

 

	 	 

attorney to transfer said Security on the books of the within-named
company with full power of substitution in the premises.

 

	Dated:	 	 

 

	Signature	 	 

 

NOTICE: The signature to this assignment must correspond with the name as it appears on the first page of the within Security
in every particular, without alteration or enlargement or any change whatever.

 

	Signature Guaranteed: 	 	 

  

NOTICE: Signature(s) must be guaranteed by an “eligible guarantor institution” that is a member or participant
in a “signature guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange
Medallion Program and the New York Stock Exchange Medallion Program).

 

    B-16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]